token,label,label_gpt
BRCA1,O,B
is,O,O
secreted,O,O
and,O,O
exhibits,O,O
properties,O,O
of,O,O
a,O,O
granin,O,O
.,O,O
Germline,O,O
mutations,O,O
in,O,O
BRCA1,O,B
are,O,O
responsible,O,O
for,O,O
most,O,O
cases,O,O
of,O,O
inherited,B,O
breast,I,B
and,I,O
ovarian,I,B
cancer,I,I
.,O,O
However,O,O
",",O,O
the,O,O
function,O,O
of,O,O
the,O,O
BRCA1,O,B
protein,O,O
has,O,O
remained,O,O
elusive,O,O
.,O,O
We,O,O
now,O,O
show,O,O
that,O,O
BRCA1,O,B
encodes,O,O
a,O,O
190,O,O
-,O,O
kD,O,O
protein,O,O
with,O,O
sequence,O,O
homology,O,O
and,O,O
biochemical,O,O
analogy,O,O
to,O,O
the,O,O
granin,O,O
protein,O,O
family,O,O
.,O,O
Interestingly,O,O
",",O,O
BRCA2,O,B
also,O,O
includes,O,O
a,O,O
motif,O,O
similar,O,O
to,O,O
the,O,O
granin,O,O
consensus,O,O
at,O,O
the,O,O
C,O,O
terminus,O,O
of,O,O
the,O,O
protein,O,O
.,O,O
Both,O,O
BRCA1,O,B
and,O,O
the,O,O
granins,O,O
localize,O,O
to,O,O
secretory,O,O
vesicles,O,O
",",O,O
are,O,O
secreted,O,O
by,O,O
a,O,O
regulated,O,O
pathway,O,O
",",O,O
are,O,O
post,O,O
-,O,O
translationally,O,O
glycosylated,O,O
and,O,O
are,O,O
responsive,O,O
to,O,O
hormones,O,O
.,O,O
As,O,O
a,O,O
regulated,O,O
secretory,O,O
protein,O,O
",",O,O
BRCA1,O,B
appears,O,O
to,O,O
function,O,O
by,O,O
a,O,O
mechanism,O,O
not,O,O
previously,O,O
described,O,O
for,O,O
tumour,B,O
suppressor,O,O
gene,O,O
products,O,O
.,O,O
.,O,O
Ovarian,B,B
cancer,I,I
risk,O,O
in,O,O
BRCA1,O,O
carriers,O,O
is,O,O
modified,O,O
by,O,O
the,O,O
HRAS1,O,B
variable,O,I
number,O,I
of,O,I
tandem,O,I
repeat,O,I
(,O,O
VNTR,O,O
),O,O
locus,O,O
.,O,O
Women,O,O
who,O,O
carry,O,O
a,O,O
mutation,O,O
in,O,O
the,O,O
BRCA1,O,O
gene,O,O
(,O,O
on,O,O
chromosome,O,O
17q21,O,O
),O,O
",",O,O
have,O,O
an,O,O
80,O,O
%,O,O
risk,O,O
of,O,O
breast,B,B
cancer,I,I
and,O,O
a,O,O
40,O,O
%,O,O
risk,O,O
of,O,O
ovarian,B,B
cancer,I,I
by,O,O
the,O,O
age,O,O
of,O,O
70,O,O
(,O,O
ref,O,O
.,O,O
1,O,O
),O,O
.,O,O
The,O,O
variable,O,O
penetrance,O,O
of,O,O
BRCA1,O,O
suggests,O,O
that,O,O
other,O,O
genetic,O,O
and,O,O
non,O,O
-,O,O
genetic,O,O
factors,O,O
play,O,O
a,O,O
role,O,O
in,O,O
tumourigenesis,O,O
in,O,O
these,O,O
individuals,O,O
.,O,O
The,O,O
HRAS1,O,B
variable,O,I
number,O,I
of,O,I
tandem,O,I
repeats,O,I
(,O,O
VNTR,O,O
),O,O
polymorphism,O,O
",",O,O
located,O,O
1,O,O
kilobase,O,O
(,O,O
kb,O,O
),O,O
downstream,O,O
of,O,O
the,O,O
HRAS1,O,B
proto,O,I
-,O,I
oncogene,O,I
(,O,O
chromosome,O,O
11p15,O,O
.,O,O
5,O,O
),O,O
is,O,O
one,O,O
possible,O,O
genetic,O,O
modifier,O,O
of,O,O
cancer,B,B
penetrance,O,I
.,O,O
Individuals,O,O
who,O,O
have,O,O
rare,O,O
alleles,O,O
of,O,O
the,O,O
VNTR,O,O
have,O,O
an,O,O
increased,O,O
risk,O,O
of,O,O
certain,O,O
types,O,O
of,O,O
cancers,B,B
",",O,O
including,O,O
breast,B,B
cancer,I,I
(,O,O
2,O,O
-,O,O
4,O,O
),O,O
.,O,O
To,O,O
investigate,O,O
whether,O,O
the,O,O
presence,O,O
of,O,O
rare,O,O
HRAS1,O,B
alleles,O,O
increases,O,O
susceptibility,O,O
to,O,O
hereditary,B,O
breast,I,B
and,I,O
ovarian,I,B
cancer,I,I
",",O,O
we,O,O
have,O,O
typed,O,O
a,O,O
panel,O,O
of,O,O
307,O,O
female,O,O
BRCA1,O,O
carriers,O,O
at,O,O
this,O,O
locus,O,O
using,O,O
a,O,O
PCR,O,O
-,O,O
based,O,O
technique,O,O
.,O,O
The,O,O
risk,O,O
for,O,O
ovarian,B,B
cancer,I,I
was,O,O
2,O,O
.,O,O
11,O,O
times,O,O
greater,O,O
for,O,O
BRCA1,O,O
carriers,O,O
harbouring,O,O
one,O,O
or,O,O
two,O,O
rare,O,O
HRAS1,O,B
alleles,O,O
",",O,O
compared,O,O
to,O,O
carriers,O,O
with,O,O
only,O,O
common,O,O
alleles,O,O
(,O,O
P,O,O
=,O,O
0,O,O
.,O,O
),O,O
.,O,O
The,O,O
magnitude,O,O
of,O,O
the,O,O
relative,O,O
risk,O,O
associated,O,O
with,O,O
a,O,O
rare,O,O
HRAS1,O,B
allele,O,O
was,O,O
not,O,O
altered,O,O
by,O,O
adjusting,O,O
for,O,O
the,O,O
other,O,O
known,O,O
risk,O,O
factors,O,O
for,O,O
hereditary,B,O
ovarian,I,O
cancer,I,O
(,O,O
5,O,O
),O,O
.,O,O
Susceptibility,O,O
to,O,O
breast,B,B
cancer,I,I
did,O,O
not,O,O
appear,O,O
to,O,O
be,O,O
affected,O,O
by,O,O
the,O,O
presence,O,O
of,O,O
rare,O,O
HRAS1,O,B
alleles,O,I
.,O,O
This,O,O
study,O,O
is,O,O
the,O,O
first,O,O
to,O,O
show,O,O
the,O,O
effect,O,O
of,O,O
a,O,O
modifying,O,O
gene,O,O
on,O,O
the,O,O
penetrance,O,O
of,O,O
an,O,O
inherited,B,O
cancer,I,O
syndrome,I,O
A,O,O
novel,O,O
homeodomain,O,O
-,O,O
encoding,O,O
gene,O,O
is,O,O
associated,O,O
with,O,O
a,O,O
large,O,O
CpG,O,O
island,O,O
interrupted,O,O
by,O,O
the,O,O
myotonic,B,O
dystrophy,I,O
unstable,O,O
(,O,O
CTG,O,O
),O,O
n,O,O
repeat,O,O
.,O,O
Myotonic,B,B
dystrophy,I,I
(,O,O
DM,B,B
),O,O
is,O,O
associated,O,O
with,O,O
a,O,O
(,O,O
CTG,O,B
),O,O
n,O,O
trinucleotide,O,O
repeat,O,O
expansion,O,O
in,O,O
the,O,O
3,O,O
-,O,O
untranslated,O,O
region,O,O
of,O,O
a,O,O
protein,O,O
kinase,O,O
-,O,O
encoding,O,O
gene,O,O
",",O,O
DMPK,O,B
",",O,O
which,O,O
maps,O,O
to,O,O
chromosome,O,O
19q13,O,O
.,O,O
3,O,O
Characterisation,O,O
of,O,O
the,O,O
expression,O,O
of,O,O
this,O,O
gene,O,O
in,O,O
patient,O,O
tissues,O,O
has,O,O
thus,O,O
far,O,O
generated,O,O
conflicting,O,O
data,O,O
on,O,O
alterations,O,O
in,O,O
the,O,O
steady,O,O
state,O,O
levels,O,O
of,O,O
DMPK,O,B
mRNA,O,I
",",O,O
and,O,O
on,O,O
the,O,O
final,O,O
DMPK,O,B
protein,O,I
levels,O,I
in,O,O
the,O,O
presence,O,O
of,O,O
the,O,O
expansion,O,O
.,O,O
The,O,O
DM,B,O
region,O,O
of,O,O
chromosome,O,O
19,O,O
is,O,O
gene,O,B
rich,O,O
",",O,O
and,O,O
it,O,O
is,O,O
possible,O,O
that,O,O
the,O,O
repeat,O,O
expansion,O,O
may,O,O
lead,O,O
to,O,O
dysfunction,O,O
of,O,O
a,O,O
number,O,O
of,O,O
transcription,O,O
units,O,O
in,O,O
the,O,O
vicinity,O,O
",",O,O
perhaps,O,O
as,O,O
a,O,O
consequence,O,O
of,O,O
chromatin,O,O
disruption,O,O
.,O,O
We,O,O
have,O,O
searched,O,O
for,O,O
genes,O,B
associated,O,O
with,O,O
a,O,O
CpG,O,O
island,O,O
at,O,O
the,O,O
3,O,O
end,O,O
of,O,O
DMPK,O,O
.,O,O
Sequencing,O,O
of,O,O
this,O,O
region,O,O
shows,O,O
that,O,O
the,O,O
island,O,O
extends,O,O
over,O,O
3,O,O
.,O,O
5,O,O
kb,O,O
and,O,O
is,O,O
interrupted,O,O
by,O,O
the,O,O
(,O,O
CTG,O,B
),O,O
n,O,O
repeat,O,O
.,O,O
Comparison,O,O
of,O,O
genomic,O,O
sequences,O,O
downstream,O,O
(,O,O
centromeric,O,O
),O,O
of,O,O
the,O,O
repeat,O,O
in,O,O
human,O,O
and,O,O
mouse,O,O
identified,O,O
regions,O,O
of,O,O
significant,O,O
homology,O,O
.,O,O
These,O,O
correspond,O,O
to,O,O
exons,O,O
of,O,O
a,O,O
gene,O,B
predicted,O,O
to,O,O
encode,O,O
a,O,O
homeodomain,O,O
protein,O,O
.,O,O
RT,O,O
-,O,O
PCR,O,O
analysis,O,O
shows,O,O
that,O,O
this,O,O
gene,O,B
",",O,O
which,O,O
we,O,O
have,O,O
called,O,O
DM,B,B
locus,O,I
-,O,I
associated,O,I
homeodomain,O,I
protein,O,I
(,O,O
DMAHP,O,B
),O,O
",",O,O
is,O,O
expressed,O,O
in,O,O
a,O,O
number,O,O
of,O,O
human,O,O
tissues,O,O
",",O,O
including,O,O
skeletal,O,O
muscle,O,O
",",O,O
heart,O,O
and,O,O
brain,O,O
.,O,O
Germline,O,O
mutations,O,O
in,O,O
the,O,O
RB1,O,B
gene,O,I
in,O,O
patients,O,O
with,O,O
hereditary,B,O
retinoblastoma,I,O
.,O,O
We,O,O
have,O,O
analyzed,O,O
the,O,O
27,O,O
exons,O,O
and,O,O
the,O,O
promoter,O,O
region,O,O
of,O,O
the,O,O
RB1,O,B
gene,O,I
in,O,O
familial,B,O
or,I,O
sporadic,I,O
bilateral,I,O
retinoblastoma,I,O
by,O,O
using,O,O
single,O,O
-,O,O
strand,O,O
conformation,O,O
polymorphism,O,O
analysis,O,O
.,O,O
For,O,O
improvement,O,O
over,O,O
previous,O,O
studies,O,O
",",O,O
a,O,O
new,O,O
set,O,O
of,O,O
primers,O,O
has,O,O
been,O,O
designed,O,O
",",O,O
which,O,O
allow,O,O
for,O,O
amplification,O,O
of,O,O
the,O,O
coding,O,O
and,O,O
splicing,O,O
sequences,O,O
only,O,O
.,O,O
The,O,O
positioning,O,O
of,O,O
the,O,O
polymerase,O,O
chain,O,O
reaction,O,O
(,O,O
PCR,O,O
),O,O
primers,O,O
was,O,O
such,O,O
that,O,O
the,O,O
resulting,O,O
PCR,O,O
products,O,O
were,O,O
of,O,O
different,O,O
sizes,O,O
",",O,O
which,O,O
enabled,O,O
us,O,O
to,O,O
analyze,O,O
two,O,O
different,O,O
exons,O,O
simultaneously,O,O
and,O,O
still,O,O
distinguish,O,O
between,O,O
the,O,O
banding,O,O
profiles,O,O
for,O,O
both,O,O
(,O,O
biplex,O,O
analysis,O,O
),O,O
.,O,O
By,O,O
using,O,O
this,O,O
approach,O,O
",",O,O
we,O,O
were,O,O
able,O,O
to,O,O
identify,O,O
mutation,O,O
in,O,O
22,O,O
new,O,O
patients,O,O
",",O,O
but,O,O
the,O,O
overall,O,O
efficiency,O,O
of,O,O
the,O,O
procedure,O,O
when,O,O
we,O,O
used,O,O
a,O,O
single,O,O
-,O,O
pass,O,O
regimen,O,O
was,O,O
only,O,O
48,O,O
%,O,O
.,O,O
The,O,O
mutations,O,O
were,O,O
small,O,O
insertions,O,O
and,O,O
deletions,O,O
and,O,O
point,O,O
mutations,O,O
in,O,O
roughly,O,O
equal,O,O
proportions,O,O
.,O,O
Type,B,O
II,I,O
human,I,O
complement,I,O
C2,I,B
deficiency,I,I
.,O,O
Allele,O,O
-,O,O
specific,O,O
amino,O,O
acid,O,O
substitutions,O,O
(,O,O
Ser189,O,O
-,O,O
-,O,O
>,O,O
Phe,O,O
;,O,O
Gly444,O,O
-,O,O
-,O,O
>,O,O
Arg,O,O
),O,O
cause,O,O
impaired,O,O
C2,O,B
secretion,O,I
.,O,O
Type,B,O
II,I,O
complement,I,O
protein,I,O
C2,I,B
deficiency,I,I
is,O,O
characterized,O,O
by,O,O
a,O,O
selective,O,O
block,O,O
in,O,O
C2,O,B
secretion,O,I
.,O,O
The,O,O
Type,O,B
II,O,I
C2,O,I
allele,O,I
(,O,O
C2Q0,O,B
),O,O
is,O,O
linked,O,O
to,O,O
two,O,O
major,O,O
histocompatibility,O,O
haplotypes,O,O
(,O,O
MHC,O,B
),O,O
that,O,O
differ,O,O
from,O,O
the,O,O
MHC,O,O
of,O,O
the,O,O
more,O,O
common,O,O
Type,B,B
I,I,I
C2,I,I
deficiency,I,I
.,O,O
To,O,O
determine,O,O
the,O,O
molecular,O,O
basis,O,O
of,O,O
Type,B,B
II,I,I
deficiency,I,I
the,O,O
two,O,O
Type,O,B
II,O,I
C2Q0,O,I
genes,O,O
were,O,O
isolated,O,O
and,O,O
transfected,O,O
separately,O,O
into,O,O
L,O,O
-,O,O
cells,O,O
.,O,O
Subsequent,O,O
molecular,O,O
biology,O,O
",",O,O
biosynthetic,O,O
",",O,O
and,O,O
immunofluorescence,O,O
studies,O,O
demonstrated,O,O
that,O,O
C2,O,B
secretion,O,O
is,O,O
impaired,O,O
in,O,O
Type,B,O
II,I,O
C2,I,B
deficiency,I,O
because,O,O
of,O,O
different,O,O
missense,O,O
mutations,O,O
at,O,O
highly,O,O
conserved,O,O
residues,O,O
in,O,O
each,O,O
of,O,O
the,O,O
C2Q0,O,B
alleles,O,O
.,O,O
One,O,O
is,O,O
in,O,O
exon,O,O
5,O,O
(,O,O
nucleotide,O,O
C566,O,O
-,O,O
-,O,O
>,O,O
T,O,O
;,O,O
Ser189,O,O
-,O,O
-,O,O
>,O,O
Phe,O,O
),O,O
of,O,O
the,O,O
C2Q0,O,B
gene,O,O
linked,O,O
to,O,O
the,O,O
MHC,O,O
haplotype,O,O
A11,O,O
",",O,O
B35,O,O
",",O,O
DRw1,O,O
",",O,O
BFS,O,O
",",O,O
C4A0B1,O,O
.,O,O
The,O,O
other,O,O
is,O,O
in,O,O
exon,O,O
11,O,O
(,O,O
G1930,O,B
-,O,I
-,O,I
>,O,O
A,O,O
;,O,O
Gly444,O,B
-,O,I
-,O,I
>,O,O
Arg,O,O
),O,O
of,O,O
the,O,O
C2Q0,O,O
gene,O,O
linked,O,O
to,O,O
the,O,O
MHC,O,O
haplotype,O,O
A2,O,O
",",O,O
B5,O,O
",",O,O
DRw4,O,O
",",O,O
BFS,O,O
",",O,O
C4A3B1,O,O
.,O,O
Each,O,O
mutant,O,O
C2,O,O
gene,O,O
product,O,O
is,O,O
retained,O,O
early,O,O
in,O,O
the,O,O
secretory,O,O
pathway,O,O
.,O,O
These,O,O
mutants,O,O
provide,O,O
models,O,O
for,O,O
elucidating,O,O
the,O,O
C2,O,O
secretory,O,O
pathway,O,O
.,O,O
.,O,O
Defective,O,O
dimerization,O,O
of,O,O
von,B,O
Willebrand,I,O
factor,O,O
subunits,O,O
due,O,O
to,O,O
a,O,O
Cys,O,B
-,O,I
>,O,O
Arg,O,O
mutation,O,O
in,O,O
type,B,O
IID,I,O
von,I,O
Willebrand,I,O
disease,I,O
.,O,O
The,O,O
same,O,O
heterozygous,O,O
T,O,B
-,O,I
>,O,I
C,O,I
transition,O,O
at,O,O
nt,O,O
8567,O,O
of,O,O
the,O,O
von,B,B
Willebrand,I,I
factor,O,I
(,O,O
vWF,O,O
),O,O
transcript,O,O
was,O,O
found,O,O
in,O,O
two,O,O
unrelated,O,O
patients,O,O
with,O,O
type,B,O
IID,I,O
von,I,B
Willebrand,I,I
disease,I,I
",",O,O
with,O,O
no,O,O
other,O,O
apparent,O,O
abnormality,O,O
.,O,O
In,O,O
one,O,O
family,O,O
",",O,O
both,O,O
alleles,O,O
were,O,O
normal,O,O
in,O,O
the,O,O
parents,O,O
and,O,O
one,O,O
sister,O,O
;,O,O
thus,O,O
",",O,O
the,O,O
mutation,O,O
originated,O,O
de,O,O
novo,O,O
in,O,O
the,O,O
proposita,O,O
.,O,O
The,O,O
second,O,O
patient,O,O
also,O,O
had,O,O
asymptomatic,O,O
parents,O,O
who,O,O
",",O,O
however,O,O
",",O,O
were,O,O
not,O,O
available,O,O
for,O,O
study,O,O
.,O,O
The,O,O
structural,O,O
consequences,O,O
of,O,O
the,O,O
identified,O,O
mutation,O,O
",",O,O
resulting,O,O
in,O,O
the,O,O
CyS2010,O,B
-,O,I
>,O,I
Arg,O,I
substitution,O,O
",",O,O
were,O,O
evaluated,O,O
by,O,O
expression,O,O
of,O,O
the,O,O
vWF,O,O
carboxyl,O,O
-,O,O
terminal,O,O
domain,O,O
containing,O,O
residues,O,O
1366,O,O
-,O,O
2050,O,O
.,O,O
Insect,O,O
cells,O,O
infected,O,O
with,O,O
recombinant,O,O
baculovirus,O,O
expressing,O,O
normal,O,O
vWF,O,B
sequence,O,O
secreted,O,O
a,O,O
disulfide,O,O
linked,O,O
dimeric,O,O
molecule,O,O
with,O,O
an,O,O
apparent,O,O
molecular,O,O
mass,O,O
of,O,O
150,O,O
kDa,O,O
before,O,O
reduction,O,O
",",O,O
yielding,O,O
a,O,O
single,O,O
band,O,O
of,O,O
80,O,O
kDa,O,O
after,O,O
disulfide,O,O
bond,O,O
reduction,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
cells,O,O
expressing,O,O
the,O,O
mutant,O,O
fragment,O,O
secreted,O,O
a,O,O
monomeric,O,O
molecule,O,O
of,O,O
apparent,O,O
molecular,O,O
mass,O,O
of,O,O
80,O,O
kDa,O,O
",",O,O
which,O,O
remained,O,O
unchanged,O,O
after,O,O
reduction,O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
CyS2010,O,O
is,O,O
essential,O,O
for,O,O
normal,O,O
dimerization,O,O
of,O,O
vWF,O,B
subunits,O,I
through,O,O
disulfide,O,O
bonding,O,O
of,O,O
carboxyl,O,O
-,O,O
terminal,O,O
domains,O,O
and,O,O
that,O,O
a,O,O
heterozygous,O,O
mutation,O,O
in,O,O
the,O,O
corresponding,O,O
codon,O,O
is,O,O
responsible,O,O
for,O,O
defective,O,O
multimer,O,O
formation,O,O
in,O,O
type,B,O
IID,I,O
von,I,B
Willebrand,I,I
disease,I,I
.,O,O
.,O,O
Wiskott,B,B
-,I,I
Aldrich,I,I
syndrome,I,I
protein,O,O
",",O,O
a,O,O
novel,O,O
effector,O,O
for,O,O
the,O,O
GTPase,O,O
CDC42Hs,O,O
",",O,O
is,O,O
implicated,O,O
in,O,O
actin,O,O
polymerization,O,O
.,O,O
The,O,O
Rho,O,B
family,O,I
of,O,I
GTPases,O,I
control,O,O
diverse,O,O
biological,O,O
processes,O,O
",",O,O
including,O,O
cell,O,O
morphology,O,O
and,O,O
mitogenesis,O,O
.,O,O
We,O,O
have,O,O
identified,O,O
WASP,O,B
",",O,O
the,O,O
protein,O,O
that,O,O
is,O,O
defective,O,O
in,O,O
Wiskott,B,B
-,I,I
Aldrich,I,I
syndrome,I,I
(,O,O
WAS,B,B
),O,O
",",O,O
as,O,O
a,O,O
novel,O,O
effector,O,O
for,O,O
CDC42Hs,O,O
",",O,O
but,O,O
not,O,O
for,O,O
the,O,O
other,O,O
Rho,O,B
family,O,I
members,O,I
",",O,O
Rac,O,O
and,O,O
Rho,O,O
.,O,O
This,O,O
interaction,O,O
is,O,O
dependent,O,O
on,O,O
the,O,O
presence,O,O
of,O,O
the,O,O
G,O,B
protein,O,I
-,O,I
binding,O,I
domain,O,I
.,O,O
Cellular,O,O
expression,O,O
of,O,O
epitope,O,O
-,O,O
tagged,O,O
WASP,O,B
produces,O,O
clusters,O,O
of,O,O
WASP,O,B
that,O,O
are,O,O
highly,O,O
enriched,O,O
in,O,O
polymerized,O,O
actin,O,O
.,O,O
This,O,O
clustering,O,O
is,O,O
not,O,O
observed,O,O
with,O,O
a,O,O
C,O,B
-,O,I
terminally,O,I
deleted,O,I
WASP,O,I
and,O,O
is,O,O
inhibited,O,O
by,O,O
coexpression,O,O
with,O,O
dominant,O,O
negative,O,O
CDC42Hs,O,B
-,O,I
N17,O,I
",",O,O
but,O,O
not,O,O
with,O,O
dominant,O,O
negative,O,O
forms,O,O
of,O,O
Rac,O,O
or,O,O
Rho,O,O
.,O,O
Thus,O,O
",",O,O
WASP,O,B
provides,O,O
a,O,O
novel,O,O
link,O,O
between,O,O
CDC42Hs,O,B
and,O,O
the,O,O
actin,O,O
cytoskeleton,O,O
",",O,O
which,O,O
suggests,O,O
a,O,O
molecular,O,O
mechanism,O,O
for,O,O
many,O,O
of,O,O
the,O,O
cellular,O,O
abnormalities,O,O
in,O,O
WAS,B,B
.,O,O
The,O,O
WASP,O,B
sequence,O,O
contains,O,O
two,O,O
novel,O,O
domains,O,O
that,O,O
are,O,O
homologous,O,O
to,O,O
other,O,O
proteins,O,O
involved,O,O
in,O,O
action,O,O
organization,O,O
.,O,O
X,B,B
-,I,I
linked,I,I
adrenoleukodystrophy,I,I
is,O,O
a,O,O
frequent,O,O
cause,O,O
of,O,O
idiopathic,O,O
Addison,B,B
',I,I
s,I,I
disease,I,I
in,O,O
young,O,O
adult,O,O
male,O,O
patients,O,O
.,O,O
X,B,B
-,I,I
Linked,I,I
adrenoleukodystrophy,I,I
(,O,O
ALD,B,B
),O,O
is,O,O
a,O,O
genetic,B,O
disease,I,O
associated,O,O
with,O,O
demyelination,B,O
of,I,O
the,I,O
central,I,O
nervous,I,O
system,I,O
",",O,O
adrenal,B,O
insufficiency,I,O
",",O,O
and,O,O
accumulation,O,O
of,O,O
very,O,O
long,O,O
chain,O,O
fatty,O,O
acids,O,O
in,O,O
tissue,O,O
and,O,O
body,O,O
fluids,O,O
.,O,O
ALD,B,B
is,O,O
due,O,O
to,O,O
mutation,O,O
of,O,O
a,O,O
gene,O,O
located,O,O
in,O,O
Xq28,O,O
that,O,O
encodes,O,O
a,O,O
peroxisomal,O,O
transporter,O,O
protein,O,O
of,O,O
unknown,O,O
function,O,O
.,O,O
The,O,O
most,O,O
common,O,O
phenotype,O,O
of,O,O
ALD,B,B
is,O,O
the,O,O
cerebral,O,O
form,O,O
(,O,O
45,O,O
%,O,O
),O,O
that,O,O
develops,O,O
in,O,O
boys,O,O
between,O,O
5,O,O
-,O,O
12,O,O
yr,O,O
.,O,O
Adrenomyeloneuropathy,B,B
(,O,O
AMN,B,B
),O,O
involves,O,O
the,O,O
spinal,O,O
cord,O,O
and,O,O
peripheral,O,O
nerves,O,O
in,O,O
young,O,O
adults,O,O
(,O,O
35,O,O
%,O,O
),O,O
.,O,O
Adrenal,B,B
insufficiency,I,I
(,O,O
Addisons,B,B
disease,I,I
),O,O
is,O,O
frequently,O,O
associated,O,O
with,O,O
AMN,B,B
or,O,O
cerebral,B,O
ALD,I,B
and,O,O
may,O,O
remain,O,O
the,O,O
only,O,O
clinical,O,O
expression,O,O
of,O,O
ALD,B,B
(,O,O
8,O,O
%,O,O
of,O,O
cases,O,O
),O,O
.,O,O
The,O,O
prevalence,O,O
of,O,O
ALD,B,B
among,O,O
adults,O,O
with,O,O
Addisons,B,O
disease,I,O
remains,O,O
unknown,O,O
.,O,O
To,O,O
evaluate,O,O
this,O,O
prevalence,O,O
",",O,O
we,O,O
performed,O,O
biochemical,O,O
analysis,O,O
of,O,O
very,O,O
long,O,O
chain,O,O
fatty,O,O
acids,O,O
in,O,O
14,O,O
male,O,O
patients,O,O
(,O,O
age,O,O
ranging,O,O
from,O,O
12,O,O
-,O,O
45,O,O
yr,O,O
at,O,O
diagnosis,O,O
),O,O
previously,O,O
diagnosed,O,O
as,O,O
having,O,O
primary,O,O
idiopathic,O,O
adrenocortical,B,O
insufficiency,I,O
.,O,O
In,O,O
5,O,O
of,O,O
14,O,O
patients,O,O
(,O,O
35,O,O
%,O,O
),O,O
",",O,O
elevated,O,O
plasma,O,O
concentrations,O,O
of,O,O
very,O,O
long,O,O
chain,O,O
fatty,O,O
acids,O,O
were,O,O
detected,O,O
.,O,O
None,O,O
of,O,O
these,O,O
patients,O,O
had,O,O
adrenocortical,O,O
antibodies,O,O
.,O,O
By,O,O
electrophysiological,O,O
tests,O,O
and,O,O
magnetic,O,O
resonance,O,O
imaging,O,O
it,O,O
was,O,O
determined,O,O
that,O,O
two,O,O
patients,O,O
had,O,O
cerebral,B,O
ALD,I,O
",",O,O
one,O,O
had,O,O
adrenomyeloneuropathy,B,O
with,O,O
cerebral,O,O
involvement,O,O
",",O,O
and,O,O
two,O,O
had,O,O
preclinical,O,O
AMN,B,O
.,O,O
Our,O,O
data,O,O
support,O,O
the,O,O
hypothesis,O,O
that,O,O
ALD,B,B
is,O,O
a,O,O
frequent,O,O
cause,O,O
of,O,O
idiopathic,O,O
Addisons,B,B
disease,I,I
in,O,O
children,O,O
and,O,O
adults,O,O
.,O,O
Tumor,B,O
suppression,O,O
and,O,O
apoptosis,O,O
of,O,O
human,O,O
prostate,B,B
carcinoma,I,I
mediated,O,O
by,O,O
a,O,O
genetic,O,O
locus,O,O
within,O,O
human,O,O
chromosome,O,O
10pter,O,O
-,O,O
q11,O,O
.,O,O
Prostate,B,B
cancer,I,I
is,O,O
the,O,O
second,O,O
leading,O,O
cause,O,O
of,O,O
male,O,O
cancer,B,B
deaths,O,I
in,O,O
the,O,O
United,O,O
States,O,O
.,O,O
Yet,O,O
",",O,O
despite,O,O
a,O,O
large,O,O
international,O,O
effort,O,O
",",O,O
little,O,O
is,O,O
known,O,O
about,O,O
the,O,O
molecular,O,O
mechanisms,O,O
that,O,O
underlie,O,O
this,O,O
devastating,O,O
disease,O,O
.,O,O
Prostate,O,B
secretory,O,I
epithelial,O,I
cells,O,I
and,O,O
androgen,O,O
-,O,O
dependent,O,O
prostate,B,B
carcinomas,I,I
undergo,O,O
apoptosis,O,O
in,O,O
response,O,O
to,O,O
androgen,O,O
deprivation,O,O
and,O,O
",",O,O
furthermore,O,O
",",O,O
most,O,O
prostate,B,B
carcinomas,I,I
become,O,O
androgen,O,O
independent,O,O
and,O,O
refractory,O,O
to,O,O
further,O,O
therapeutic,O,O
manipulations,O,O
during,O,O
disease,O,O
progression,O,O
.,O,O
Definition,O,O
of,O,O
the,O,O
genetic,O,B
events,O,I
that,O,O
trigger,O,O
apoptosis,O,O
in,O,O
the,O,O
prostate,O,O
could,O,O
provide,O,O
important,O,O
insights,O,O
into,O,O
critical,O,O
pathways,O,O
in,O,O
normal,O,O
development,O,O
as,O,O
well,O,O
as,O,O
elucidate,O,O
the,O,O
perturbations,O,O
of,O,O
those,O,O
key,O,O
pathways,O,O
in,O,O
neoplastic,O,O
transformation,O,O
.,O,O
We,O,O
report,O,O
the,O,O
functional,O,O
definition,O,O
of,O,O
a,O,O
novel,O,O
genetic,O,B
locus,O,I
within,O,O
human,O,O
chromosome,O,O
10pter,O,O
-,O,O
q11,O,O
that,O,O
mediates,O,O
both,O,O
in,O,O
vivo,O,O
tumor,O,O
suppression,O,O
and,O,O
in,O,O
vitro,O,O
apoptosis,O,O
of,O,O
prostatic,B,O
adenocarcinoma,I,O
cells,O,O
.,O,O
A,O,O
defined,O,O
fragment,O,O
of,O,O
human,O,O
chromosome,O,O
10,O,B
was,O,O
transferred,O,O
via,O,O
microcell,O,O
fusion,O,O
into,O,O
a,O,O
prostate,B,O
adenocarcinoma,I,O
cell,O,O
line,O,O
.,O,O
Microcell,O,O
hybrids,O,O
containing,O,O
only,O,O
the,O,O
region,O,O
10pter,O,O
-,O,O
q11,O,O
were,O,O
suppressed,O,O
for,O,O
tumorigenicity,O,O
following,O,O
injection,O,O
of,O,O
microcell,O,O
hybrids,O,O
into,O,O
nude,O,O
mice,O,O
.,O,O
Furthermore,O,O
",",O,O
the,O,O
complemented,O,O
hybrids,O,O
undergo,O,O
programmed,O,O
cell,O,O
death,O,O
in,O,O
vitro,O,O
via,O,O
a,O,O
mechanism,O,O
that,O,O
does,O,O
not,O,O
require,O,O
nuclear,O,O
localization,O,O
of,O,O
p53,O,B
.,O,O
These,O,O
data,O,O
functionally,O,O
define,O,O
a,O,O
novel,O,O
genetic,O,O
locus,O,O
",",O,O
designated,O,O
PAC1,O,B
",",O,O
for,O,O
prostate,O,B
adenocarcinoma,O,I
1,O,I
",",O,O
involved,O,O
in,O,O
tumor,O,O
suppression,O,O
of,O,O
human,O,O
prostate,B,B
carcinoma,I,I
and,O,O
furthermore,O,O
strongly,O,O
suggest,O,O
that,O,O
the,O,O
cell,O,O
death,O,O
pathway,O,O
can,O,O
be,O,O
functionally,O,O
restored,O,O
in,O,O
prostatic,B,B
adenocarcinoma,I,I
.,O,O
Low,O,O
incidence,O,O
of,O,O
BRCA2,O,O
mutations,O,O
in,O,O
breast,B,B
carcinoma,I,I
and,O,O
other,O,O
cancers,B,O
.,O,O
Inherited,O,O
mutant,O,O
alleles,O,O
of,O,O
familial,O,B
tumour,B,I
suppressor,O,I
genes,O,I
predispose,O,O
individuals,O,O
to,O,O
particular,O,O
types,O,O
of,O,O
cancer,B,B
.,O,O
In,O,O
addition,O,O
to,O,O
an,O,O
involvement,O,O
in,O,O
inherited,O,O
susceptibility,O,O
to,O,O
cancer,B,B
",",O,O
these,O,O
tumour,B,B
suppressor,O,I
genes,O,I
are,O,O
targets,O,O
for,O,O
somatic,O,O
mutations,O,O
in,O,O
sporadic,B,B
cancers,I,I
of,O,O
the,O,O
same,O,O
type,O,O
found,O,O
in,O,O
the,O,O
familial,O,B
forms,O,I
.,O,O
An,O,O
exception,O,O
is,O,O
BRCA1,O,O
",",O,O
which,O,O
contributes,O,O
to,O,O
a,O,O
significant,O,O
fraction,O,O
of,O,O
familial,B,O
breast,I,B
and,I,O
ovarian,I,B
cancer,I,I
",",O,O
but,O,O
undergoes,O,O
mutation,O,O
at,O,O
very,O,O
low,O,O
rates,O,O
in,O,O
sporadic,B,B
breast,I,I
and,I,O
ovarian,I,B
cancers,I,I
.,O,O
This,O,O
finding,O,O
suggests,O,O
that,O,O
other,O,O
genes,O,O
may,O,O
be,O,O
the,O,O
principal,O,O
targets,O,O
for,O,O
somatic,O,O
mutation,O,O
in,O,O
breast,B,B
carcinoma,I,I
.,O,O
A,O,O
second,O,O
",",O,O
recently,O,O
identified,O,O
familial,B,O
breast,I,B
cancer,I,I
gene,O,O
",",O,O
BRCA2,O,O
(,O,O
refs,O,O
5,O,O
-,O,O
8,O,O
),O,O
",",O,O
accounts,O,O
for,O,O
a,O,O
proportion,O,O
of,O,O
breast,B,B
cancer,I,I
roughly,O,O
equal,O,O
to,O,O
BRCA1,O,O
.,O,O
Like,O,O
BRCA1,O,O
",",O,O
BRCA2,O,B
behaves,O,O
as,O,O
a,O,O
dominantly,O,O
inherited,O,O
tumour,B,O
suppressor,O,O
gene,O,O
.,O,O
Individuals,O,O
who,O,O
inherit,O,O
one,O,O
mutant,O,O
allele,O,O
are,O,O
at,O,O
increased,O,O
risk,O,O
for,O,O
breast,B,B
cancer,I,I
",",O,O
and,O,O
the,O,O
tumours,B,O
they,O,O
develop,O,O
lose,O,O
the,O,O
wild,O,O
-,O,O
type,O,O
allele,O,O
by,O,O
heterozygous,O,O
deletion,O,O
.,O,O
The,O,O
BRCA2,O,B
coding,O,I
sequence,O,I
is,O,O
huge,O,O
",",O,O
composed,O,O
of,O,O
26,O,O
exons,O,O
that,O,O
span,O,O
10,O,O
",",O,O
443,O,O
bp,O,O
.,O,O
Here,O,O
we,O,O
investigate,O,O
the,O,O
rate,O,O
of,O,O
BRCA2,O,B
mutation,O,O
in,O,O
sporadic,B,B
breast,I,I
cancers,I,I
and,O,O
in,O,O
a,O,O
set,O,O
of,O,O
cell,O,O
lines,O,O
that,O,O
represent,O,O
twelve,O,O
other,O,O
tumour,B,O
types,O,O
.,O,O
Surprisingly,O,O
",",O,O
mutations,O,O
in,O,O
BRCA2,O,B
are,O,O
infrequent,O,O
in,O,O
cancers,B,O
including,O,O
breast,B,B
carcinoma,I,I
.,O,O
However,O,O
",",O,O
a,O,O
probable,O,O
germline,O,O
mutation,O,O
in,O,O
a,O,O
pancreatic,B,B
tumour,I,I
cell,O,I
line,O,I
suggests,O,O
a,O,O
role,O,O
for,O,O
BRCA2,O,B
in,O,O
susceptibility,O,O
to,O,O
pancreatic,B,B
cancer,I,I
.,O,O
.,O,O
Founding,O,O
BRCA1,O,O
mutations,O,O
in,O,O
hereditary,B,O
breast,I,B
and,I,O
ovarian,I,B
cancer,I,I
in,O,O
southern,O,O
Sweden,O,O
.,O,O
Nine,O,O
different,O,O
germ,O,O
-,O,O
line,O,O
mutations,O,O
in,O,O
the,O,O
BRCA1,O,O
breast,B,B
and,I,O
ovarian,I,B
cancer,I,I
susceptibility,O,I
gene,O,I
were,O,O
identified,O,O
in,O,O
15,O,O
of,O,O
47,O,O
kindreds,O,O
from,O,O
southern,O,O
Sweden,O,O
",",O,O
by,O,O
use,O,O
of,O,O
SSCP,O,O
and,O,O
heteroduplex,O,O
analysis,O,O
of,O,O
all,O,O
exons,O,O
and,O,O
flanking,O,O
intron,O,O
region,O,O
and,O,O
by,O,O
a,O,O
protein,O,O
-,O,O
truncation,O,O
test,O,O
for,O,O
exon,O,O
11,O,O
",",O,O
followed,O,O
by,O,O
direct,O,O
sequencing,O,O
.,O,O
All,O,O
but,O,O
one,O,O
of,O,O
the,O,O
mutations,O,O
are,O,O
predicted,O,O
to,O,O
give,O,O
rise,O,O
to,O,O
premature,O,O
translation,O,O
termination,O,O
and,O,O
include,O,O
seven,O,O
frameshift,O,O
insertions,O,O
or,O,O
deletions,O,O
",",O,O
a,O,O
nonsense,O,O
mutation,O,O
",",O,O
and,O,O
a,O,O
splice,O,O
acceptor,O,O
site,O,O
mutation,O,O
.,O,O
The,O,O
remaining,O,O
mutation,O,O
is,O,O
a,O,O
missense,O,O
mutation,O,O
(,O,O
Cys61Gly,O,O
),O,O
in,O,O
the,O,O
zinc,O,B
-,O,I
binding,O,I
motif,O,I
.,O,O
Four,O,O
novel,O,O
Swedish,O,O
founding,O,O
mutations,O,O
were,O,O
identified,O,O
the,O,O
nucleotide,O,O
2595,O,O
deletion,O,O
A,O,O
was,O,O
found,O,O
in,O,O
five,O,O
families,O,O
",",O,O
the,O,O
C,O,O
1806,O,O
T,O,O
nonsense,O,O
mutation,O,O
in,O,O
three,O,O
families,O,O
",",O,O
the,O,O
3166,O,O
insertion,O,O
TGAGA,O,O
in,O,O
three,O,O
families,O,O
",",O,O
and,O,O
the,O,O
nucleotide,O,O
1201,O,O
deletion,O,O
11,O,O
in,O,O
two,O,O
families,O,O
.,O,O
Analysis,O,O
of,O,O
the,O,O
intragenic,O,O
polymorphism,O,O
D17S855,O,O
supports,O,O
common,O,O
origins,O,O
of,O,O
the,O,O
mutations,O,O
.,O,O
Eleven,O,O
of,O,O
the,O,O
15,O,O
kindreds,O,O
manifesting,O,O
BRCA1,O,O
mutations,O,O
were,O,O
breast,B,B
-,I,I
ovarian,I,I
cancer,I,I
families,O,O
",",O,O
several,O,O
of,O,O
them,O,O
with,O,O
a,O,O
predominant,O,O
ovarian,B,B
cancer,I,I
phenotype,O,O
.,O,O
The,O,O
set,O,O
of,O,O
32,O,O
families,O,O
in,O,O
which,O,O
no,O,O
BRCA1,O,O
alterations,O,O
were,O,O
detected,O,O
included,O,O
1,O,O
breast,B,B
-,I,I
ovarian,I,I
cancer,I,I
kindred,O,O
manifesting,O,O
clear,O,O
linkage,O,O
to,O,O
the,O,O
BRCA1,O,O
region,O,O
and,O,O
loss,O,O
of,O,O
the,O,O
wild,O,O
-,O,O
type,O,O
chromosome,O,O
in,O,O
associated,O,O
tumors,B,O
.,O,O
Other,O,O
tumor,B,B
types,O,I
found,O,O
in,O,O
BRCA1,O,O
mutation,O,O
/,O,O
haplotype,O,O
carriers,O,O
included,O,O
prostatic,B,B
",",I,O
pancreas,I,B
",",I,O
skin,I,B
",",I,O
and,I,O
lung,I,B
cancer,I,I
",",O,O
a,O,O
malignant,B,B
melanoma,I,I
",",O,O
an,O,O
oligodendroglioma,B,B
",",O,O
and,O,O
a,O,O
carcinosarcoma,B,B
.,O,O
In,O,O
all,O,O
",",O,O
12,O,O
of,O,O
16,O,O
kindreds,O,O
manifesting,O,O
BRCA1,O,O
mutation,O,O
or,O,O
linkage,O,O
contained,O,O
ovarian,B,B
cancer,I,I
",",O,O
as,O,O
compared,O,O
with,O,O
only,O,O
6,O,O
of,O,O
the,O,O
remaining,O,O
31,O,O
families,O,O
(,O,O
P,O,O
<,O,O
.,O,O
),O,O
.,O,O
The,O,O
present,O,O
study,O,O
confirms,O,O
the,O,O
involvement,O,O
of,O,O
BRCA1,O,O
in,O,O
disease,O,O
predisposition,O,O
for,O,O
a,O,O
subset,O,O
of,O,O
hereditary,B,O
breast,I,B
cancer,I,I
families,O,O
often,O,O
characterized,O,O
by,O,O
ovarian,B,B
cancers,I,I
.,O,O
Rapid,O,O
detection,O,O
of,O,O
regionally,O,O
clustered,O,O
germ,O,O
-,O,O
line,O,O
BRCA1,O,O
mutations,O,O
by,O,O
multiplex,O,O
heteroduplex,O,O
analysis,O,O
.,O,O
UKCCCR,O,O
Familial,O,O
Ovarian,B,B
Cancer,I,I
Study,O,I
Group,O,I
.,O,O
Germ,O,O
-,O,O
line,O,O
mutations,O,O
of,O,O
the,O,O
BRCA1,O,O
gene,O,O
are,O,O
responsible,O,O
for,O,O
a,O,O
substantial,O,O
proportion,O,O
of,O,O
families,O,O
with,O,O
multiple,O,O
cases,O,O
of,O,O
early,O,O
-,O,O
onset,O,O
breast,B,B
and,I,O
/,I,O
or,I,O
ovarian,I,B
cancer,I,I
.,O,O
Since,O,O
the,O,O
isolation,O,O
of,O,O
BRCA1,O,O
last,O,O
year,O,O
",",O,O
>,O,O
65,O,O
distinct,O,O
mutations,O,O
scattered,O,O
throughout,O,O
the,O,O
coding,O,O
region,O,O
have,O,O
been,O,O
detected,O,O
",",O,O
making,O,O
analysis,O,O
of,O,O
the,O,O
gene,O,O
time,O,O
consuming,O,O
and,O,O
technically,O,O
challenging,O,O
.,O,O
We,O,O
have,O,O
developed,O,O
a,O,O
multiplex,O,O
heteroduplex,O,O
analysis,O,O
that,O,O
is,O,O
designed,O,O
to,O,O
analyze,O,O
one,O,O
-,O,O
quarter,O,O
of,O,O
the,O,O
coding,O,O
sequence,O,O
in,O,O
a,O,O
single,O,O
-,O,O
step,O,O
screening,O,O
procedure,O,O
and,O,O
that,O,O
will,O,O
detect,O,O
approximately,O,O
50,O,O
%,O,O
of,O,O
all,O,O
BRCA1,O,B
mutations,O,O
so,O,O
far,O,O
reported,O,O
in,O,O
breast,B,O
/,I,O
ovarian,I,O
cancer,I,O
families,O,O
.,O,O
We,O,O
have,O,O
used,O,O
this,O,O
technique,O,O
to,O,O
analyze,O,O
BRCA1,O,B
in,O,O
162,O,O
families,O,O
with,O,O
a,O,O
history,O,O
of,O,O
breast,B,O
and,I,O
/,I,O
or,I,O
ovarian,I,O
cancer,I,O
and,O,O
identified,O,O
12,O,O
distinct,O,O
mutations,O,O
in,O,O
35,O,O
families,O,O
.,O,O
.,O,O
A,O,O
previously,O,O
undescribed,O,O
mutation,O,O
within,O,O
the,O,O
tetramerisation,O,O
domain,O,O
of,O,O
TP53,O,B
in,O,O
a,O,O
family,O,O
with,O,O
Li,B,B
-,I,I
Fraumeni,I,I
syndrome,I,I
.,O,O
We,O,O
report,O,O
details,O,O
of,O,O
a,O,O
family,O,O
with,O,O
classic,O,O
Li,B,B
-,I,I
Fraumeni,I,I
syndrome,I,I
in,O,O
which,O,O
there,O,O
is,O,O
a,O,O
mutation,O,O
in,O,O
codon,O,O
344,O,O
of,O,O
the,O,O
tumour,B,B
suppressor,O,I
gene,O,I
TP53,O,I
.,O,O
Codon,O,O
344,O,O
is,O,O
a,O,O
key,O,O
residue,O,O
within,O,O
the,O,O
tetramerisation,O,O
domain,O,O
",",O,O
and,O,O
the,O,O
amino,O,O
acid,O,O
substitution,O,O
of,O,O
a,O,O
proline,O,O
for,O,O
a,O,O
leucine,O,O
is,O,O
predicted,O,O
to,O,O
have,O,O
profound,O,O
implications,O,O
for,O,O
tetramerisation,O,O
and,O,O
potentially,O,O
DNA,O,O
binding,O,O
.,O,O
This,O,O
is,O,O
the,O,O
first,O,O
report,O,O
of,O,O
a,O,O
mutation,O,O
at,O,O
this,O,O
residue,O,O
in,O,O
either,O,O
sporadic,B,B
tumours,I,I
or,O,O
in,O,O
the,O,O
germline,O,O
and,O,O
the,O,O
first,O,O
report,O,O
of,O,O
a,O,O
germline,O,O
mutation,O,O
within,O,O
the,O,O
tetramerisation,O,O
domain,O,O
.,O,O
The,O,O
family,O,O
does,O,O
not,O,O
appear,O,O
to,O,O
be,O,O
remarkable,O,O
in,O,O
the,O,O
spectrum,O,O
of,O,O
tumours,B,O
",",O,O
and,O,O
there,O,O
is,O,O
loss,O,O
of,O,O
the,O,O
wild,O,O
-,O,O
type,O,O
allele,O,O
in,O,O
a,O,O
leiomyosarcoma,B,B
from,O,O
the,O,O
proband,O,O
.,O,O
A,O,O
cell,O,O
line,O,O
has,O,O
been,O,O
established,O,O
from,O,O
the,O,O
tumour,B,B
of,O,O
the,O,O
proband,O,O
and,O,O
cytogenetic,O,O
and,O,O
molecular,O,O
studies,O,O
carried,O,O
out,O,O
",",O,O
providing,O,O
an,O,O
extensive,O,O
analysis,O,O
in,O,O
this,O,O
family,O,O
.,O,O
The,O,O
spectrum,O,O
of,O,O
RB1,O,B
germ,O,I
-,O,I
line,O,I
mutations,O,O
in,O,O
hereditary,B,B
retinoblastoma,I,I
.,O,O
We,O,O
have,O,O
searched,O,O
for,O,O
germ,O,I
-,O,I
line,O,I
RB1,O,B
mutations,O,O
in,O,O
119,O,O
patients,O,O
with,O,O
hereditary,B,B
retinoblastoma,I,I
.,O,O
Previous,O,O
investigations,O,O
by,O,O
Southern,O,O
blot,O,O
hybridization,O,O
and,O,O
PCR,O,O
fragment,O,O
-,O,O
length,O,O
analysis,O,O
had,O,O
revealed,O,O
mutations,O,O
in,O,O
48,O,O
patients,O,O
.,O,O
Here,O,O
we,O,O
report,O,O
on,O,O
the,O,O
analysis,O,O
of,O,O
the,O,O
remaining,O,O
71,O,O
patients,O,O
.,O,O
By,O,O
applying,O,O
heteroduplex,O,O
analysis,O,O
",",O,O
nonisotopic,O,O
SSCP,O,O
",",O,O
and,O,O
direct,O,O
sequencing,O,O
",",O,O
we,O,O
detected,O,O
germ,O,O
-,O,O
line,O,O
mutations,O,O
resulting,O,O
in,O,O
premature,O,O
termination,O,O
codons,O,O
or,O,O
disruption,O,O
of,O,O
splice,O,O
signals,O,O
in,O,O
51,O,O
(,O,O
72,O,O
%,O,O
),O,O
of,O,O
the,O,O
71,O,O
patients,O,O
.,O,O
Four,O,O
patients,O,O
also,O,O
showed,O,O
rare,O,O
sequence,O,O
variants,O,O
.,O,O
No,O,O
region,O,O
of,O,O
the,O,O
RB1,O,B
gene,O,I
was,O,O
preferentially,O,O
involved,O,O
in,O,O
single,O,O
base,O,O
substitutions,O,O
.,O,O
Recurrent,O,O
transitions,O,O
were,O,O
observed,O,O
at,O,O
most,O,O
of,O,O
the,O,O
14,O,O
codons,O,O
within,O,O
the,O,O
RB1,O,B
.,O,O
No,O,O
mutation,O,O
was,O,O
observed,O,O
in,O,O
exons,O,O
25,O,O
-,O,O
27,O,O
",",O,O
although,O,O
this,O,O
region,O,O
contains,O,O
two,O,O
CGA,O,O
codons,O,O
.,O,O
This,O,O
suggests,O,O
that,O,O
mutations,O,O
within,O,O
the,O,O
3,O,O
-,O,O
terminal,O,O
region,O,O
of,O,O
the,O,O
RB1,O,B
gene,O,I
may,O,O
not,O,O
be,O,O
oncogenic,O,O
.,O,O
When,O,O
these,O,O
data,O,O
were,O,O
combined,O,O
with,O,O
the,O,O
results,O,O
of,O,O
our,O,O
previous,O,O
investigations,O,O
",",O,O
mutations,O,O
were,O,O
identified,O,O
in,O,O
a,O,O
total,O,O
of,O,O
99,O,O
(,O,O
83,O,O
%,O,O
),O,O
of,O,O
119,O,O
patients,O,O
.,O,O
The,O,O
spectrum,O,O
comprises,O,O
15,O,O
%,O,O
large,O,O
deletions,O,O
",",O,O
26,O,O
%,O,O
small,O,O
length,O,O
alterations,O,O
",",O,O
and,O,O
42,O,O
%,O,O
base,O,O
substitutions,O,O
.,O,O
No,O,O
correlation,O,O
between,O,O
the,O,O
location,O,O
of,O,O
frameshift,O,O
or,O,O
nonsense,O,O
mutations,O,O
and,O,O
phenotypic,O,O
features,O,O
",",O,O
including,O,O
age,O,O
at,O,O
diagnosis,O,O
",",O,O
the,O,O
number,O,O
of,O,O
tumor,B,O
foci,O,O
",",O,O
and,O,O
manifestation,O,O
of,O,O
nonocular,B,O
tumors,I,O
was,O,O
observed,O,O
.,O,O
Phenotypic,O,O
characterization,O,O
of,O,O
individuals,O,O
with,O,O
30,O,O
-,O,O
40,O,O
CAG,O,O
repeats,O,O
in,O,O
the,O,O
Huntington,B,B
disease,I,I
(,O,O
HD,B,O
),O,O
gene,O,O
reveals,O,O
HD,B,B
cases,O,O
with,O,O
36,O,O
repeats,O,O
and,O,O
apparently,O,O
normal,O,O
elderly,O,O
individuals,O,O
with,O,O
36,O,O
-,O,O
39,O,O
repeats,O,O
.,O,O
Abnormal,O,O
CAG,O,B
expansions,O,I
in,O,O
the,O,O
IT,O,B
-,O,I
15,O,I
gene,O,I
are,O,O
associated,O,O
with,O,O
Huntington,B,B
disease,I,I
(,O,O
HD,B,B
),O,O
.,O,O
In,O,O
the,O,O
diagnostic,O,O
setting,O,O
it,O,O
is,O,O
necessary,O,O
to,O,O
define,O,O
the,O,O
limits,O,O
of,O,O
the,O,O
CAG,O,B
size,O,I
ranges,O,I
on,O,O
normal,O,O
and,O,O
HD,B,B
-,O,I
associated,O,I
chromosomes,O,I
.,O,O
Most,O,O
large,O,O
analyses,O,O
that,O,O
defined,O,O
the,O,O
limits,O,O
of,O,O
the,O,O
normal,O,O
and,O,O
pathological,O,O
size,O,O
ranges,O,O
employed,O,O
PCR,O,O
assays,O,O
",",O,O
which,O,O
included,O,O
the,O,O
CAG,O,B
repeats,O,I
and,O,O
a,O,O
CCG,O,O
repeat,O,O
tract,O,O
that,O,O
was,O,O
thought,O,O
to,O,O
be,O,O
invariant,O,O
.,O,O
Many,O,O
of,O,O
these,O,O
experiments,O,O
found,O,O
an,O,O
overlap,O,O
between,O,O
the,O,O
normal,O,O
and,O,O
disease,O,O
size,O,O
ranges,O,O
.,O,O
Subsequent,O,O
findings,O,O
that,O,O
the,O,O
CCG,O,B
repeats,O,I
vary,O,O
by,O,O
8,O,O
trinucleotide,O,O
lengths,O,O
suggested,O,O
that,O,O
the,O,O
limits,O,O
of,O,O
the,O,O
normal,O,O
and,O,O
disease,O,O
size,O,O
ranges,O,O
should,O,O
be,O,O
reevaluated,O,O
with,O,O
assays,O,O
that,O,O
exclude,O,O
the,O,O
CCG,O,B
polymorphism,O,I
.,O,O
Since,O,O
patients,O,O
with,O,O
between,O,O
30,O,O
and,O,O
40,O,O
repeats,O,O
are,O,O
rare,O,O
",",O,O
a,O,O
consortium,O,O
was,O,O
assembled,O,O
to,O,O
collect,O,O
such,O,O
individuals,O,O
.,O,O
All,O,O
178,O,O
samples,O,O
were,O,O
reanalyzed,O,O
in,O,O
Cambridge,O,O
by,O,O
using,O,O
assays,O,O
specific,O,O
for,O,O
the,O,O
CAG,O,B
repeats,O,I
.,O,O
We,O,O
have,O,O
optimized,O,O
methods,O,O
for,O,O
reliable,O,O
sizing,O,O
of,O,O
CAG,O,B
repeats,O,I
and,O,O
show,O,O
cases,O,O
that,O,O
demonstrate,O,O
the,O,O
dangers,O,O
of,O,O
using,O,O
PCR,O,O
assays,O,O
that,O,O
include,O,O
both,O,O
the,O,O
CAG,O,B
and,O,O
CCG,O,B
polymorphisms,O,I
.,O,O
Seven,O,O
HD,B,O
patients,O,O
had,O,O
36,O,O
repeats,O,O
",",O,O
which,O,O
confirms,O,O
that,O,O
this,O,O
allele,O,O
is,O,O
associated,O,O
with,O,O
disease,O,O
.,O,O
Individuals,O,O
without,O,O
apparent,O,O
symptoms,O,O
or,O,O
signs,O,O
of,O,O
HD,B,O
were,O,O
found,O,O
at,O,O
36,O,O
repeats,O,O
(,O,O
aged,O,O
74,O,O
",",O,O
78,O,O
",",O,O
79,O,O
",",O,O
and,O,O
87,O,O
years,O,O
),O,O
",",O,O
37,O,O
repeats,O,O
(,O,O
aged,O,O
69,O,O
years,O,O
),O,O
",",O,O
38,O,O
repeats,O,O
(,O,O
aged,O,O
69,O,O
and,O,O
90,O,O
years,O,O
),O,O
",",O,O
and,O,O
39,O,O
repeats,O,O
(,O,O
aged,O,O
67,O,O
",",O,O
90,O,O
",",O,O
and,O,O
95,O,O
years,O,O
),O,O
.,O,O
The,O,O
detailed,O,O
case,O,O
histories,O,O
of,O,O
an,O,O
exceptional,O,O
case,O,O
from,O,O
this,O,O
series,O,O
will,O,O
be,O,O
presented,O,O
a,O,O
95,O,O
-,O,O
year,O,O
-,O,O
old,O,O
man,O,O
with,O,O
39,O,O
repeats,O,O
who,O,O
did,O,O
not,O,O
have,O,O
classical,O,O
features,O,O
of,O,O
HD,B,O
.,O,O
The,O,O
apparently,O,O
healthy,O,O
survival,O,O
into,O,O
old,O,O
age,O,O
of,O,O
some,O,O
individuals,O,O
with,O,O
36,O,O
-,O,O
39,O,O
repeats,O,O
suggests,O,O
that,O,O
the,O,O
HD,B,B
mutation,O,I
may,O,O
not,O,O
always,O,O
be,O,O
fully,O,O
penetrant,O,O
.,O,O
Identification,O,O
and,O,O
expression,O,O
of,O,O
eight,O,O
novel,O,O
mutations,O,O
among,O,O
non,O,O
-,O,O
Jewish,O,O
patients,O,O
with,O,O
Canavan,B,B
disease,I,I
.,O,O
Canavan,B,B
disease,I,I
is,O,O
inherited,O,O
as,O,O
an,O,O
autosomal,O,O
recessive,O,O
trait,O,O
that,O,O
is,O,O
caused,O,O
by,O,O
the,O,O
deficiency,B,O
of,I,O
aspartoacylase,I,O
(,O,O
ASPA,O,O
),O,O
.,O,O
The,O,O
majority,O,O
of,O,O
patients,O,O
with,O,O
Canavan,B,B
disease,I,I
are,O,O
from,O,O
an,O,O
Ashkenazi,O,O
Jewish,O,O
background,O,O
.,O,O
Mutations,O,O
in,O,O
ASPA,O,B
that,O,O
lead,O,O
to,O,O
loss,O,O
of,O,O
enzymatic,O,O
activity,O,O
have,O,O
been,O,O
identified,O,O
",",O,O
and,O,O
E285A,O,B
and,O,O
Y231X,O,B
are,O,O
the,O,O
two,O,O
predominant,O,O
mutations,O,O
that,O,O
account,O,O
for,O,O
97,O,O
%,O,O
of,O,O
the,O,O
mutant,O,O
chromosomes,O,O
in,O,O
Ashkenazi,O,O
Jewish,O,O
patients,O,O
.,O,O
The,O,O
current,O,O
study,O,O
was,O,O
aimed,O,O
at,O,O
finding,O,O
the,O,O
molecular,O,O
basis,O,O
of,O,O
Canavan,B,B
disease,I,I
in,O,O
25,O,O
independent,O,O
patients,O,O
of,O,O
non,O,O
-,O,O
Jewish,O,O
background,O,O
.,O,O
Eight,O,O
novel,O,O
and,O,O
three,O,O
previously,O,O
characterized,O,O
mutations,O,O
accounted,O,O
for,O,O
80,O,O
%,O,O
(,O,O
40,O,O
/,O,O
50,O,O
),O,O
of,O,O
mutant,O,O
chromosomes,O,O
.,O,O
The,O,O
A305E,O,O
missense,O,O
mutation,O,O
accounted,O,O
for,O,O
48,O,O
%,O,O
(,O,O
24,O,O
/,O,O
50,O,O
),O,O
of,O,O
mutant,O,O
chromosomes,O,O
in,O,O
patients,O,O
of,O,O
western,O,O
European,O,O
descent,O,O
",",O,O
while,O,O
the,O,O
two,O,O
predominant,O,O
Jewish,O,O
mutations,O,O
each,O,O
accounted,O,O
for,O,O
a,O,O
single,O,O
mutant,O,O
chromosome,O,O
.,O,O
The,O,O
eight,O,O
novel,O,O
mutations,O,O
identified,O,O
included,O,O
1,O,O
-,O,O
and,O,O
4,O,O
-,O,O
bp,O,O
deletions,O,O
(,O,O
32,O,O
deltaT,O,O
and,O,O
876,O,O
deltaAGAA,O,O
",",O,O
respectively,O,O
),O,O
and,O,O
I16T,O,O
",",O,O
G27R,O,O
",",O,O
D114E,O,O
",",O,O
G123E,O,O
",",O,O
C152Y,O,O
",",O,O
and,O,O
R168C,O,O
missense,O,O
mutations,O,O
.,O,O
The,O,O
homozygous,O,O
32,O,O
deltaT,O,O
deletion,O,O
was,O,O
identified,O,O
in,O,O
the,O,O
only,O,O
known,O,O
patient,O,O
of,O,O
African,O,O
-,O,O
American,O,O
origin,O,O
with,O,O
Canavan,B,B
disease,I,I
.,O,O
The,O,O
heterozygosity,O,O
for,O,O
876,O,O
deltaAGAA,O,O
mutation,O,O
was,O,O
identified,O,O
in,O,O
three,O,O
independent,O,O
patients,O,O
from,O,O
England,O,O
.,O,O
Six,O,O
single,O,O
-,O,O
base,O,O
changes,O,O
leading,O,O
to,O,O
missense,O,O
mutations,O,O
were,O,O
identified,O,O
in,O,O
patients,O,O
from,O,O
Turkey,O,O
(,O,O
D114E,O,B
",",O,O
R168C,O,B
),O,O
",",O,O
The,O,O
Netherlands,O,O
(,O,O
I16T,O,B
),O,O
",",O,O
Germany,O,O
(,O,O
G27R,O,B
),O,O
",",O,O
Ireland,O,O
(,O,O
C152Y,O,B
),O,O
",",O,O
and,O,O
Canada,O,O
(,O,O
G123E,O,B
),O,O
.,O,O
A,O,O
PCR,O,O
-,O,O
based,O,O
protocol,O,O
is,O,O
described,O,O
that,O,O
was,O,O
used,O,O
to,O,O
introduce,O,O
mutations,O,O
in,O,O
wild,O,O
-,O,O
type,O,O
cDNA,O,O
.,O,O
In,O,O
vitro,O,O
expression,O,O
of,O,O
mutant,O,O
cDNA,O,O
clones,O,O
demonstrated,O,O
that,O,O
all,O,O
of,O,O
these,O,O
mutations,O,O
led,O,O
to,O,O
a,O,O
deficiency,B,O
of,I,O
ASPA,I,O
and,O,O
should,O,O
therefore,O,O
result,O,O
in,O,O
Canavan,B,B
disease,I,I
.,O,O
Identification,O,O
and,O,O
chromosomal,O,O
localization,O,O
of,O,O
Atm,O,B
",",O,O
the,O,O
mouse,O,O
homolog,O,O
of,O,O
the,O,O
ataxia,B,B
-,I,I
telangiectasia,I,I
gene,O,I
.,O,O
Atm,O,B
",",O,O
the,O,O
mouse,O,O
homolog,O,O
of,O,O
the,O,O
human,O,O
ATM,O,O
gene,O,O
defective,O,O
in,O,O
ataxia,B,B
-,I,I
telangiectasia,I,I
(,O,O
A,B,B
-,I,I
T,I,I
),O,O
",",O,O
has,O,O
been,O,O
identified,O,O
.,O,O
The,O,O
entire,O,O
coding,O,O
sequence,O,O
of,O,O
the,O,O
Atm,O,B
transcript,O,O
was,O,O
cloned,O,O
and,O,O
found,O,O
to,O,O
contain,O,O
an,O,O
open,O,O
reading,O,O
frame,O,O
encoding,O,O
a,O,O
protein,O,O
of,O,O
3066,O,O
amino,O,O
acids,O,O
with,O,O
84,O,O
%,O,O
overall,O,O
identity,O,O
and,O,O
91,O,O
%,O,O
similarity,O,O
to,O,O
the,O,O
human,O,O
ATM,O,O
protein,O,O
.,O,O
Variable,O,O
levels,O,O
of,O,O
expression,O,O
of,O,O
Atm,O,B
were,O,O
observed,O,O
in,O,O
different,O,O
tissues,O,O
.,O,O
Fluorescence,O,O
in,O,O
situ,O,O
hybridization,O,O
and,O,O
linkage,O,O
analysis,O,O
located,O,O
the,O,O
Atm,O,B
gene,O,O
on,O,O
mouse,O,O
chromosome,O,O
9,O,O
",",O,O
band,O,O
9C,O,O
",",O,O
in,O,O
a,O,O
region,O,O
homologous,O,O
to,O,O
the,O,O
ATM,O,O
region,O,O
on,O,O
human,O,O
chromosome,O,O
11q22,O,O
-,O,O
q23,O,O
.,O,O
The,O,O
mouse,O,O
homolog,O,O
of,O,O
the,O,O
Wiskott,B,O
-,I,O
Aldrich,I,O
syndrome,I,O
protein,O,O
(,O,O
WASP,O,O
),O,O
gene,O,O
is,O,O
highly,O,O
conserved,O,O
and,O,O
maps,O,O
near,O,O
the,O,O
scurfy,O,O
(,O,O
sf,O,O
),O,O
mutation,O,O
on,O,O
the,O,O
X,O,O
chromosome,O,O
.,O,O
The,O,O
mouse,O,O
WASP,O,B
gene,O,O
",",O,O
the,O,O
homolog,O,O
of,O,O
the,O,O
gene,O,O
mutated,O,O
in,O,O
Wiskott,B,B
-,I,I
Aldrich,I,I
syndrome,I,I
",",O,O
has,O,O
been,O,O
isolated,O,O
and,O,O
sequenced,O,O
.,O,O
the,O,O
predicted,O,O
amino,O,O
acid,O,O
sequence,O,O
is,O,O
86,O,O
%,O,O
identical,O,O
to,O,O
the,O,O
human,O,O
WASP,O,B
sequence,O,O
.,O,O
A,O,O
distinct,O,O
feature,O,O
of,O,O
the,O,O
mouse,O,O
gene,O,O
is,O,O
an,O,O
expanded,O,O
polymorphic,O,O
GGA,O,O
trinucleotide,O,O
repeat,O,O
that,O,O
codes,O,O
for,O,O
polyglycine,O,O
and,O,O
varies,O,O
from,O,O
15,O,O
to,O,O
17,O,O
triplets,O,O
in,O,O
different,O,O
Mus,O,O
musculus,O,O
strains,O,O
.,O,O
The,O,O
genomic,O,O
structure,O,O
of,O,O
the,O,O
mouse,O,B
WASP,O,I
gene,O,O
is,O,O
expressed,O,O
as,O,O
an,O,O
approximately,O,O
2,O,O
.,O,O
4,O,O
-,O,O
kb,O,O
mRNA,O,O
in,O,O
thymus,O,O
and,O,O
spleen,O,O
.,O,O
Chromosomal,O,O
mapping,O,O
in,O,O
an,O,O
interspecific,O,O
M,O,O
.,O,O
Musculus,O,O
/,O,O
M,O,O
.,O,O
spretus,O,O
backcross,O,O
placed,O,O
the,O,O
Wasp,O,B
locus,O,O
near,O,O
the,O,O
centromere,O,O
of,O,O
the,O,O
mouse,O,B
X,O,I
chromosome,O,I
",",O,O
inseparable,O,O
from,O,O
Gata1,O,O
",",O,O
Tcfe3,O,O
",",O,O
and,O,O
scurfy,O,O
(,O,O
sf,O,O
),O,O
.,O,O
This,O,O
localization,O,O
makes,O,O
Wasp,O,B
a,O,O
candidate,O,O
for,O,O
involvement,O,O
in,O,O
scurfy,O,O
",",O,O
a,O,O
T,O,B
cell,O,I
-,O,I
mediated,O,I
fatal,B,O
lymphoreticular,I,O
disease,I,O
of,O,O
mice,O,O
that,O,O
has,O,O
previously,O,O
been,O,O
proposed,O,O
as,O,O
a,O,O
mouse,O,O
homolog,O,O
of,O,O
Wiskott,B,B
-,I,I
Aldrich,I,I
syndrome,I,I
.,O,O
Northern,O,O
analysis,O,O
of,O,O
sf,O,O
tissue,O,O
samples,O,O
indicated,O,O
the,O,O
presence,O,O
of,O,O
WASP,O,B
mRNA,O,O
in,O,O
liver,O,O
and,O,O
skin,O,O
",",O,O
presumably,O,O
as,O,O
a,O,O
consequence,O,O
of,O,O
lymphocytic,O,O
infiltration,O,O
",",O,O
but,O,O
non,O,O
abnormalities,O,O
in,O,O
the,O,O
amount,O,O
or,O,O
size,O,O
of,O,O
mRNA,O,O
present,O,O
.,O,O
Colchicine,O,O
in,O,O
breast,O,B
milk,O,I
of,O,O
patients,O,O
with,O,O
familial,B,B
Mediterranean,I,I
fever,I,I
.,O,O
OBJECTIVE,O,O
.,O,O
To,O,O
clarify,O,O
whether,O,O
colchicine,O,O
is,O,O
excreted,O,O
in,O,O
breast,O,B
milk,O,I
",",O,O
and,O,O
to,O,O
compare,O,O
its,O,O
concentrations,O,O
in,O,O
the,O,O
serum,O,O
and,O,O
breast,O,B
milk,O,I
of,O,O
lactating,O,O
women,O,O
who,O,O
have,O,O
familial,B,B
Mediterranean,I,I
fever,I,I
(,O,O
FMF,B,O
),O,O
.,O,O
METHODS,O,O
.,O,O
Using,O,O
a,O,O
specific,O,O
radioimmunoassay,O,O
",",O,O
we,O,O
determined,O,O
colchicine,O,O
concentrations,O,O
in,O,O
the,O,O
serum,O,O
and,O,O
breast,O,B
milk,O,I
of,O,O
4,O,O
patients,O,O
at,O,O
various,O,O
time,O,O
points,O,O
",",O,O
following,O,O
oral,O,O
administration,O,O
of,O,O
the,O,O
drug,O,O
.,O,O
The,O,O
study,O,O
evaluated,O,O
4,O,O
patients,O,O
with,O,O
FMF,B,B
who,O,O
had,O,O
been,O,O
taking,O,O
colchicine,O,O
on,O,O
a,O,O
long,O,O
-,O,O
term,O,O
basis,O,O
.,O,O
RESULTS,O,O
.,O,O
Colchicine,O,O
was,O,O
found,O,O
to,O,O
be,O,O
excreted,O,O
in,O,O
breast,O,B
milk,O,I
.,O,O
Its,O,O
levels,O,O
ranged,O,O
between,O,O
1,O,O
.,O,O
9,O,O
and,O,O
8,O,O
.,O,O
6,O,O
ng,O,O
/,O,O
ml,O,O
",",O,O
which,O,O
were,O,O
similar,O,O
to,O,O
those,O,O
found,O,O
in,O,O
the,O,O
serum,O,O
(,O,O
parallel,O,O
concentration,O,O
time,O,O
curves,O,O
),O,O
.,O,O
However,O,O
",",O,O
there,O,O
appeared,O,O
to,O,O
be,O,O
a,O,O
considerable,O,O
variation,O,O
in,O,O
colchicine,O,O
milk,O,B
concentration,O,I
among,O,O
the,O,O
different,O,O
patients,O,O
",",O,O
which,O,O
might,O,O
be,O,O
related,O,O
to,O,O
individual,O,O
breast,O,B
milk,O,I
composition,O,I
and,O,O
",",O,O
possibly,O,O
",",O,O
to,O,O
other,O,O
nutritional,O,O
or,O,O
metabolic,O,O
factors,O,O
.,O,O
CONCLUSION,O,O
.,O,O
The,O,O
extensive,O,O
peripheral,O,O
tissue,O,O
binding,O,O
and,O,O
relatively,O,O
low,O,O
concentration,O,O
of,O,O
colchicine,O,O
in,O,O
breast,O,B
milk,O,I
suggests,O,O
that,O,O
the,O,O
amount,O,O
ingested,O,O
by,O,O
the,O,O
infant,O,O
is,O,O
small,O,O
.,O,O
Furthermore,O,O
",",O,O
based,O,O
on,O,O
our,O,O
clinical,O,O
experience,O,O
",",O,O
nursing,O,O
appears,O,O
to,O,O
be,O,O
safe,O,O
for,O,O
lactating,O,O
women,O,O
with,O,O
FMF,B,O
who,O,O
continue,O,O
to,O,O
take,O,O
colchicine,O,O
.,O,O
Abnormal,O,O
myotonic,B,B
dystrophy,I,I
protein,O,I
kinase,O,I
levels,O,O
produce,O,O
only,O,O
mild,O,O
myopathy,B,O
in,O,O
mice,O,O
.,O,O
Myotonic,B,B
dystrophy,I,I
(,O,O
DM,B,B
),O,O
is,O,O
commonly,O,O
associated,O,O
with,O,O
CTG,O,O
repeat,O,O
expansions,O,O
within,O,O
the,O,O
gene,O,O
for,O,O
DM,O,B
-,O,I
protein,O,I
kinase,O,I
(,O,O
DMPK,O,B
),O,O
.,O,O
The,O,O
effect,O,O
of,O,O
altered,O,O
expression,O,O
levels,O,O
of,O,O
DMPK,O,B
",",O,O
which,O,O
is,O,O
ubiquitously,O,O
expressed,O,O
in,O,O
all,O,O
muscle,O,O
cell,O,O
lineages,O,O
during,O,O
development,O,O
",",O,O
was,O,O
examined,O,O
by,O,O
disrupting,O,O
the,O,O
endogenous,O,O
Dmpk,O,B
gene,O,I
and,O,O
overexpressing,O,O
a,O,O
normal,O,O
human,O,O
DMPK,O,B
transgene,O,I
in,O,O
mice,O,O
.,O,O
Nullizygous,O,O
(,O,O
-,O,O
/,O,O
-,O,O
),O,O
mice,O,O
showed,O,O
only,O,O
inconsistent,O,O
and,O,O
minor,O,O
size,O,O
changes,O,O
in,O,O
head,O,O
and,O,O
neck,O,O
muscle,O,O
fibres,O,O
at,O,O
older,O,O
age,O,O
",",O,O
animals,O,O
with,O,O
the,O,O
highest,O,O
DMPK,O,B
transgene,O,I
expression,O,I
showed,O,O
hypertrophic,B,O
cardiomyopathy,I,O
and,O,O
enhanced,O,O
neonatal,O,O
mortality,O,O
.,O,O
However,O,O
",",O,O
both,O,O
models,O,O
lack,O,O
other,O,O
frequent,O,O
DM,B,O
symptoms,O,O
including,O,O
the,O,O
fibre,O,O
-,O,O
type,O,O
dependent,O,O
atrophy,B,O
",",O,O
myotonia,B,O
",",O,O
cataract,B,O
and,O,O
male,B,O
-,I,O
infertility,I,O
.,O,O
These,O,O
results,O,O
strengthen,O,O
the,O,O
contention,O,O
that,O,O
simple,O,O
loss,O,O
-,O,O
or,O,O
gain,O,O
-,O,O
of,O,O
-,O,O
expression,O,O
of,O,O
DMPK,O,B
is,O,O
not,O,O
the,O,O
only,O,O
crucial,O,O
requirement,O,O
for,O,O
development,O,O
of,O,O
the,O,O
disease,O,O
.,O,O
Mice,O,O
lacking,O,O
the,O,O
myotonic,B,B
dystrophy,I,I
protein,O,I
kinase,O,I
develop,O,O
a,O,O
late,O,O
onset,O,O
progressive,O,O
myopathy,B,O
.,O,O
Myotonic,B,B
dystrophy,I,I
(,O,O
DM,B,B
),O,O
is,O,O
an,O,O
autosomal,B,O
dominant,I,O
disorder,I,O
resulting,O,O
from,O,O
the,O,O
expansion,O,O
of,O,O
a,O,O
CTG,O,O
repeat,O,O
in,O,O
the,O,O
3,O,O
untranslated,O,O
region,O,O
of,O,O
a,O,O
putative,O,O
protein,O,O
kinase,O,O
(,O,O
DMPK,O,B
),O,O
.,O,O
To,O,O
elucidate,O,O
the,O,O
role,O,O
of,O,O
DMPK,O,B
in,O,O
DM,B,B
pathogenesis,O,O
we,O,O
have,O,O
developed,O,O
Dmpk,B,B
deficient,I,O
(,O,O
Dmpk,O,B
-,O,I
/,O,I
-,O,I
),O,O
mice,O,O
.,O,O
Dmpk,O,B
-,O,I
/,O,I
-,O,I
mice,O,O
develop,O,O
a,O,O
late,O,O
-,O,O
onset,O,O
",",O,O
progressive,B,O
skeletal,I,O
myopathy,I,O
that,O,O
shares,O,O
some,O,O
pathological,O,O
features,O,O
with,O,O
DM,B,B
.,O,O
Muscles,O,O
from,O,O
mature,O,O
mice,O,O
show,O,O
variation,O,O
in,O,O
fibre,O,O
size,O,O
",",O,O
increased,O,O
fibre,B,O
degeneration,I,O
and,O,O
fibrosis,B,O
.,O,O
Adult,O,O
Dmpk,O,B
-,O,I
/,O,I
-,O,I
mice,O,O
show,O,O
ultrastructural,O,O
changes,O,O
in,O,O
muscle,O,O
and,O,O
a,O,O
50,O,O
%,O,O
decrease,O,O
in,O,O
force,O,O
generation,O,O
compared,O,O
to,O,O
young,O,O
mice,O,O
.,O,O
Our,O,O
results,O,O
indicate,O,O
that,O,O
DMPK,O,B
may,O,O
be,O,O
necessary,O,O
for,O,O
the,O,O
maintenance,O,O
of,O,O
skeletal,O,O
muscle,O,O
structure,O,O
and,O,O
function,O,O
and,O,O
suggest,O,O
that,O,O
a,O,O
decrease,O,O
in,O,O
DMPK,O,B
levels,O,O
may,O,O
contribute,O,O
to,O,O
DM,B,O
pathology,O,O
.,O,O
The,O,O
tumor,B,O
suppressor,O,O
gene,O,B
Brca1,O,O
is,O,O
required,O,O
for,O,O
embryonic,O,O
cellular,O,O
proliferation,O,O
in,O,O
the,O,O
mouse,O,O
.,O,O
Mutations,O,O
of,O,O
the,O,O
BRCA1,O,O
gone,O,O
in,O,O
humans,O,O
are,O,O
associated,O,O
with,O,O
predisposition,O,O
to,O,O
breast,B,B
and,I,O
ovarian,I,B
cancers,I,I
.,O,O
We,O,O
show,O,O
here,O,O
that,O,O
Brca1,O,O
+,O,O
/,O,O
-,O,O
mice,O,O
are,O,O
normal,O,O
and,O,O
fertile,O,O
lack,O,O
tumors,B,O
by,O,O
age,O,O
eleven,O,O
months,O,O
.,O,O
Homozygous,O,O
Brca1,O,O
(,O,O
5,O,O
-,O,O
6,O,O
),O,O
mutant,O,O
mice,O,O
die,O,O
before,O,O
day,O,O
7,O,O
.,O,O
5,O,O
of,O,O
embryogenesis,O,O
.,O,O
Mutant,O,O
embryos,O,O
are,O,O
poorly,O,O
developed,O,O
",",O,O
with,O,O
no,O,O
evidence,O,O
of,O,O
mesoderm,O,O
formation,O,O
.,O,O
The,O,O
extraembryonic,O,O
region,O,O
is,O,O
abnormal,O,O
",",O,O
but,O,O
aggregation,O,O
with,O,O
wild,O,O
-,O,O
type,O,O
tetraploid,O,O
embryos,O,O
does,O,O
not,O,O
rescue,O,O
the,O,O
lethality,O,O
.,O,O
In,O,O
vivo,O,O
",",O,O
mutant,O,O
embryos,O,O
do,O,O
not,O,O
exhibit,O,O
increased,O,O
apoptosis,O,O
but,O,O
show,O,O
reduced,O,O
cell,O,O
proliferation,O,O
accompanied,O,O
by,O,O
decreased,O,O
expression,O,O
of,O,O
cyclin,O,O
E,O,O
and,O,O
mdm,O,O
-,O,O
2,O,O
",",O,O
a,O,O
regulator,O,O
of,O,O
p53,O,O
activity,O,O
.,O,O
The,O,O
expression,O,O
of,O,O
cyclin,O,B
-,O,I
dependent,O,I
kinase,O,I
inhibitor,O,I
p21,O,B
is,O,O
dramatically,O,O
increased,O,O
in,O,O
the,O,O
mutant,O,O
embryos,O,O
.,O,O
Buttressing,O,O
these,O,O
in,O,O
vivo,O,O
observations,O,O
is,O,O
the,O,O
fact,O,O
that,O,O
mutant,O,O
blastocyst,O,O
growth,O,O
is,O,O
grossly,O,O
impaired,O,O
in,O,O
vitro,O,O
.,O,O
Thus,O,O
",",O,O
the,O,O
death,O,O
of,O,O
Brca1,O,O
(,O,O
5,O,O
-,O,O
6,O,O
),O,O
mutant,O,O
embryos,O,O
prior,O,O
to,O,O
gastrulation,O,O
may,O,O
be,O,O
due,O,O
to,O,O
a,O,O
failure,O,O
of,O,O
the,O,O
proliferative,O,O
burst,O,O
required,O,O
for,O,O
the,O,O
development,O,O
of,O,O
the,O,O
different,O,O
germ,O,O
layers,O,O
.,O,O
Increased,O,O
coronary,B,B
heart,I,I
disease,I,I
in,O,O
Japanese,O,O
-,O,O
American,O,O
men,O,O
with,O,O
mutation,O,O
in,O,O
the,O,O
cholesteryl,O,B
ester,O,I
transfer,O,I
protein,O,I
gene,O,I
despite,O,O
increased,O,O
HDL,O,O
levels,O,O
.,O,O
Plasma,O,O
high,O,O
density,O,O
lipoprotein,O,O
(,O,O
HDL,O,O
),O,O
levels,O,O
are,O,O
strongly,O,O
genetically,O,O
determined,O,O
and,O,O
show,O,O
a,O,O
general,O,O
inverse,O,O
relationship,O,O
with,O,O
coronary,B,B
heart,I,I
disease,I,I
(,O,O
CHD,B,O
),O,O
.,O,O
The,O,O
cholesteryl,O,B
ester,O,I
transfer,O,I
protein,O,I
(,O,O
CETP,O,O
),O,O
mediates,O,O
the,O,O
transfer,O,O
of,O,O
cholesteryl,O,B
esters,O,I
from,O,O
HDL,O,O
to,O,O
other,O,O
lipoproteins,O,O
and,O,O
is,O,O
a,O,O
key,O,O
participant,O,O
in,O,O
the,O,O
reverse,O,O
transport,O,O
of,O,O
cholesterol,O,B
from,O,O
the,O,O
periphery,O,O
to,O,O
the,O,O
liver,O,O
.,O,O
A,O,O
high,O,O
prevalence,O,O
of,O,O
two,O,O
different,O,O
CETP,O,O
gene,O,O
mutations,O,O
(,O,O
D442G,O,O
",",O,O
5,O,O
.,O,O
1,O,O
%,O,O
;,O,O
intron,O,O
14G,O,O
A,O,O
",",O,O
0,O,O
.,O,O
5,O,O
%,O,O
),O,O
",",O,O
was,O,O
found,O,O
in,O,O
3,O,O
",",O,O
469,O,O
men,O,O
of,O,O
Japanese,O,O
ancestry,O,O
in,O,O
the,O,O
Honolulu,O,O
Heart,O,O
Program,O,O
and,O,O
mutations,O,O
were,O,O
associated,O,O
with,O,O
decreased,O,O
CETP,O,B
(,O,O
-,O,O
35,O,O
%,O,O
),O,O
and,O,O
increased,O,O
HDL,O,B
chol,O,I
levels,O,O
(,O,O
+,O,O
10,O,O
%,O,O
for,O,O
D442G,O,O
),O,O
.,O,O
However,O,O
",",O,O
the,O,O
overall,O,O
prevalence,O,O
of,O,O
definite,O,O
CHD,B,O
was,O,O
21,O,O
%,O,O
in,O,O
men,O,O
with,O,O
mutations,O,O
and,O,O
16,O,O
%,O,O
in,O,O
men,O,O
without,O,O
mutations,O,O
.,O,O
The,O,O
relative,O,O
risk,O,O
(,O,O
RR,O,O
),O,O
of,O,O
CHD,B,O
was,O,O
1,O,O
.,O,O
43,O,O
in,O,O
men,O,O
with,O,O
mutations,O,O
(,O,O
P,O,O
<,O,O
.,O,O
),O,O
;,O,O
after,O,O
adjustment,O,O
for,O,O
CHD,B,O
risk,O,O
factors,O,O
",",O,O
the,O,O
RR,O,O
was,O,O
1,O,O
.,O,O
55,O,O
(,O,O
P,O,O
=,O,O
.,O,O
),O,O
;,O,O
after,O,O
additional,O,O
adjustment,O,O
for,O,O
HDL,O,O
levels,O,O
",",O,O
the,O,O
RR,O,O
was,O,O
1,O,O
.,O,O
68,O,O
(,O,O
P,O,O
=,O,O
.,O,O
),O,O
.,O,O
Similar,O,O
RR,O,O
values,O,O
were,O,O
obtained,O,O
for,O,O
the,O,O
D442G,O,O
mutation,O,O
alone,O,O
.,O,O
Increased,O,O
CHD,B,O
in,O,O
men,O,O
with,O,O
mutations,O,O
was,O,O
primarily,O,O
observed,O,O
for,O,O
HDL,O,O
chol,O,O
41,O,O
-,O,O
60,O,O
mg,O,O
/,O,O
dl,O,O
;,O,O
for,O,O
HDL,O,O
chol,O,O
>,O,O
60,O,O
mg,O,O
/,O,O
dl,O,O
men,O,O
with,O,O
and,O,O
without,O,O
mutations,O,O
had,O,O
low,O,O
CHD,B,O
prevalence,O,O
.,O,O
Thus,O,O
",",O,O
genetic,O,O
CETP,B,B
deficiency,I,I
appears,O,O
to,O,O
be,O,O
an,O,O
independent,O,O
risk,O,O
factor,O,O
for,O,O
CHD,B,B
",",O,O
primarily,O,O
due,O,O
to,O,O
increased,O,O
CHD,B,B
prevalence,O,O
in,O,O
men,O,O
with,O,O
the,O,O
D442G,O,O
mutation,O,O
and,O,O
HDL,O,B
cholesterol,O,I
between,O,O
41,O,O
and,O,O
60,O,O
mg,O,O
/,O,O
dl,O,O
.,O,O
The,O,O
findings,O,O
suggest,O,O
that,O,O
both,O,O
HDL,O,B
concentration,O,I
and,O,O
the,O,O
dynamics,O,O
of,O,O
cholesterol,O,O
transport,O,O
through,O,O
HDL,O,B
(,O,O
i,O,O
.,O,O
e,O,O
.,O,O
",",O,O
reverse,O,O
cholesterol,O,O
transport,O,O
),O,O
determine,O,O
the,O,O
anti,O,O
-,O,O
atherogenicity,O,O
of,O,O
the,O,O
HDL,O,B
fraction,O,O
.,O,O
Mapping,O,O
the,O,O
homolog,O,O
of,O,O
the,O,O
human,O,O
Rb1,O,B
gene,O,O
to,O,O
chromosome,O,O
14,O,O
of,O,O
higher,O,O
primates,O,O
.,O,O
The,O,O
Rb1,O,B
gene,O,O
has,O,O
been,O,O
implicated,O,O
with,O,O
retinoblastoma,B,O
and,O,O
is,O,O
located,O,O
on,O,O
human,O,O
Chromosome,O,O
(,O,O
Chr,O,O
),O,O
13q14,O,O
.,O,O
2,O,O
2,O,O
.,O,O
A,O,O
unique,O,O
sequence,O,O
human,O,O
Rb1,O,B
cosmid,O,O
DNA,O,O
probe,O,O
has,O,O
been,O,O
used,O,O
to,O,O
localize,O,O
this,O,O
region,O,O
on,O,O
apes,O,O
Chr,O,O
14,O,O
by,O,O
the,O,O
FISH,O,O
technique,O,O
.,O,O
The,O,O
conservation,O,O
of,O,O
the,O,O
Rb1,O,B
gene,O,O
in,O,O
higher,O,O
primates,O,O
at,O,O
the,O,O
corresponding,O,O
equivalent,O,O
chromosome,O,O
locus,O,O
(,O,O
14q14,O,O
),O,O
of,O,O
the,O,O
human,O,O
may,O,O
serve,O,O
as,O,O
a,O,O
phylogenetic,O,O
marker,O,O
to,O,O
further,O,O
trace,O,O
the,O,O
evolutionary,O,O
pathway,O,O
of,O,O
human,O,O
descent,O,O
.,O,O
Wiskott,B,B
-,I,I
Aldrich,I,I
syndrome,I,I
:,O,O
no,O,O
strict,O,O
genotype,O,O
-,O,O
phenotype,O,O
correlations,O,O
but,O,O
clustering,O,O
of,O,O
missense,O,O
mutations,O,O
in,O,O
the,O,O
amino,O,B
-,O,I
terminal,O,I
part,O,I
of,O,I
the,O,I
WASP,O,O
gene,O,O
product,O,O
.,O,O
The,O,O
Wiskott,B,B
-,I,I
Aldrich,I,I
syndrome,I,I
protein,O,I
(,O,O
WASP,O,B
),O,O
gene,O,O
was,O,O
found,O,O
to,O,O
be,O,O
mutated,O,O
in,O,O
patients,O,O
presenting,O,O
with,O,O
WAS,B,B
and,O,O
in,O,O
patients,O,O
showing,O,O
X,B,B
-,I,I
linked,I,I
thrombocytopenia,I,I
.,O,O
Mutation,O,O
analysis,O,O
in,O,O
19,O,O
families,O,O
of,O,O
German,O,O
",",O,O
Swiss,O,O
and,O,O
Turkish,O,O
descent,O,O
by,O,O
single,O,O
-,O,O
strand,O,O
conformation,O,O
polymorphism,O,O
and,O,O
sequencing,O,O
resulted,O,O
in,O,O
the,O,O
detection,O,O
of,O,O
seven,O,O
novel,O,O
and,O,O
10,O,O
known,O,O
mutations,O,O
.,O,O
A,O,O
striking,O,O
clustering,O,O
of,O,O
missense,O,O
mutations,O,O
in,O,O
the,O,O
first,O,O
four,O,O
exons,O,O
contrasted,O,O
with,O,O
a,O,O
random,O,O
distribution,O,O
of,O,O
nonsense,O,O
mutations,O,O
.,O,O
More,O,O
than,O,O
85,O,O
%,O,O
of,O,O
all,O,O
known,O,O
missense,O,O
mutations,O,O
were,O,O
localized,O,O
in,O,O
the,O,O
amino,O,B
-,O,I
terminal,O,I
stretch,O,I
of,O,O
the,O,O
WASP,O,B
gene,O,I
product,O,I
;,O,O
this,O,O
region,O,O
contained,O,O
a,O,O
mutational,O,O
hot,O,O
spot,O,O
at,O,O
codon,O,O
86,O,O
.,O,O
No,O,O
genotype,O,O
-,O,O
phenotype,O,O
correlation,O,O
emerged,O,O
after,O,O
a,O,O
comparison,O,O
of,O,O
the,O,O
identified,O,O
mutations,O,O
with,O,O
the,O,O
resulting,O,O
clinical,O,O
picture,O,O
for,O,O
a,O,O
classical,O,O
WAS,B,B
phenotype,O,I
.,O,O
A,O,O
substitution,O,O
at,O,O
codon,O,O
86,O,O
resulted,O,O
in,O,O
an,O,O
extremely,O,O
variable,O,O
expression,O,O
of,O,O
the,O,O
disease,O,O
in,O,O
a,O,O
large,O,O
Swiss,O,O
family,O,O
.,O,O
An,O,O
extended,O,O
homology,O,O
search,O,O
revealed,O,O
a,O,O
distant,O,O
relationship,O,O
of,O,O
this,O,O
stretch,O,O
to,O,O
the,O,O
vasodilator,O,B
-,O,I
stimulated,O,I
phosphoprotein,O,I
(,O,O
VASP,O,B
),O,O
",",O,O
which,O,O
is,O,O
involved,O,O
in,O,O
the,O,O
maintenance,O,O
of,O,O
cyto,O,O
-,O,O
architecture,O,O
by,O,O
interacting,O,O
with,O,O
actin,O,B
-,O,I
like,O,I
filaments,O,I
.,O,O
Influence,O,O
of,O,O
PAX6,O,B
gene,O,I
dosage,O,I
on,O,O
development,O,O
:,O,O
overexpression,O,O
causes,O,O
severe,O,O
eye,B,B
abnormalities,I,I
.,O,O
Aniridia,B,B
in,O,O
man,O,O
and,O,O
Small,O,B
eye,O,I
in,O,O
mice,O,O
are,O,O
semidominant,B,O
developmental,I,O
disorders,I,O
caused,O,O
by,O,O
mutations,O,O
within,O,O
the,O,O
paired,O,O
box,O,O
gene,O,O
PAX6,O,B
.,O,O
Whereas,O,O
heterozygotes,O,O
suffer,O,O
from,O,O
iris,B,B
hypoplasia,I,I
",",O,O
homozygous,O,O
mice,O,O
lack,O,O
eyes,O,B
and,O,O
nasal,O,B
cavities,O,I
and,O,O
exhibit,O,O
brain,B,B
abnormalities,I,I
.,O,O
To,O,O
investigate,O,O
the,O,O
role,O,O
of,O,O
gene,O,B
dosage,O,I
in,O,O
more,O,O
detail,O,O
",",O,O
we,O,O
have,O,O
generated,O,O
yeast,O,O
artificial,O,O
chromosome,O,O
transgenic,O,O
mice,O,O
carrying,O,O
the,O,O
human,O,O
PAX6,O,B
locus,O,I
.,O,O
When,O,O
crossed,O,O
onto,O,O
the,O,O
Small,O,O
eye,O,O
background,O,O
",",O,O
the,O,O
transgene,O,O
rescues,O,O
the,O,O
mutant,O,O
phenotype,O,O
.,O,O
Strikingly,O,O
",",O,O
mice,O,O
carrying,O,O
multiple,O,O
copies,O,O
on,O,O
a,O,O
wild,O,O
-,O,O
type,O,O
background,O,O
show,O,O
specific,O,O
developmental,B,O
abnormalities,I,O
of,I,O
the,I,O
eye,I,O
",",O,O
but,O,O
not,O,O
of,O,O
other,O,O
tissues,O,O
expressing,O,O
the,O,O
gene,O,B
.,O,O
Thus,O,O
",",O,O
at,O,O
least,O,O
five,O,O
different,O,O
eye,O,O
phenotypes,O,O
are,O,O
associated,O,O
with,O,O
changes,O,O
in,O,O
PAX6,O,B
expression,O,O
.,O,O
We,O,O
provide,O,O
evidence,O,O
that,O,O
not,O,O
only,O,O
reduced,O,O
",",O,O
but,O,O
also,O,O
increased,O,O
levels,O,O
of,O,O
transcriptional,O,O
regulators,O,O
can,O,O
cause,O,O
developmental,B,O
defects,I,O
.,O,O
Heterodimer,O,O
formation,O,O
and,O,O
activity,O,O
in,O,O
the,O,O
human,O,O
enzyme,O,O
galactose,O,O
-,O,O
1,O,O
-,O,O
phosphate,O,O
uridylyltransferase,O,O
.,O,O
One,O,O
of,O,O
the,O,O
fundamental,O,O
questions,O,O
concerning,O,O
expression,O,O
and,O,O
function,O,O
of,O,O
dimeric,O,O
enzymes,O,O
involves,O,O
the,O,O
impact,O,O
of,O,O
naturally,O,O
occurring,O,O
mutations,O,O
on,O,O
subunit,O,O
assembly,O,O
and,O,O
heterodimer,O,O
activity,O,O
.,O,O
This,O,O
question,O,O
is,O,O
of,O,O
particular,O,O
interest,O,O
for,O,O
the,O,O
human,O,O
enzyme,O,O
galactose,O,B
-,O,I
l,O,I
-,O,I
phosphate,O,I
uridylyl,O,I
-,O,I
transferase,O,I
(,O,O
GALT,O,B
),O,O
",",O,O
impairment,O,O
of,O,O
which,O,O
results,O,O
in,O,O
the,O,O
inherited,B,O
metabolic,I,O
disorder,I,O
galactosemia,B,B
",",O,O
because,O,O
many,O,O
if,O,O
not,O,O
most,O,O
patients,O,O
studied,O,O
to,O,O
date,O,O
are,O,O
compound,O,O
heterozygotes,O,O
rather,O,O
than,O,O
TRUE,O,O
molecular,O,O
homozygotes,O,O
.,O,O
Furthermore,O,O
",",O,O
the,O,O
broad,O,O
range,O,O
of,O,O
phenotypic,O,O
severity,O,O
observed,O,O
in,O,O
these,O,O
patients,O,O
raises,O,O
the,O,O
possibility,O,O
that,O,O
allelic,O,O
combination,O,O
",",O,O
not,O,O
just,O,O
allelic,O,O
constitution,O,O
",",O,O
may,O,O
play,O,O
some,O,O
role,O,O
in,O,O
determining,O,O
outcome,O,O
.,O,O
In,O,O
the,O,O
work,O,O
described,O,O
herein,O,O
",",O,O
we,O,O
have,O,O
selected,O,O
two,O,O
distinct,O,O
naturally,O,O
occurring,O,O
mutations,O,O
of,O,O
GALT,O,B
",",O,O
Q188R,O,O
and,O,O
R333W,O,O
",",O,O
and,O,O
asked,O,O
the,O,O
questions,O,O
(,O,O
i,O,O
),O,O
what,O,O
are,O,O
the,O,O
impacts,O,O
of,O,O
these,O,O
mutations,O,O
on,O,O
subunit,O,O
assembly,O,O
",",O,O
and,O,O
(,O,O
ii,O,O
),O,O
if,O,O
heterodimers,O,O
do,O,O
form,O,O
",",O,O
are,O,O
they,O,O
active,O,O
?,O,O
To,O,O
answer,O,O
these,O,O
questions,O,O
",",O,O
we,O,O
have,O,O
established,O,O
a,O,O
yeast,O,O
system,O,O
for,O,O
the,O,O
coexpression,O,O
of,O,O
epitope,O,O
-,O,O
tagged,O,O
alleles,O,O
of,O,O
human,O,O
GALT,O,B
and,O,O
investigated,O,O
both,O,O
the,O,O
extent,O,O
of,O,O
specific,O,O
GALT,O,B
subunit,O,O
interactions,O,O
and,O,O
the,O,O
activity,O,O
of,O,O
defined,O,O
heterodimer,O,O
pools,O,O
.,O,O
We,O,O
have,O,O
found,O,O
that,O,O
both,O,O
homodimers,O,O
and,O,O
heterodimers,O,O
do,O,O
form,O,O
involving,O,O
each,O,O
of,O,O
the,O,O
mutant,O,O
subunits,O,O
tested,O,O
and,O,O
that,O,O
both,O,O
heterodimer,O,O
pools,O,O
retain,O,O
substantial,O,O
enzymatic,O,O
activity,O,O
.,O,O
These,O,O
results,O,O
are,O,O
significant,O,O
not,O,O
only,O,O
in,O,O
terms,O,O
of,O,O
their,O,O
implications,O,O
for,O,O
furthering,O,O
our,O,O
understanding,O,O
of,O,O
galactosemia,B,O
and,O,O
GALT,O,B
holoenzyme,O,I
structure,O,I
-,O,I
function,O,I
relationships,O,I
but,O,O
also,O,O
because,O,O
the,O,O
system,O,O
described,O,O
may,O,O
serve,O,O
as,O,O
a,O,O
model,O,O
for,O,O
similar,O,O
studies,O,O
of,O,O
other,O,O
complexes,O,O
composed,O,O
of,O,O
multiple,O,O
subunits,O,O
.,O,O
.,O,O
Cleavage,O,O
of,O,O
huntingtin,O,B
by,O,O
apopain,O,O
",",O,O
a,O,O
proapoptotic,O,O
cysteine,O,O
protease,O,O
",",O,O
is,O,O
modulated,O,O
by,O,O
the,O,O
polyglutamine,O,O
tract,O,O
.,O,O
Apoptosis,O,O
has,O,O
recently,O,O
been,O,O
recognized,O,O
as,O,O
a,O,O
mode,O,O
of,O,O
cell,O,O
death,O,O
in,O,O
Huntington,B,B
disease,I,I
(,O,O
HD,B,O
),O,O
.,O,O
Apopain,O,O
",",O,O
a,O,O
human,O,O
counterpart,O,O
of,O,O
the,O,O
nematode,O,O
cysteine,O,O
protease,O,O
death,O,O
-,O,O
gene,O,O
product,O,O
",",O,O
CED,O,B
-,O,I
3,O,I
",",O,O
has,O,O
a,O,O
key,O,O
role,O,O
in,O,O
proteolytic,O,O
events,O,O
leading,O,O
to,O,O
apoptosis,O,O
.,O,O
Here,O,O
we,O,O
show,O,O
that,O,O
apoptotic,O,O
extracts,O,O
and,O,O
apopain,O,O
itself,O,O
specifically,O,O
cleave,O,O
the,O,O
HD,B,B
gene,O,I
product,O,O
",",O,O
huntingtin,O,O
.,O,O
The,O,O
rate,O,O
of,O,O
cleavage,O,O
increases,O,O
with,O,O
the,O,O
length,O,O
of,O,O
the,O,O
huntingtin,O,O
polyglutamine,O,O
tract,O,O
",",O,O
providing,O,O
an,O,O
explanation,O,O
for,O,O
the,O,O
gain,O,O
-,O,O
of,O,O
-,O,O
function,O,O
associated,O,O
with,O,O
CAG,O,O
expansion,O,O
.,O,O
Our,O,O
results,O,O
show,O,O
that,O,O
huntingtin,O,O
is,O,O
cleaved,O,O
by,O,O
cysteine,O,O
proteases,O,O
and,O,O
suggest,O,O
that,O,O
HD,B,B
might,O,O
be,O,O
a,O,O
disorder,B,O
of,I,O
inappropriate,I,O
apoptosis,I,O
.,O,O
.,O,O
The,O,O
5,O,O
',O,O
end,O,O
of,O,O
the,O,O
BRCA1,O,B
gene,O,I
lies,O,O
within,O,O
a,O,O
duplicated,O,O
region,O,O
of,O,O
human,O,O
chromosome,O,O
17q21,O,O
.,O,O
To,O,O
begin,O,O
to,O,O
address,O,O
the,O,O
hypothesis,O,O
that,O,O
abnormal,O,O
regulation,O,O
of,O,O
the,O,O
breast,B,O
/,I,O
ovarian,I,O
cancer,I,O
susceptibility,O,O
gene,O,O
BRCA1,O,B
is,O,O
a,O,O
critical,O,O
step,O,O
in,O,O
sporadic,O,O
breast,O,O
/,O,O
ovarian,O,O
tumorigenesis,O,O
",",O,O
we,O,O
have,O,O
determined,O,O
the,O,O
detailed,O,O
structure,O,O
of,O,O
the,O,O
BRCA1,O,B
genomic,O,I
region,O,I
.,O,O
We,O,O
show,O,O
that,O,O
this,O,O
region,O,O
of,O,O
the,O,O
genome,O,O
contains,O,O
a,O,O
tandem,O,O
duplication,O,O
of,O,O
approximately,O,O
30,O,O
kilobases,O,O
",",O,O
which,O,O
results,O,O
in,O,O
two,O,O
copies,O,O
of,O,O
BRCA1,O,B
exons,O,I
1,O,I
and,O,I
2,O,I
",",O,O
of,O,O
exons,O,O
1,O,O
and,O,O
3,O,O
of,O,O
the,O,O
adjacent,O,O
1A1,O,O
-,O,O
3B,O,O
gene,O,O
and,O,O
of,O,O
the,O,O
previously,O,O
reported,O,O
295,O,O
base,O,O
pair,O,O
intergenic,O,O
region,O,O
.,O,O
Sequence,O,O
analysis,O,O
of,O,O
the,O,O
duplicated,O,O
exons,O,O
of,O,O
BRCA1,O,B
and,O,I
1A1,O,O
-,O,O
3B,O,O
and,O,O
flanking,O,O
genomic,O,O
DNA,O,O
reveals,O,O
maintenance,O,O
of,O,O
the,O,O
intron,O,O
-,O,O
exon,O,O
structure,O,O
and,O,O
a,O,O
high,O,O
degree,O,O
of,O,O
nucleotide,O,O
sequence,O,O
identity,O,O
",",O,O
suggesting,O,O
that,O,O
these,O,O
are,O,O
non,O,O
-,O,O
processed,O,O
pseudogenes,O,O
and,O,O
that,O,O
the,O,O
duplication,O,O
is,O,O
a,O,O
recent,O,O
event,O,O
in,O,O
evolutionary,O,O
terms,O,O
.,O,O
We,O,O
also,O,O
show,O,O
that,O,O
a,O,O
processed,O,O
pseudogene,O,O
of,O,O
the,O,O
acidic,O,B
ribosomal,O,I
phosphoprotein,O,I
P1,O,I
(,O,O
ARPP1,O,B
),O,O
is,O,O
inserted,O,O
directly,O,O
upstream,O,O
of,O,O
pseudo,O,O
-,O,O
BRCA1,O,O
exon,O,O
1A,O,O
.,O,O
We,O,O
believe,O,O
that,O,O
these,O,O
findings,O,O
could,O,O
not,O,O
only,O,O
confound,O,O
BRCA1,O,O
mutation,O,O
analysis,O,O
",",O,O
but,O,O
could,O,O
have,O,O
implications,O,O
for,O,O
the,O,O
normal,O,O
and,O,O
abnormal,O,O
regulation,O,O
of,O,O
BRCA1,O,O
transcription,O,O
",",O,O
translation,O,O
and,O,O
function,O,O
.,O,O
.,O,O
Deletion,O,O
of,O,O
small,O,O
nuclear,O,O
ribonucleoprotein,O,O
polypeptide,O,O
N,O,B
(,O,O
SNRPN,O,B
),O,O
in,O,O
Prader,B,O
-,I,O
Willi,I,O
syndrome,I,O
detected,O,O
by,O,O
fluorescence,O,O
in,O,O
situ,O,O
hybridization,O,O
:,O,O
two,O,O
sibs,O,O
with,O,O
the,O,O
typical,O,O
phenotype,O,O
without,O,O
a,O,O
cytogenetic,O,O
deletion,O,O
in,O,O
chromosome,O,O
15q,O,O
.,O,O
The,O,O
small,O,O
nuclear,O,O
ribonucleoprotein,O,O
polypeptide,O,O
N,O,B
(,O,O
SNRPN,O,B
),O,O
gene,O,O
is,O,O
regarded,O,O
as,O,O
one,O,O
of,O,O
the,O,O
candidates,O,O
for,O,O
Prader,B,O
-,I,O
Willi,I,O
syndrome,I,O
(,O,O
PWS,B,O
),O,O
.,O,O
We,O,O
describe,O,O
two,O,O
sibs,O,O
with,O,O
typical,O,O
PWS,B,B
presenting,O,O
deletion,O,O
of,O,O
SNRPN,O,B
detected,O,O
by,O,O
fluorescence,O,O
in,O,O
situ,O,O
hybridization,O,O
(,O,O
FISH,O,O
),O,O
.,O,O
Neither,O,O
a,O,O
cytogenetically,O,O
detectable,O,O
15q12,O,O
deletion,O,O
nor,O,O
a,O,O
deletion,O,O
for,O,O
the,O,O
D15S11,O,O
",",O,O
D15S10,O,O
",",O,O
and,O,O
GABRB3,O,B
cosmid,O,I
probes,O,I
were,O,O
found,O,O
in,O,O
either,O,O
patient,O,O
.,O,O
This,O,O
implies,O,O
a,O,O
smaller,O,O
deletion,O,O
limited,O,O
to,O,O
the,O,O
PWS,B,B
critical,O,I
region,O,I
.,O,O
FISH,O,O
with,O,O
a,O,O
SNRPN,O,B
probe,O,O
will,O,O
permit,O,O
analysis,O,O
of,O,O
PWS,B,B
patients,O,O
with,O,O
limited,O,O
deletions,O,O
not,O,O
detectable,O,O
with,O,O
other,O,O
probes,O,O
.,O,O
Expression,O,O
of,O,O
the,O,O
von,B,B
Hippel,I,I
-,I,I
Lindau,I,I
disease,I,I
tumour,I,I
suppressor,O,I
gene,O,I
during,O,O
human,O,O
embryogenesis,O,O
.,O,O
The,O,O
von,B,B
Hippel,I,I
-,I,I
Lindau,I,I
(,I,O
VHL,I,B
),I,O
disease,I,I
product,O,I
is,O,O
thought,O,O
to,O,O
down,O,O
-,O,O
regulate,O,O
transcription,O,O
by,O,O
antagonizing,O,O
elongin,O,O
-,O,O
enhanced,O,O
transcriptional,O,O
elongation,O,O
.,O,O
Germline,O,O
VHL,B,B
gene,O,I
mutations,O,O
predispose,O,O
to,O,O
the,O,O
development,O,O
of,O,O
retinal,B,O
",",I,O
cerebellar,I,O
and,I,O
spinal,I,O
haemangioblastomas,I,O
",",O,O
renal,B,B
cell,I,I
carcinoma,I,I
and,O,O
phaeochromocytoma,B,O
.,O,O
In,O,O
addition,O,O
",",O,O
somatic,O,O
Inactivation,O,O
of,O,O
the,O,O
VHL,B,B
gene,O,I
is,O,O
frequent,O,O
in,O,O
sporadic,B,B
renal,I,I
cell,I,I
carcinoma,I,I
and,O,O
haemangioblastoma,B,O
.,O,O
Regulation,O,O
of,O,O
transcript,O,O
elongation,O,O
is,O,O
an,O,O
important,O,O
control,O,O
mechanism,O,O
for,O,O
gene,O,O
expression,O,O
and,O,O
the,O,O
VHL,B,B
gene,O,I
might,O,O
modify,O,O
the,O,O
expression,O,O
of,O,O
proto,O,O
-,O,O
oncogenes,O,O
and,O,O
growth,O,O
suppressor,O,O
genes,O,O
during,O,O
embryogenesis,O,O
.,O,O
We,O,O
therefore,O,O
investigated,O,O
the,O,O
expression,O,O
of,O,O
VHL,B,B
mRNA,O,I
during,O,O
human,O,O
embryogenesis,O,O
by,O,O
in,O,O
situ,O,O
hybridization,O,O
studies,O,O
at,O,O
4,O,O
",",O,O
6,O,O
and,O,O
10,O,O
weeks,O,O
post,O,O
conception,O,O
.,O,O
Although,O,O
VHL,B,B
mRNA,O,I
was,O,O
expressed,O,O
in,O,O
all,O,O
three,O,O
germ,O,O
layers,O,O
",",O,O
strong,O,O
expression,O,O
was,O,O
noted,O,O
in,O,O
the,O,O
central,O,O
nervous,O,O
system,O,O
",",O,O
kidneys,O,B
",",O,O
testis,O,B
and,O,O
lung,O,B
.,O,O
Within,O,O
the,O,O
kidney,O,B
",",O,O
VHL,B,B
mRNA,O,I
was,O,O
differentially,O,O
expressed,O,O
within,O,O
renal,O,O
tubules,O,O
suggesting,O,O
that,O,O
the,O,O
VHL,B,B
gene,O,I
product,O,I
may,O,O
have,O,O
a,O,O
specific,O,O
role,O,O
in,O,O
kidney,O,B
development,O,O
.,O,O
Two,O,O
alternatively,O,O
spliced,O,O
VHL,B,B
mRNAs,O,O
characterized,O,O
by,O,O
inclusion,O,O
(,O,O
isoform,O,O
I,O,O
),O,O
or,O,O
exclusion,O,O
(,O,O
isoform,O,O
II,O,O
),O,O
of,O,O
exon,O,O
2,O,O
are,O,O
transcribed,O,O
in,O,O
adult,O,O
tissues,O,O
.,O,O
To,O,O
investigate,O,O
if,O,O
the,O,O
two,O,O
isoforms,O,O
are,O,O
differentially,O,O
expressed,O,O
during,O,O
embryogenesis,O,O
",",O,O
VHL,B,B
mRNA,O,O
was,O,O
reverse,O,O
transcribed,O,O
from,O,O
13,O,O
fetal,O,O
tissues,O,O
(,O,O
8,O,O
-,O,O
10,O,O
weeks,O,O
gestation,O,O
),O,O
.,O,O
The,O,O
quantitative,O,O
distribution,O,O
of,O,O
VHL,B,B
mRNA,O,O
within,O,O
fetal,O,O
tissues,O,O
reflected,O,O
that,O,O
seen,O,O
by,O,O
in,O,O
situ,O,O
hybridization,O,O
and,O,O
the,O,O
ratio,O,O
of,O,O
the,O,O
two,O,O
VHL,B,B
isoforms,O,O
was,O,O
similar,O,O
between,O,O
tissues,O,O
.,O,O
Although,O,O
the,O,O
genes,O,O
regulated,O,O
by,O,O
the,O,O
VHL,B,B
gene,O,O
product,O,O
have,O,O
not,O,O
yet,O,O
been,O,O
identified,O,O
",",O,O
our,O,O
findings,O,O
are,O,O
compatible,O,O
with,O,O
the,O,O
hypothesis,O,O
that,O,O
VHL,B,B
-,O,I
mediated,O,I
control,O,I
of,O,I
transcriptional,O,I
elongation,O,I
may,O,O
have,O,O
a,O,O
role,O,O
in,O,O
normal,O,O
human,O,O
development,O,O
.,O,O
.,O,O
Genetic,O,O
heterogeneity,O,O
in,O,O
hereditary,B,B
breast,I,I
cancer,I,I
:,O,O
role,O,O
of,O,O
BRCA1,O,O
and,O,O
BRCA2,O,O
.,O,O
The,O,O
common,O,O
hereditary,O,B
forms,O,I
of,O,I
breast,B,I
cancer,I,I
have,O,O
been,O,O
largely,O,O
attributed,O,O
to,O,O
the,O,O
inheritance,O,O
of,O,O
mutations,O,O
in,O,O
the,O,O
BRCA1,O,O
or,O,O
BRCA2,O,O
genes,O,O
.,O,O
However,O,O
",",O,O
it,O,O
is,O,O
not,O,O
yet,O,O
clear,O,O
what,O,O
proportion,O,O
of,O,O
hereditary,B,B
breast,I,I
cancer,I,I
is,O,O
explained,O,O
by,O,O
BRCA1,O,O
and,O,O
BRCA2,O,O
or,O,O
by,O,O
some,O,O
other,O,O
unidentified,O,O
susceptibility,O,O
gene,O,O
(,O,O
s,O,O
),O,O
.,O,O
We,O,O
describe,O,O
the,O,O
proportion,O,O
of,O,O
hereditary,B,O
breast,I,B
cancer,I,I
explained,O,O
by,O,O
BRCA1,O,O
or,O,O
BRCA2,O,O
in,O,O
a,O,O
sample,O,O
of,O,O
North,O,O
American,O,O
hereditary,B,O
breast,I,B
cancers,I,I
and,O,O
assess,O,O
the,O,O
evidence,O,O
for,O,O
additional,O,O
susceptibility,O,O
genes,O,O
that,O,O
may,O,O
confer,O,O
hereditary,B,O
breast,I,B
or,I,O
ovarian,I,O
cancer,I,I
risk,O,O
.,O,O
Twenty,O,O
-,O,O
three,O,O
families,O,O
were,O,O
identified,O,O
through,O,O
two,O,O
high,O,O
-,O,O
risk,O,O
breast,B,B
cancer,I,I
research,O,O
programs,O,O
.,O,O
Genetic,O,O
analysis,O,O
was,O,O
undertaken,O,O
to,O,O
establish,O,O
linkage,O,O
between,O,O
the,O,O
breast,B,B
or,I,O
ovarian,I,B
cancer,I,I
cases,O,O
and,O,O
markers,O,O
on,O,O
chromosomes,O,O
17q,O,O
(,O,O
BRCA1,O,O
),O,O
and,O,O
13q,O,O
(,O,O
BRCA2,O,O
),O,O
.,O,O
Mutation,O,O
analysis,O,O
in,O,O
the,O,O
BRCA1,O,O
and,O,O
BRCA2,O,O
genes,O,O
was,O,O
also,O,O
undertaken,O,O
in,O,O
all,O,O
families,O,O
.,O,O
The,O,O
pattern,O,O
of,O,O
hereditary,B,O
cancer,I,B
in,O,O
14,O,O
(,O,O
61,O,O
%,O,O
),O,O
of,O,O
the,O,O
23,O,O
families,O,O
studied,O,O
was,O,O
attributed,O,O
to,O,O
BRCA1,O,O
by,O,O
a,O,O
combination,O,O
of,O,O
linkage,O,O
and,O,O
mutation,O,O
analyses,O,O
.,O,O
No,O,O
families,O,O
were,O,O
attributed,O,O
to,O,O
BRCA2,O,B
.,O,O
Five,O,O
families,O,O
(,O,O
22,O,O
%,O,O
),O,O
provided,O,O
evidence,O,O
against,O,O
linkage,O,O
to,O,O
both,O,O
BRCA1,O,B
and,O,O
BRCA2,O,B
.,O,O
No,O,O
BRCA1,O,B
or,O,O
BRCA2,O,B
mutations,O,O
were,O,O
detected,O,O
in,O,O
these,O,O
five,O,O
families,O,O
.,O,O
The,O,O
BRCA1,O,B
or,O,O
BRCA2,O,B
status,O,O
of,O,O
four,O,O
families,O,O
(,O,O
17,O,O
%,O,O
),O,O
could,O,O
not,O,O
be,O,O
determined,O,O
.,O,O
BRCA1,O,B
and,O,O
BRCA2,O,B
probably,O,O
explain,O,O
the,O,O
majority,O,O
of,O,O
hereditary,B,O
breast,I,B
cancer,I,I
that,O,O
exists,O,O
in,O,O
the,O,O
North,O,O
American,O,O
population,O,O
.,O,O
However,O,O
",",O,O
one,O,O
or,O,O
more,O,O
additional,O,O
genes,O,B
may,O,O
yet,O,O
be,O,O
found,O,O
that,O,O
explain,O,O
some,O,O
proportion,O,O
of,O,O
hereditary,B,O
breast,I,B
cancer,I,I
.,O,O
An,O,O
intronic,O,O
mutation,O,O
in,O,O
a,O,O
lariat,O,O
branchpoint,O,O
sequence,O,O
is,O,O
a,O,O
direct,O,O
cause,O,O
of,O,O
an,O,O
inherited,B,O
human,I,O
disorder,I,O
(,O,O
fish,B,O
-,I,O
eye,I,O
disease,I,O
),O,O
.,O,O
The,O,O
first,O,O
step,O,O
in,O,O
the,O,O
splicing,O,O
of,O,O
an,O,O
intron,O,O
from,O,O
nuclear,O,O
precursors,O,O
of,O,O
mRNA,O,O
results,O,O
in,O,O
the,O,O
formation,O,O
of,O,O
a,O,O
lariat,O,O
structure,O,O
.,O,O
A,O,O
distinct,O,O
intronic,O,O
nucleotide,O,O
sequence,O,O
",",O,O
known,O,O
as,O,O
the,O,O
branchpoint,O,O
region,O,O
",",O,O
plays,O,O
a,O,O
central,O,O
role,O,O
in,O,O
this,O,O
process,O,O
.,O,O
We,O,O
here,O,O
describe,O,O
a,O,O
point,O,O
mutation,O,O
in,O,O
such,O,O
a,O,O
sequence,O,O
.,O,O
Three,O,O
sisters,O,O
were,O,O
shown,O,O
to,O,O
suffer,O,O
from,O,O
fish,B,B
-,I,I
eye,I,I
disease,I,I
(,O,O
FED,B,O
),O,O
",",O,O
a,O,O
disorder,O,O
which,O,O
is,O,O
caused,O,O
by,O,O
mutations,O,O
in,O,O
the,O,O
gene,O,O
coding,O,O
for,O,O
lecithin,O,B
cholesterol,O,I
acyltransferase,O,I
(,O,O
LCAT,O,O
),O,O
.,O,O
Sequencing,O,O
of,O,O
the,O,O
LCAT,O,B
gene,O,O
of,O,O
all,O,O
three,O,O
probands,O,O
revealed,O,O
compound,O,O
heterozygosity,O,O
for,O,O
a,O,O
missense,O,O
mutation,O,O
in,O,O
exon,O,O
4,O,O
which,O,O
is,O,O
reported,O,O
to,O,O
underlie,O,O
the,O,O
FED,B,O
phenotype,O,O
",",O,O
and,O,O
a,O,O
point,O,O
mutation,O,O
located,O,O
in,O,O
intron,O,O
4,O,O
(,O,O
IVS4,O,O
T,O,B
-,O,I
22C,O,I
),O,O
.,O,O
By,O,O
performing,O,O
in,O,O
vitro,O,O
expression,O,O
of,O,O
LCAT,O,B
minigenes,O,O
and,O,O
reverse,O,O
transcriptase,O,O
PCR,O,O
on,O,O
mRNA,O,O
isolated,O,O
from,O,O
leukocytes,O,O
of,O,O
the,O,O
patient,O,O
",",O,O
this,O,O
gene,O,O
defect,O,O
was,O,O
shown,O,O
to,O,O
cause,O,O
a,O,O
allele,O,O
as,O,O
the,O,O
result,O,O
of,O,O
complete,O,O
intron,O,O
retention,O,O
.,O,O
In,O,O
conclusion,O,O
",",O,O
we,O,O
demonstrated,O,O
that,O,O
a,O,O
point,O,O
mutation,O,O
in,O,O
a,O,O
lariat,O,O
branchpoint,O,O
consensus,O,O
sequence,O,O
causes,O,O
a,O,O
allele,O,O
in,O,O
a,O,O
patient,O,O
with,O,O
FED,B,B
.,O,O
In,O,O
addition,O,O
",",O,O
our,O,O
finding,O,O
illustrates,O,O
the,O,O
importance,O,O
of,O,O
this,O,O
sequence,O,O
for,O,O
normal,O,O
human,O,O
mRNA,O,O
processing,O,O
.,O,O
Finally,O,O
",",O,O
this,O,O
report,O,O
provides,O,O
a,O,O
widely,O,O
applicable,O,O
strategy,O,O
which,O,O
ensures,O,O
fast,O,O
and,O,O
effective,O,O
screening,O,O
for,O,O
intronic,O,O
defects,O,O
that,O,O
underlie,O,O
differential,O,O
gene,O,B
expression,O,I
.,O,O
.,O,O
Mutations,O,O
associated,O,O
with,O,O
variant,O,O
phenotypes,O,O
in,O,O
ataxia,B,B
-,I,I
telangiectasia,I,I
.,O,O
We,O,O
have,O,O
identified,O,O
14,O,O
families,O,O
with,O,O
ataxia,B,B
-,I,I
telangiectasia,I,I
(,O,O
A,B,B
-,I,I
T,I,I
),O,O
in,O,O
which,O,O
mutation,O,O
of,O,O
the,O,O
ATM,O,O
gene,O,O
is,O,O
associated,O,O
with,O,O
a,O,O
less,O,O
severe,O,O
clinical,O,O
and,O,O
cellular,O,O
phenotype,O,O
(,O,O
approximately,O,O
10,O,O
%,O,O
-,O,O
15,O,O
%,O,O
of,O,O
A,B,B
-,I,I
T,I,I
families,O,O
identified,O,O
in,O,O
the,O,O
United,O,O
Kingdom,O,O
),O,O
.,O,O
In,O,O
10,O,O
of,O,O
these,O,O
families,O,O
",",O,O
all,O,O
the,O,O
homozygotes,O,O
have,O,O
a,O,O
137,O,O
-,O,O
bp,O,O
insertion,O,O
in,O,O
their,O,O
cDNA,O,O
caused,O,O
by,O,O
a,O,O
point,O,O
mutation,O,O
in,O,O
a,O,O
sequence,O,O
resembling,O,O
a,O,O
splice,O,O
-,O,O
donor,O,O
site,O,O
.,O,O
The,O,O
second,O,O
A,B,B
-,I,I
T,I,I
allele,O,O
has,O,O
a,O,O
different,O,O
mutation,O,O
in,O,O
each,O,O
patient,O,O
.,O,O
We,O,O
show,O,O
that,O,O
the,O,O
less,O,O
severe,O,O
phenotype,O,O
in,O,O
these,O,O
patients,O,O
is,O,O
caused,O,O
by,O,O
some,O,O
degree,O,O
of,O,O
normal,O,O
splicing,O,O
",",O,O
which,O,O
occurs,O,O
as,O,O
an,O,O
alternative,O,O
product,O,O
from,O,O
the,O,O
insertion,O,O
-,O,O
containing,O,O
allele,O,O
.,O,O
The,O,O
level,O,O
of,O,O
the,O,O
137,O,O
-,O,O
bp,O,O
PCR,O,O
product,O,O
containing,O,O
the,O,O
insertion,O,O
was,O,O
lowest,O,O
in,O,O
two,O,O
patients,O,O
who,O,O
showed,O,O
a,O,O
later,O,O
onset,O,O
of,O,O
cerebellar,B,B
ataxia,I,I
.,O,O
A,O,B
further,O,O
four,O,O
families,O,O
who,O,O
do,O,O
not,O,O
have,O,O
this,O,O
insertion,O,O
have,O,O
been,O,O
identified,O,O
.,O,O
Mutations,O,O
detected,O,O
in,O,O
two,O,O
of,O,O
four,O,O
of,O,O
these,O,O
are,O,O
missense,O,O
mutations,O,O
",",O,O
normally,O,O
rare,O,O
in,O,O
A,B,B
-,I,I
T,I,I
patients,O,O
.,O,O
The,O,O
demonstration,O,O
of,O,O
mutations,O,O
giving,O,O
rise,O,O
to,O,O
a,O,O
slightly,O,O
milder,O,O
phenotype,O,O
in,O,O
A,B,B
-,I,I
T,I,I
raises,O,O
the,O,O
interesting,O,O
question,O,O
of,O,O
what,O,O
range,O,O
of,O,O
phenotypes,O,O
might,O,O
occur,O,O
in,O,O
individuals,O,O
in,O,O
whom,O,O
both,O,O
mutations,O,O
are,O,O
milder,O,O
.,O,O
One,O,O
possibility,O,O
might,O,O
be,O,O
that,O,O
individuals,O,O
who,O,O
are,O,O
compound,O,O
heterozygotes,O,O
for,O,O
ATM,O,O
mutations,O,O
are,O,O
more,O,O
common,O,O
than,O,O
we,O,O
realize,O,O
.,O,O
Mutation,O,O
of,O,O
the,O,O
VHL,O,B
gene,O,I
is,O,O
associated,O,O
exclusively,O,O
with,O,O
the,O,O
development,O,O
of,O,O
non,B,B
-,I,I
papillary,I,I
renal,I,I
cell,I,I
carcinomas,I,I
.,O,O
To,O,O
define,O,O
the,O,O
possible,O,O
role,O,O
of,O,O
the,O,O
VHL,B,B
gene,O,I
in,O,O
the,O,O
development,O,O
of,O,O
sporadic,B,B
renal,I,I
cell,I,I
carcinomas,I,I
",",O,O
91,O,O
different,O,O
parenchymal,B,O
tumours,I,O
of,I,O
the,I,O
kidney,I,O
have,O,O
been,O,O
investigated,O,O
for,O,O
mutation,O,O
of,O,O
the,O,O
VHL,B,B
gene,O,I
by,O,O
single,O,O
strand,O,O
conformation,O,O
polymorphism,O,O
(,O,O
SSCP,O,O
),O,O
and,O,O
/,O,O
or,O,O
heteroduplex,O,O
(,O,O
HD,O,O
),O,O
techniques,O,O
.,O,O
Chromosome,O,O
3p,O,O
deletion,O,O
was,O,O
detected,O,O
in,O,O
98,O,O
per,O,O
cent,O,O
of,O,O
non,B,O
-,I,O
papillary,I,O
renal,I,B
cell,I,I
carcinomas,I,I
and,O,O
in,O,O
25,O,O
per,O,O
cent,O,O
of,O,O
chromophobe,O,B
renal,B,I
cell,I,I
carcinomas,I,I
.,O,O
In,O,O
22,O,O
of,O,O
the,O,O
43,O,O
non,B,O
-,I,O
papillary,I,O
renal,I,B
cell,I,I
carcinomas,I,I
",",O,O
abnormally,O,O
migrating,O,O
DNA,O,O
bands,O,O
were,O,O
detected,O,O
by,O,O
SSCP,O,O
and,O,O
/,O,O
or,O,O
HD,O,O
analysis,O,O
.,O,O
No,O,O
mobility,O,O
shift,O,O
was,O,O
seen,O,O
in,O,O
any,O,O
of,O,O
the,O,O
23,O,O
chromophobe,O,B
renal,B,I
cell,I,I
carcinomas,I,I
.,O,O
In,O,O
addition,O,O
",",O,O
15,O,O
papillary,B,B
renal,I,I
cell,I,I
tumours,I,I
and,O,O
ten,O,O
renal,B,B
oncocytomas,I,I
",",O,O
which,O,O
are,O,O
characterized,O,O
by,O,O
genetic,O,O
changes,O,O
other,O,O
than,O,O
loss,O,O
of,O,O
chromosome,O,O
3p,O,O
sequences,O,O
",",O,O
were,O,O
analysed,O,O
for,O,O
mutation,O,O
of,O,O
the,O,O
VHL,B,O
gene,O,O
.,O,O
None,O,O
of,O,O
these,O,O
tumours,B,O
showed,O,O
abnormal,O,O
migration,O,O
patterns,O,O
.,O,O
The,O,O
results,O,O
indicate,O,O
that,O,O
mutation,O,O
of,O,O
the,O,O
VHL,B,O
gene,O,O
is,O,O
associated,O,O
exclusively,O,O
with,O,O
the,O,O
development,O,O
of,O,O
non,B,B
-,I,I
papillary,I,I
renal,I,I
cell,I,I
carcinoma,I,I
.,O,O
The,O,O
Emery,B,B
-,I,I
Dreifuss,I,I
muscular,I,I
dystrophy,I,I
protein,O,O
",",O,O
emerin,O,B
",",O,O
is,O,O
a,O,O
nuclear,O,O
membrane,O,O
protein,O,O
.,O,O
A,O,O
large,O,O
fragment,O,O
of,O,O
emerin,O,B
cDNA,O,I
was,O,O
prepared,O,O
by,O,O
PCR,O,O
and,O,O
expressed,O,O
as,O,O
a,O,O
recombinant,O,O
protein,O,O
in,O,O
Escherichia,O,O
coli,O,O
.,O,O
Using,O,O
this,O,O
as,O,O
immunogen,O,O
",",O,O
we,O,O
prepared,O,O
a,O,O
panel,O,O
of,O,O
12,O,O
monoclonal,O,O
antibodies,O,O
which,O,O
recognise,O,O
at,O,O
least,O,O
four,O,O
different,O,O
epitopes,O,O
on,O,O
emerin,O,B
in,O,O
order,O,O
to,O,O
ensure,O,O
that,O,O
emerin,O,B
can,O,O
be,O,O
distinguished,O,O
from,O,O
non,O,O
-,O,O
specific,O,O
cross,O,O
-,O,O
reacting,O,O
proteins,O,O
.,O,O
All,O,O
the,O,O
mAbs,O,O
recognised,O,O
a,O,O
34,O,O
kDa,O,O
protein,O,O
in,O,O
all,O,O
tissues,O,O
tested,O,O
",",O,O
though,O,O
minor,O,O
emerin,O,B
-,O,I
related,O,I
bands,O,I
were,O,O
also,O,O
detected,O,O
in,O,O
some,O,O
tissues,O,O
.,O,O
Immunofluorescence,O,O
microscopy,O,O
showed,O,O
that,O,O
emerin,O,B
is,O,O
located,O,O
at,O,O
the,O,O
nuclear,O,O
rim,O,O
in,O,O
all,O,O
tissues,O,O
examined,O,O
.,O,O
A,O,O
muscle,O,O
biopsy,O,O
from,O,O
an,O,O
Emery,B,O
-,I,O
Dreifuss,I,O
muscular,I,O
dystrophy,I,O
(,O,O
EMDM,B,O
),O,O
patient,O,O
showed,O,O
complete,O,O
absence,O,O
of,O,O
emerin,O,B
by,O,O
both,O,O
Western,O,O
blotting,O,O
and,O,O
immunohistochemistry,O,O
",",O,O
suggesting,O,O
a,O,O
simple,O,O
diagnostic,O,O
antibody,O,O
test,O,O
for,O,O
EDMD,B,O
families,O,O
.,O,O
Biochemical,O,O
fractionation,O,O
of,O,O
brain,O,B
and,O,O
liver,O,B
tissues,O,I
showed,O,O
that,O,O
emerin,O,B
was,O,O
present,O,O
in,O,O
nuclei,O,O
purified,O,O
by,O,O
centrifugation,O,O
through,O,O
65,O,O
%,O,O
sucrose,O,O
and,O,O
was,O,O
absent,O,O
from,O,O
soluble,O,O
fractions,O,O
(,O,O
post,O,O
-,O,O
100,O,O
",",O,O
g,O,O
),O,O
.,O,O
From,O,O
these,O,O
results,O,O
",",O,O
together,O,O
with,O,O
sequence,O,O
and,O,O
structural,O,O
homologies,O,O
between,O,O
emerin,O,B
",",O,O
thymopoietins,O,O
and,O,O
the,O,O
nuclear,O,O
lamina,O,O
-,O,O
associated,O,O
protein,O,O
",",O,O
LAP2,O,O
",",O,O
we,O,O
suggest,O,O
that,O,O
emerin,O,B
will,O,O
prove,O,O
to,O,O
be,O,O
one,O,O
member,O,O
of,O,O
a,O,O
family,O,O
of,O,O
inner,O,O
nuclear,O,O
membrane,O,O
proteins,O,O
.,O,O
.,O,O
Mutation,O,O
of,O,O
MSH3,O,B
in,O,O
endometrial,B,B
cancer,I,I
and,O,O
evidence,O,O
for,O,O
its,O,O
functional,O,O
role,O,O
in,O,O
heteroduplex,O,O
repair,O,O
.,O,O
Many,O,O
human,O,O
tumours,B,O
have,O,O
length,O,O
alterations,O,O
in,O,O
repetitive,O,O
sequence,O,O
elements,O,O
.,O,O
Although,O,O
this,O,O
microsatellite,B,O
instability,I,O
has,O,O
been,O,O
attributed,O,O
to,O,O
mutations,O,O
in,O,O
four,O,O
DNA,O,O
mismatch,O,O
repair,O,O
genes,O,O
in,O,O
hereditary,B,O
nonpolyposis,I,O
colorectal,I,O
cancer,I,O
(,O,O
HNPCC,B,O
),O,O
kindreds,O,O
",",O,O
many,O,O
sporadic,B,B
tumours,I,I
exhibit,O,O
instability,O,O
but,O,O
no,O,O
detectable,O,O
mutations,O,O
in,O,O
these,O,O
genes,O,O
.,O,O
It,O,O
is,O,O
therefore,O,O
of,O,O
interest,O,O
to,O,O
identify,O,O
other,O,O
genes,O,B
that,O,O
contribute,O,O
to,O,O
this,O,O
instability,O,O
.,O,O
In,O,O
yeast,O,O
",",O,O
mutations,O,O
in,O,O
several,O,O
genes,O,B
",",O,O
including,O,O
RTH,O,B
and,O,O
MSH3,O,B
",",O,O
cause,O,O
microsatellite,O,O
instability,O,O
.,O,O
Thus,O,O
",",O,O
we,O,O
screened,O,O
16,O,O
endometrial,B,O
carcinomas,I,O
with,O,O
microsatellite,O,O
instability,O,O
for,O,O
alterations,O,O
in,O,O
FEN1,O,B
(,O,O
the,O,O
human,O,O
homolog,O,O
of,O,O
RTH,O,B
),O,O
and,O,O
in,O,O
MSH3,O,B
(,O,O
refs,O,O
12,O,O
-,O,O
14,O,O
),O,O
.,O,O
Although,O,O
we,O,O
found,O,O
no,O,O
FEN1,O,B
mutations,O,O
",",O,O
a,O,O
frameshift,O,O
mutation,O,O
in,O,O
MSH3,O,B
was,O,O
observed,O,O
in,O,O
an,O,O
endometrial,B,B
carcinoma,I,I
and,O,O
in,O,O
an,O,O
endometrial,B,B
carcinoma,I,I
cell,O,I
line,O,I
.,O,O
Extracts,O,O
of,O,O
the,O,O
cell,O,O
line,O,O
were,O,O
deficient,O,O
in,O,O
repair,O,O
of,O,O
DNA,O,O
substrates,O,O
containing,O,O
mismatches,O,O
or,O,O
extra,O,O
nucleotides,O,O
.,O,O
Introducing,O,O
chromosome,O,O
5,O,O
",",O,O
encoding,O,O
the,O,O
MSH3,O,B
gene,O,I
",",O,O
into,O,O
the,O,O
mutant,O,O
cell,O,O
line,O,O
increased,O,O
the,O,O
stability,O,O
of,O,O
some,O,O
but,O,O
not,O,O
all,O,O
microsatellites,O,O
.,O,O
Extracts,O,O
of,O,O
these,O,O
cells,O,O
repaired,O,O
certain,O,O
substrates,O,O
containing,O,O
extra,O,O
nucleotides,O,O
",",O,O
but,O,O
were,O,O
deficient,O,O
in,O,O
repair,O,O
of,O,O
those,O,O
containing,O,O
mismatches,O,O
or,O,O
other,O,O
extra,O,O
nucleotides,O,O
.,O,O
A,O,O
subsequent,O,O
search,O,O
revealed,O,O
a,O,O
second,O,O
gene,O,B
mutation,O,O
in,O,O
HHUA,O,O
cells,O,O
",",O,O
a,O,O
missense,O,O
mutation,O,O
in,O,O
the,O,O
MSH6,O,B
gene,O,O
.,O,O
Together,O,O
the,O,O
data,O,O
suggest,O,O
that,O,O
the,O,O
MSH3,O,B
gene,O,O
encodes,O,O
a,O,O
product,O,O
that,O,O
functions,O,O
in,O,O
repair,O,O
of,O,O
some,O,O
but,O,O
not,O,O
all,O,O
pre,O,O
-,O,O
mutational,O,O
intermediates,O,O
",",O,O
its,O,O
mutation,O,O
in,O,O
tumours,B,O
can,O,O
result,O,O
in,O,O
genomic,O,O
instability,O,O
and,O,O
",",O,O
as,O,O
in,O,O
yeast,O,O
",",O,O
MSH3,O,B
and,O,O
MSH6,O,B
are,O,O
partially,O,O
redundant,O,O
for,O,O
mismatch,O,O
repair,O,O
.,O,O
.,O,O
Comparative,O,O
genome,O,O
mapping,O,O
of,O,O
the,O,O
ataxia,B,B
-,I,I
telangiectasia,I,I
region,O,I
in,O,O
mouse,O,O
",",O,O
rat,O,O
",",O,O
and,O,O
Syrian,O,O
hamster,O,O
.,O,O
Chromosomal,O,O
locations,O,O
of,O,O
the,O,O
Atm,O,O
(,O,O
ataxia,B,B
-,I,I
telangiectasia,I,I
(,O,O
AT,B,O
),O,O
-,O,O
mutated,O,O
),O,O
and,O,O
Acat1,O,O
(,O,O
mitochondrial,O,O
acetoacetyl,O,O
-,O,O
CoA,O,O
thiolase,O,O
),O,O
genes,O,O
in,O,O
mouse,O,O
",",O,O
rat,O,O
",",O,O
and,O,O
Syrian,O,O
hamster,O,O
were,O,O
determined,O,O
by,O,O
direct,O,O
R,O,O
-,O,O
banding,O,O
FISH,O,O
.,O,O
Both,O,O
genes,O,O
were,O,O
colocalized,O,O
to,O,O
the,O,O
C,O,O
-,O,O
D,O,O
band,O,O
of,O,O
mouse,O,O
chromosome,O,O
9,O,O
",",O,O
the,O,O
proximal,O,O
end,O,O
of,O,O
q24,O,O
.,O,O
1,O,O
of,O,O
rat,O,O
chromosome,O,O
8,O,O
",",O,O
and,O,O
qa4,O,O
-,O,O
qa5,O,O
of,O,O
Syrian,O,O
hamster,O,O
chromosome,O,O
12,O,O
.,O,O
The,O,O
regions,O,O
in,O,O
the,O,O
mouse,O,O
and,O,O
rat,O,O
were,O,O
homologous,O,O
to,O,O
human,O,O
chromosome,O,O
11q,O,O
.,O,O
Fine,O,O
genetic,O,O
linkage,O,O
mapping,O,O
of,O,O
the,O,O
mouse,O,O
AT,B,O
region,O,O
was,O,O
performed,O,O
using,O,O
the,O,O
interspecific,O,O
backcross,O,O
mice,O,O
.,O,O
Atm,O,B
",",O,O
Acat1,O,B
",",O,O
and,O,O
Npat,O,B
",",O,O
which,O,O
is,O,O
a,O,O
new,O,O
gene,O,O
isolated,O,O
from,O,O
the,O,O
AT,O,O
region,O,O
",",O,O
and,O,O
12,O,O
flanking,O,O
microsatellite,O,O
DNA,O,O
markers,O,O
were,O,O
examined,O,O
.,O,O
No,O,O
recombinations,O,O
were,O,O
found,O,O
among,O,O
the,O,O
Atm,O,B
",",O,O
Npat,O,B
",",O,O
Acat1,O,B
",",O,O
and,O,O
D9Mit6,O,O
loci,O,O
",",O,O
and,O,O
these,O,O
loci,O,O
were,O,O
mapped,O,O
2,O,O
.,O,O
0,O,O
cM,O,O
distal,O,O
to,O,O
D9Mit99,O,O
and,O,O
1,O,O
.,O,O
3,O,O
cM,O,O
proximal,O,O
to,O,O
D9Mit102,O,O
.,O,O
Comparison,O,O
of,O,O
the,O,O
linkage,O,O
map,O,O
of,O,O
mouse,O,O
chromosome,O,O
9,O,O
(,O,O
MMU9,O,O
),O,O
and,O,O
that,O,O
of,O,O
human,O,O
chromosome,O,O
11,O,O
(,O,O
HSA11,O,O
),O,O
indicates,O,O
that,O,O
there,O,O
is,O,O
a,O,O
chromosomal,O,O
rearrangement,O,O
due,O,O
to,O,O
an,O,O
inversion,O,O
between,O,O
Ets1,O,O
and,O,O
Atm,O,B
-,O,I
Npat,O,I
-,O,I
Acat1,O,I
and,O,O
that,O,O
the,O,O
inversion,O,O
of,O,O
MMU9,O,O
originated,O,O
from,O,O
the,O,O
chromosomal,O,O
breakage,O,O
at,O,O
the,O,O
boundary,O,O
between,O,O
Gria4,O,O
and,O,O
Atm,O,B
-,O,I
Npat,O,I
-,O,I
Acat1,O,I
on,O,O
HSA11,O,O
.,O,O
This,O,O
type,O,O
of,O,O
inversion,O,O
appeared,O,O
to,O,O
be,O,O
conserved,O,O
in,O,O
the,O,O
three,O,O
rodent,O,O
species,O,O
",",O,O
mouse,O,B
",",O,O
rat,O,B
",",O,O
and,O,O
Syrian,O,B
hamster,O,I
",",O,O
using,O,O
additional,O,O
comparative,O,O
mapping,O,O
data,O,O
with,O,O
the,O,O
Rck,O,B
gene,O,I
An,O,O
animal,O,O
model,O,O
for,O,O
Norrie,B,B
disease,I,I
(,O,O
ND,B,O
),O,O
:,O,O
gene,O,O
targeting,O,O
of,O,O
the,O,O
mouse,O,B
ND,B,O
gene,O,O
.,O,O
In,O,O
order,O,O
to,O,O
elucidate,O,O
the,O,O
cellular,O,O
and,O,O
molecular,O,O
processes,O,O
which,O,O
are,O,O
involved,O,O
in,O,O
Norrie,B,B
disease,I,I
(,O,O
ND,B,O
),O,O
",",O,O
we,O,O
have,O,O
used,O,O
gene,O,O
targeting,O,O
technology,O,O
to,O,O
generate,O,O
ND,B,O
mutant,O,O
mice,O,O
.,O,O
The,O,O
murine,O,O
homologue,O,O
of,O,O
the,O,O
ND,B,B
gene,O,I
was,O,O
cloned,O,O
and,O,O
shown,O,O
to,O,O
encode,O,O
a,O,O
polypeptide,O,O
that,O,O
shares,O,O
94,O,O
%,O,O
of,O,O
the,O,O
amino,O,O
acid,O,O
sequence,O,O
with,O,O
its,O,O
human,O,O
counterpart,O,O
.,O,O
RNA,O,O
in,O,O
situ,O,O
hybridization,O,O
revealed,O,O
expression,O,O
in,O,O
retina,O,O
",",O,O
brain,O,O
and,O,O
the,O,O
olfactory,O,O
bulb,O,O
and,O,O
epithelium,O,O
of,O,O
2,O,O
week,O,O
old,O,O
mice,O,O
.,O,O
Hemizygous,O,O
mice,O,O
carrying,O,O
a,O,O
replacement,O,O
mutation,O,O
in,O,O
exon,O,O
2,O,O
of,O,O
the,O,O
ND,B,B
gene,O,I
developed,O,O
retrolental,O,O
structures,O,O
in,O,O
the,O,O
vitreous,O,O
body,O,O
and,O,O
showed,O,O
an,O,O
overall,O,O
disorganization,O,O
of,O,O
the,O,O
retinal,O,O
ganglion,O,O
cell,O,O
layer,O,O
.,O,O
The,O,O
outer,O,O
plexiform,O,O
layer,O,O
disappears,O,O
occasionally,O,O
",",O,O
resulting,O,O
in,O,O
a,O,O
juxtaposed,O,O
inner,O,O
and,O,O
outer,O,O
nuclear,O,O
layer,O,O
.,O,O
At,O,O
the,O,O
same,O,O
regions,O,O
",",O,O
the,O,O
outer,O,O
segments,O,O
of,O,O
the,O,O
photoreceptor,O,O
cell,O,O
layer,O,O
are,O,O
no,O,O
longer,O,O
present,O,O
.,O,O
These,O,O
ocular,O,O
findings,O,O
are,O,O
consistent,O,O
with,O,O
observations,O,O
in,O,O
ND,B,O
patients,O,O
and,O,O
the,O,O
generated,O,O
mouse,O,O
line,O,O
provides,O,O
a,O,O
faithful,O,O
model,O,O
for,O,O
study,O,O
of,O,O
early,O,O
pathogenic,O,O
events,O,O
in,O,O
this,O,O
severe,O,O
X,B,B
-,I,I
linked,I,I
recessive,I,I
neurological,I,I
disorder,I,I
.,O,O
.,O,O
The,O,O
hybrid,O,O
PAX3,O,B
-,O,I
FKHR,O,B
fusion,O,O
protein,O,O
of,O,O
alveolar,B,B
rhabdomyosarcoma,I,I
transforms,O,O
fibroblasts,O,O
in,O,O
culture,O,O
.,O,O
Pediatric,B,O
alveolar,I,B
rhabdomyosarcoma,I,I
is,O,O
characterized,O,O
by,O,O
a,O,O
chromosomal,O,O
translocation,O,O
that,O,O
fuses,O,O
parts,O,O
of,O,O
the,O,O
PAX3,O,B
and,O,O
FKHR,O,B
genes,O,O
.,O,O
PAX3,O,B
codes,O,O
for,O,O
a,O,O
transcriptional,O,O
regulator,O,O
that,O,O
controls,O,O
developmental,O,O
programs,O,O
",",O,O
and,O,O
FKHR,O,B
codes,O,O
for,O,O
a,O,O
forkhead,O,O
-,O,O
winged,O,O
helix,O,O
protein,O,O
",",O,O
also,O,O
a,O,O
likely,O,O
transcription,O,O
factor,O,O
.,O,O
The,O,O
PAX3,O,B
-,O,I
FKHR,O,I
fusion,O,O
product,O,O
retains,O,O
the,O,O
DNA,O,O
binding,O,O
domains,O,O
of,O,O
the,O,O
PAX3,O,B
protein,O,O
and,O,O
the,O,O
putative,O,O
activator,O,O
domain,O,O
of,O,O
the,O,O
FKHR,O,B
protein,O,O
.,O,O
The,O,O
PAX3,O,B
-,O,I
FKHR,O,I
protein,O,O
has,O,O
been,O,O
shown,O,O
to,O,O
function,O,O
as,O,O
a,O,O
transcriptional,O,O
activator,O,O
.,O,O
Using,O,O
the,O,O
RCAS,O,O
retroviral,O,O
vector,O,O
",",O,O
we,O,O
have,O,O
introduced,O,O
the,O,O
PAX3,O,B
-,O,I
FKHR,O,I
gene,O,O
into,O,O
chicken,O,O
embryo,O,O
fibroblasts,O,O
.,O,O
Expression,O,O
of,O,O
the,O,O
PAX3,O,B
-,O,I
FKHR,O,I
protein,O,O
in,O,O
these,O,O
cells,O,O
leads,O,O
to,O,O
transformation,O,O
the,O,O
cells,O,O
become,O,O
enlarged,O,O
",",O,O
grow,O,O
tightly,O,O
packed,O,O
and,O,O
in,O,O
multiple,O,O
layers,O,O
",",O,O
and,O,O
acquire,O,O
the,O,O
ability,O,O
for,O,O
anchorage,O,O
-,O,O
independent,O,O
growth,O,O
.,O,O
This,O,O
cellular,O,O
transformation,O,O
in,O,O
vitro,O,O
will,O,O
facilitate,O,O
studies,O,O
on,O,O
the,O,O
mechanism,O,O
of,O,O
PAX3,O,B
-,O,I
FKHR,O,I
-,O,I
induced,O,I
oncogenesis,O,I
.,O,O
.,O,O
Somatic,O,O
-,O,O
cell,O,O
selection,O,O
is,O,O
a,O,O
major,O,O
determinant,O,O
of,O,O
the,O,O
blood,O,O
-,O,O
cell,O,O
phenotype,O,O
in,O,O
heterozygotes,O,O
for,O,O
glucose,O,B
-,O,I
6,O,I
-,O,I
phosphate,O,I
dehydrogenase,O,I
mutations,O,O
causing,O,O
severe,O,O
enzyme,B,O
deficiency,I,O
.,O,O
X,O,O
-,O,O
chromosome,O,O
inactivation,O,O
in,O,O
mammals,O,O
is,O,O
regarded,O,O
as,O,O
an,O,O
essentially,O,O
random,O,O
process,O,O
",",O,O
but,O,O
the,O,O
resulting,O,O
somatic,O,O
-,O,O
cell,O,O
mosaicism,O,O
creates,O,O
the,O,O
opportunity,O,O
for,O,O
cell,O,O
selection,O,O
.,O,O
In,O,O
most,O,O
people,O,O
with,O,O
red,O,O
-,O,O
blood,O,O
-,O,O
cell,O,O
glucose,B,B
-,I,I
6,I,I
-,I,I
phosphate,I,I
dehydrogenase,I,I
(,I,O
G6PD,I,O
),I,O
deficiency,I,O
",",O,O
the,O,O
enzyme,O,O
-,O,O
deficient,O,O
phenotype,O,O
is,O,O
only,O,O
moderately,O,O
expressed,O,O
in,O,O
nucleated,O,O
cells,O,O
.,O,O
However,O,O
",",O,O
in,O,O
a,O,O
small,O,O
subset,O,O
of,O,O
hemizygous,O,O
males,O,O
who,O,O
suffer,O,O
from,O,O
chronic,B,O
nonspherocytic,I,O
hemolytic,I,O
anemia,I,O
",",O,O
the,O,O
underlying,O,O
mutations,O,O
(,O,O
designated,O,O
class,O,O
I,O,O
),O,O
cause,O,O
more,O,O
-,O,O
severe,O,O
G6PD,B,O
deficiency,I,O
",",O,O
and,O,O
this,O,O
might,O,O
provide,O,O
an,O,O
opportunity,O,O
for,O,O
selection,O,O
in,O,O
heterozygous,O,O
females,O,O
during,O,O
development,O,O
.,O,O
In,O,O
order,O,O
to,O,O
test,O,O
this,O,O
possibility,O,O
we,O,O
have,O,O
analyzed,O,O
four,O,O
heterozygotes,O,O
for,O,O
class,O,O
I,O,O
G6PD,O,B
mutations,O,O
two,O,O
with,O,O
G6PD,O,B
Portici,O,I
(,O,O
1178G,O,O
-,O,O
-,O,O
>,O,O
A,O,O
),O,O
and,O,O
two,O,O
with,O,O
G6PD,O,B
Bari,O,I
(,O,O
1187C,O,O
-,O,O
-,O,O
>,O,O
T,O,O
),O,O
.,O,O
We,O,O
found,O,O
that,O,O
in,O,O
fractionated,O,O
blood,O,O
cell,O,O
types,O,O
(,O,O
including,O,O
erythroid,O,O
",",O,O
myeloid,O,O
",",O,O
and,O,O
lymphoid,O,O
cell,O,O
lineages,O,O
),O,O
there,O,O
was,O,O
a,O,O
significant,O,O
excess,O,O
of,O,O
G6PD,O,B
-,O,I
normal,O,I
cells,O,I
.,O,O
The,O,O
significant,O,O
concordance,O,O
that,O,O
we,O,O
have,O,O
observed,O,O
in,O,O
the,O,O
degree,O,O
of,O,O
imbalance,O,O
in,O,O
the,O,O
different,O,O
blood,O,O
-,O,O
cell,O,O
lineages,O,O
indicates,O,O
that,O,O
a,O,O
selective,O,O
mechanism,O,O
is,O,O
likely,O,O
to,O,O
operate,O,O
at,O,O
the,O,O
level,O,O
of,O,O
pluripotent,O,O
blood,O,O
stem,O,O
cells,O,O
.,O,O
Thus,O,O
",",O,O
it,O,O
appears,O,O
that,O,O
severe,O,O
G6PD,B,B
deficiency,I,I
affects,O,O
adversely,O,O
the,O,O
proliferation,O,O
or,O,O
the,O,O
survival,O,O
of,O,O
nucleated,O,O
blood,O,O
cells,O,O
and,O,O
that,O,O
this,O,O
phenotypic,O,O
characteristic,O,O
is,O,O
critical,O,O
during,O,O
hematopoiesis,O,O
.,O,O
.,O,O
Analysis,O,O
of,O,O
meiotic,O,O
segregation,O,O
",",O,O
using,O,O
single,O,O
-,O,O
sperm,O,O
typing,O,O
:,O,O
meiotic,O,O
drive,O,O
at,O,O
the,O,O
myotonic,B,B
dystrophy,I,I
locus,O,O
.,O,O
Meiotic,O,O
drive,O,O
at,O,O
the,O,O
myotonic,B,B
dystrophy,I,I
(,O,O
DM,B,O
),O,O
locus,O,O
has,O,O
recently,O,O
been,O,O
suggested,O,O
as,O,O
being,O,O
responsible,O,O
for,O,O
maintaining,O,O
the,O,O
frequency,O,O
",",O,O
in,O,O
the,O,O
human,O,O
population,O,O
",",O,O
of,O,O
DM,B,O
chromosomes,O,O
capable,O,O
of,O,O
expansion,O,O
to,O,O
the,O,O
disease,O,O
state,O,O
.,O,O
In,O,O
order,O,O
to,O,O
test,O,O
this,O,O
hypothesis,O,O
",",O,O
we,O,O
have,O,O
studied,O,O
samples,O,O
of,O,O
single,O,O
sperm,O,O
from,O,O
three,O,O
individuals,O,O
heterozygous,O,O
at,O,O
the,O,O
DM,B,B
locus,O,I
",",O,O
each,O,O
with,O,O
one,O,O
allele,O,O
larger,O,O
and,O,O
one,O,O
allele,O,O
smaller,O,O
than,O,O
19,O,O
CTG,O,B
repeats,O,I
.,O,O
To,O,O
guard,O,O
against,O,O
the,O,O
possible,O,O
problem,O,O
of,O,O
differential,O,O
PCR,O,O
amplification,O,O
rates,O,O
based,O,O
on,O,O
the,O,O
lengths,O,O
of,O,O
the,O,O
alleles,O,O
",",O,O
the,O,O
sperm,O,O
were,O,O
also,O,O
typed,O,O
at,O,O
another,O,O
closely,O,O
linked,O,O
marker,O,O
whose,O,O
allele,O,O
size,O,O
was,O,O
unrelated,O,O
to,O,O
the,O,O
allele,O,O
size,O,O
at,O,O
the,O,O
DM,B,B
locus,O,I
.,O,O
Using,O,O
statistical,O,O
models,O,O
specifically,O,O
designed,O,O
to,O,O
study,O,O
single,O,O
-,O,O
sperm,O,O
segregation,O,O
data,O,O
",",O,O
we,O,O
find,O,O
no,O,O
evidence,O,O
of,O,O
meiotic,O,O
segregation,O,O
distortion,O,O
.,O,O
The,O,O
upper,O,O
limit,O,O
of,O,O
the,O,O
two,O,O
-,O,O
sided,O,O
95,O,O
%,O,O
confidence,O,O
interval,O,O
for,O,O
the,O,O
estimate,O,O
of,O,O
the,O,O
common,O,O
segregation,O,O
probability,O,O
for,O,O
the,O,O
three,O,O
donors,O,O
is,O,O
at,O,O
or,O,O
below,O,O
.,O,O
515,O,O
for,O,O
all,O,O
models,O,O
considered,O,O
",",O,O
and,O,O
no,O,O
statistically,O,O
significant,O,O
difference,O,O
from,O,O
.,O,O
5,O,O
is,O,O
detected,O,O
in,O,O
any,O,O
of,O,O
the,O,O
models,O,O
.,O,O
This,O,O
suggests,O,O
that,O,O
any,O,O
greater,O,O
amount,O,O
of,O,O
segregation,O,O
distortion,O,O
at,O,O
the,O,O
myotonic,B,B
dystrophy,I,I
locus,O,I
must,O,O
result,O,O
from,O,O
events,O,O
following,O,O
sperm,O,O
ejaculation,O,O
.,O,O
LPP,O,O
",",O,O
the,O,O
preferred,O,O
fusion,O,O
partner,O,O
gene,O,O
of,O,O
HMGIC,O,O
in,O,O
lipomas,B,O
",",O,O
is,O,O
a,O,O
novel,O,O
member,O,O
of,O,O
the,O,O
LIM,O,O
protein,O,O
gene,O,O
family,O,O
.,O,O
A,O,O
major,O,O
cytogenetic,O,O
subgroup,O,O
of,O,O
lipomas,B,O
is,O,O
characterized,O,O
by,O,O
recurrent,O,O
chromosome,O,O
aberrations,O,O
",",O,O
mainly,O,O
translocations,O,O
",",O,O
that,O,O
involve,O,O
chromosome,O,O
segment,O,O
12q13,O,O
-,O,O
q15,O,O
.,O,O
Multiple,O,O
chromosomes,O,O
have,O,O
been,O,O
found,O,O
as,O,O
the,O,O
translocation,O,O
partners,O,O
of,O,O
chromosome,O,B
12,O,I
but,O,O
3q27,O,O
-,O,O
q28,O,O
is,O,O
preferentially,O,O
involved,O,O
.,O,O
In,O,O
previous,O,O
studies,O,O
",",O,O
it,O,O
has,O,O
been,O,O
shown,O,O
that,O,O
the,O,O
high,O,O
mobility,O,O
group,O,O
(,O,O
HMG,O,B
),O,O
protein,O,O
gene,O,O
HMGIC,O,O
at,O,O
12q15,O,O
is,O,O
consistently,O,O
rearranged,O,O
as,O,O
a,O,O
consequence,O,O
of,O,O
these,O,O
translocations,O,O
.,O,O
Here,O,O
",",O,O
we,O,O
report,O,O
the,O,O
identification,O,O
and,O,O
characterization,O,O
of,O,O
the,O,O
chromosome,O,O
3,O,O
-,O,O
derived,O,O
translocation,O,O
partner,O,O
gene,O,B
",",O,O
which,O,O
we,O,O
have,O,O
designated,O,O
LPP,O,B
(,O,O
lipoma,B,B
preferred,O,I
partner,O,I
gene,O,I
),O,O
.,O,O
Using,O,O
3,O,O
-,O,O
RACE,O,O
analysis,O,O
of,O,O
HMGIC,O,O
fusion,O,O
transcripts,O,O
in,O,O
lipoma,B,B
cell,O,I
line,O,I
Li,O,B
-,O,I
501,O,I
/,O,I
SV40,O,I
",",O,O
ectopic,O,O
genetic,O,O
sequences,O,O
were,O,O
obtained,O,O
",",O,O
which,O,O
by,O,O
CASH,O,O
(,O,O
chromosome,O,O
assignment,O,O
using,O,O
somatic,O,O
cell,O,O
hybrids,O,O
),O,O
and,O,O
FISH,O,O
(,O,O
fluorescence,O,O
in,O,O
situ,O,O
hybridization,O,O
),O,O
analysis,O,O
were,O,O
found,O,O
to,O,O
originate,O,O
from,O,O
chromosome,O,O
segment,O,O
3q27,O,O
-,O,O
q28,O,O
.,O,O
In,O,O
Northern,O,O
blot,O,O
analysis,O,O
",",O,O
an,O,O
mRNA,O,O
of,O,O
over,O,O
10,O,B
kb,O,I
was,O,O
detected,O,O
by,O,O
these,O,O
ectopic,O,O
sequences,O,O
in,O,O
a,O,O
variety,O,O
of,O,O
human,O,O
tissues,O,O
but,O,O
not,O,O
in,O,O
brain,O,O
and,O,O
peripheral,O,O
blood,O,O
leukocytes,O,O
.,O,O
Upon,O,O
partial,O,O
cDNA,O,O
cloning,O,O
",",O,O
features,O,O
of,O,O
the,O,O
genetic,O,O
organization,O,O
of,O,O
LPP,O,B
were,O,O
established,O,O
.,O,O
The,O,O
gene,O,O
was,O,O
found,O,O
to,O,O
span,O,O
a,O,O
genomic,O,O
region,O,O
of,O,O
over,O,O
400,O,B
kb,O,I
.,O,O
Nucleotide,O,O
sequence,O,O
analysis,O,O
of,O,O
a,O,O
composite,O,O
cDNA,O,O
of,O,O
LPP,O,B
revealed,O,O
an,O,O
open,O,O
reading,O,O
frame,O,O
of,O,O
1836,O,O
nucleotides,O,O
encoding,O,O
a,O,O
proline,O,O
-,O,O
rich,O,O
protein,O,O
containing,O,O
a,O,O
leucine,O,O
-,O,O
zipper,O,O
motif,O,O
in,O,O
its,O,O
amino,O,O
-,O,O
terminal,O,O
region,O,O
and,O,O
three,O,O
LIM,O,O
domains,O,O
in,O,O
its,O,O
carboxy,O,O
-,O,O
terminal,O,O
region,O,O
.,O,O
The,O,O
LPP,O,B
-,O,I
encoded,O,I
protein,O,I
should,O,O
be,O,O
classified,O,O
as,O,O
a,O,O
novel,O,O
member,O,O
of,O,O
the,O,O
group,O,O
3,O,O
proteins,O,O
of,O,O
the,O,O
LIM,O,O
protein,O,O
gene,O,O
family,O,O
.,O,O
Using,O,O
reverse,O,O
transcriptase,O,O
combined,O,O
with,O,O
polymerase,O,O
chain,O,O
reactions,O,O
in,O,O
the,O,O
analysis,O,O
of,O,O
a,O,O
number,O,O
of,O,O
lipoma,B,B
cell,O,I
lines,O,I
and,O,O
primary,B,O
lipomas,I,B
",",O,O
it,O,O
appeared,O,O
that,O,O
LPP,O,B
is,O,O
frequently,O,O
rearranged,O,O
also,O,O
in,O,O
cases,O,O
without,O,O
a,O,O
cytogenetically,O,O
detectable,O,O
involvement,O,O
of,O,O
3q27,O,O
-,O,O
q28,O,O
.,O,O
Two,O,O
alternative,O,O
HMGIC,O,O
/,O,O
LPP,O,B
hybrid,O,O
transcripts,O,O
have,O,O
been,O,O
detected,O,O
;,O,O
the,O,O
difference,O,O
between,O,O
them,O,O
is,O,O
mainly,O,O
the,O,O
presence,O,O
of,O,O
either,O,O
two,O,O
or,O,O
three,O,O
LIM,O,O
domains,O,O
in,O,O
the,O,O
predicted,O,O
HMGI,O,O
-,O,O
C,O,O
/,O,O
LPP,O,B
fusion,O,O
proteins,O,O
.,O,O
.,O,O
Absence,O,O
of,O,O
disease,O,O
phenotype,O,O
and,O,O
intergenerational,O,O
stability,O,O
of,O,O
the,O,O
CAG,O,B
repeat,O,I
in,O,O
transgenic,O,O
mice,O,O
expressing,O,O
the,O,O
human,O,O
Huntington,B,B
disease,I,I
transcript,O,I
.,O,O
The,O,O
mutation,O,O
underlying,O,O
Huntington,B,B
disease,I,I
(,O,O
HD,B,O
),O,O
is,O,O
CAG,O,B
expansion,O,I
in,O,O
the,O,O
first,O,O
exon,O,O
of,O,O
the,O,O
HD,B,O
gene,O,O
.,O,O
In,O,O
order,O,O
to,O,O
investigate,O,O
the,O,O
role,O,O
of,O,O
CAG,O,B
expansion,O,I
in,O,O
the,O,O
pathogenesis,O,O
of,O,O
HD,B,O
",",O,O
we,O,O
have,O,O
produced,O,O
transgenic,O,O
mice,O,O
containing,O,O
the,O,O
full,O,O
length,O,O
human,O,O
HD,B,O
cDNA,O,O
with,O,O
44,O,O
CAG,O,B
repeats,O,I
.,O,O
By,O,O
1,O,O
year,O,O
",",O,O
these,O,O
mice,O,O
have,O,O
no,O,O
behavioral,B,O
abnormalities,I,O
and,O,O
morphometric,O,O
analysis,O,O
at,O,O
6,O,O
(,O,O
one,O,O
animal,O,O
),O,O
and,O,O
9,O,O
(,O,O
two,O,O
animals,O,O
),O,O
months,O,O
age,O,O
revealed,O,O
no,O,O
changes,O,O
.,O,O
Despite,O,O
high,O,O
levels,O,O
of,O,O
mRNA,O,O
expression,O,O
",",O,O
there,O,O
was,O,O
no,O,O
evidence,O,O
of,O,O
the,O,O
HD,B,B
gene,O,I
product,O,I
in,O,O
any,O,O
of,O,O
these,O,O
transgenic,O,O
mice,O,O
.,O,O
In,O,O
vitro,O,O
transfection,O,O
studies,O,O
indicated,O,O
that,O,O
the,O,O
inclusion,O,O
of,O,O
120,O,O
bp,O,O
of,O,O
the,O,O
5,O,O
UTR,O,O
in,O,O
the,O,O
cDNA,O,O
construct,O,O
and,O,O
the,O,O
presence,O,O
of,O,O
a,O,O
frameshift,O,O
mutation,O,O
at,O,O
nucleotide,O,O
2349,O,O
prevented,O,O
expression,O,O
of,O,O
the,O,O
HD,B,B
cDNA,O,I
.,O,O
These,O,O
findings,O,O
suggest,O,O
that,O,O
the,O,O
pathogenesis,O,O
of,O,O
HD,B,B
is,O,O
not,O,O
mediated,O,O
through,O,O
DNA,O,O
-,O,O
protein,O,O
interaction,O,O
and,O,O
that,O,O
presence,O,O
of,O,O
the,O,O
RNA,O,O
transcript,O,O
with,O,O
an,O,O
expanded,O,O
CAG,O,B
repeat,O,I
is,O,O
insufficient,O,O
to,O,O
cause,O,O
the,O,O
disease,O,O
.,O,O
Rather,O,O
",",O,O
translation,O,O
of,O,O
the,O,O
CAG,O,B
is,O,O
crucial,O,O
for,O,O
the,O,O
pathogenesis,O,O
of,O,O
HD,B,B
.,O,O
In,O,O
contrast,O,O
to,O,O
that,O,O
seen,O,O
in,O,O
humans,O,O
",",O,O
the,O,O
CAG,O,B
repeat,O,I
in,O,O
these,O,O
mice,O,O
was,O,O
remarkably,O,O
stable,O,O
in,O,O
97,O,O
meioses,O,O
.,O,O
This,O,O
suggests,O,O
that,O,O
genomic,O,O
sequences,O,O
may,O,O
play,O,O
a,O,O
critical,O,O
role,O,O
in,O,O
influencing,O,O
repeat,O,O
instability,O,O
.,O,O
FISH,O,O
studies,O,O
in,O,O
a,O,O
patient,O,O
with,O,O
sporadic,B,B
aniridia,I,I
and,O,O
t,O,O
(,O,O
7,O,O
;,O,O
11,O,O
),O,O
(,O,O
q31,O,O
.,O,O
2,O,O
;,O,O
p13,O,O
),O,O
.,O,O
A,O,O
2,O,O
year,O,O
old,O,O
female,O,O
presenting,O,O
with,O,O
bilateral,B,O
sporadic,I,B
aniridia,I,I
was,O,O
found,O,O
to,O,O
have,O,O
an,O,O
apparently,O,O
balanced,O,O
reciprocal,O,O
translocation,O,O
with,O,O
a,O,O
chromosome,O,O
11,O,O
breakpoint,O,O
within,O,O
band,O,O
p13,O,O
.,O,O
Fluorescence,O,O
in,O,O
situ,O,O
hybridisation,O,O
(,O,O
FISH,O,O
),O,O
studies,O,O
with,O,O
distal,O,O
11p13,O,O
specific,O,O
cosmids,O,O
showed,O,O
that,O,O
the,O,O
chromosome,O,O
11,O,O
breakpoint,O,O
lay,O,O
between,O,O
the,O,O
aniridia,B,B
(,O,O
PAX6,O,B
),O,O
locus,O,O
and,O,O
a,O,O
region,O,O
approximately,O,O
100,O,O
kb,O,O
distal,O,O
to,O,O
PAX6,O,B
defined,O,O
by,O,O
the,O,O
cosmid,O,O
FO2121,O,O
.,O,O
Although,O,O
this,O,O
patient,O,O
did,O,O
not,O,O
have,O,O
a,O,O
detectable,O,O
deletion,O,O
within,O,O
PAX6,O,B
",",O,O
her,O,O
aniridia,B,B
may,O,O
have,O,O
resulted,O,O
from,O,O
a,O,O
disruption,O,O
of,O,O
the,O,O
distal,O,O
chromatin,O,O
domain,O,O
containing,O,O
either,O,O
enhancers,O,O
or,O,O
regulators,O,O
for,O,O
PAX6,O,B
.,O,O
This,O,O
case,O,O
may,O,O
therefore,O,O
be,O,O
another,O,O
example,O,O
of,O,O
aniridia,B,B
caused,O,O
by,O,O
a,O,O
position,O,O
effect,O,O
as,O,O
recently,O,O
described,O,O
in,O,O
two,O,O
familial,B,O
aniridia,I,B
patients,O,O
in,O,O
which,O,O
the,O,O
phenotype,O,O
cosegregated,O,O
with,O,O
chromosome,B,O
abnormalities,I,O
with,O,O
11p13,O,O
breakpoints,O,O
.,O,O
Muscle,O,O
expression,O,O
of,O,O
glucose,B,O
-,I,O
6,I,O
-,I,O
phosphate,I,O
dehydrogenase,I,O
deficiency,I,O
in,O,O
different,O,O
variants,O,O
.,O,O
Muscle,O,O
expression,O,O
of,O,O
G6PD,B,B
deficiency,I,I
has,O,O
been,O,O
investigated,O,O
in,O,O
Mediterranean,O,O
",",O,O
Seattle,O,O
-,O,O
like,O,O
and,O,O
A,O,O
-,O,O
variants,O,O
.,O,O
G6PD,O,B
activity,O,O
was,O,O
detected,O,O
in,O,O
samples,O,O
obtained,O,O
from,O,O
biopsies,O,O
on,O,O
the,O,O
quadriceps,O,O
muscle,O,O
of,O,O
seven,O,O
males,O,O
and,O,O
one,O,O
female,O,O
.,O,O
The,O,O
type,O,O
of,O,O
genetic,O,O
variant,O,O
was,O,O
determined,O,O
by,O,O
molecular,O,O
analysis,O,O
of,O,O
DNA,O,O
",",O,O
extracted,O,O
from,O,O
blood,O,O
samples,O,O
.,O,O
All,O,O
variants,O,O
showed,O,O
the,O,O
enzyme,O,O
defect,O,O
in,O,O
muscle,O,O
.,O,O
A,O,O
statistically,O,O
significant,O,O
relationship,O,O
was,O,O
found,O,O
in,O,O
the,O,O
activity,O,O
of,O,O
G6PD,O,B
between,O,O
erythrocytes,O,O
and,O,O
muscle,O,O
of,O,O
the,O,O
male,O,O
subjects,O,O
(,O,O
r,O,O
=,O,O
0,O,O
.,O,O
968,O,O
;,O,O
p,O,O
=,O,O
0,O,O
.,O,O
),O,O
.,O,O
The,O,O
equation,O,O
for,O,O
the,O,O
best,O,O
fit,O,O
line,O,O
was,O,O
Y,O,O
=,O,O
0,O,O
.,O,O
390X,O,O
+,O,O
0,O,O
.,O,O
198,O,O
198,O,O
.,O,O
The,O,O
results,O,O
suggest,O,O
that,O,O
",",O,O
for,O,O
a,O,O
given,O,O
variant,O,O
",",O,O
the,O,O
extent,O,O
of,O,O
the,O,O
enzyme,O,O
defect,O,O
in,O,O
muscle,O,O
may,O,O
be,O,O
determined,O,O
",",O,O
using,O,O
this,O,O
equation,O,O
",",O,O
from,O,O
the,O,O
G6PD,O,B
activity,O,O
of,O,O
erythrocytes,O,O
Gene,O,O
therapy,O,O
for,O,O
phenylketonuria,B,O
.,O,O
Classical,O,O
phenylketonuria,B,B
(,O,O
PKU,B,B
),O,O
is,O,O
an,O,O
autosomal,B,O
recessive,I,O
disorder,I,O
caused,O,O
by,O,O
a,O,O
deficiency,B,O
of,I,O
hepatic,I,O
phenylalanine,I,B
hydroxylase,I,I
(,O,O
PAH,O,B
),O,O
.,O,O
Limitations,O,O
of,O,O
the,O,O
current,O,O
dietary,O,O
treatment,O,O
for,O,O
PKU,B,B
have,O,O
led,O,O
to,O,O
the,O,O
development,O,O
of,O,O
potential,O,O
treatments,O,O
based,O,O
on,O,O
somatic,O,O
gene,O,B
transfer,O,I
.,O,O
Three,O,O
different,O,O
vector,O,O
systems,O,O
have,O,O
been,O,O
examined,O,O
.,O,O
Vectors,O,O
derived,O,O
from,O,O
a,O,O
recombinant,O,O
retrovirus,O,O
or,O,O
a,O,O
DNA,O,O
/,O,O
protein,O,O
complex,O,O
can,O,O
efficiently,O,O
transduce,O,O
the,O,O
PAH,O,B
cDNA,O,I
into,O,O
PAH,B,B
-,I,I
deficient,I,I
hepatocytes,O,I
in,O,O
vitro,O,O
",",O,O
but,O,O
the,O,O
application,O,O
of,O,O
these,O,O
vector,O,O
systems,O,O
is,O,O
presently,O,O
limited,O,O
by,O,O
their,O,O
low,O,O
transduction,O,O
efficiency,O,O
in,O,O
vivo,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
a,O,O
vector,O,O
derived,O,O
from,O,O
a,O,O
recombinant,O,O
adenovirus,O,O
can,O,O
restore,O,O
10,O,O
%,O,O
-,O,O
80,O,O
%,O,O
of,O,O
normal,O,O
hepatic,O,O
PAH,O,B
activity,O,O
into,O,O
PAH,B,B
-,I,I
deficient,I,I
mice,O,O
",",O,O
which,O,O
completely,O,O
normalizes,O,O
serum,O,O
phenylalanine,O,O
levels,O,O
.,O,O
This,O,O
treatment,O,O
is,O,O
transient,O,O
and,O,O
cannot,O,O
be,O,O
effectively,O,O
re,O,O
-,O,O
administered,O,O
due,O,O
to,O,O
the,O,O
presence,O,O
of,O,O
neutralizing,O,O
antibodies,O,O
directed,O,O
against,O,O
the,O,O
recombinant,O,O
adenoviral,O,B
vector,O,I
.,O,O
However,O,O
",",O,O
these,O,O
findings,O,O
suggest,O,O
that,O,O
PKU,B,O
can,O,O
be,O,O
completely,O,O
corrected,O,O
by,O,O
somatic,O,O
gene,O,B
therapy,O,I
",",O,O
and,O,O
provide,O,O
some,O,O
direction,O,O
for,O,O
the,O,O
future,O,O
development,O,O
of,O,O
adenoviral,O,B
vectors,O,I
.,O,O
.,O,O
Exon,O,O
-,O,O
intron,O,O
structure,O,O
of,O,O
the,O,O
human,O,O
neuronal,O,O
nicotinic,O,O
acetylcholine,O,O
receptor,O,O
alpha,O,B
4,O,I
subunit,O,I
(,O,O
CHRNA4,O,B
),O,O
.,O,O
The,O,O
human,O,O
neuronal,O,O
nicotinic,O,O
acetylcholine,O,O
receptor,O,O
alpha,O,B
4,O,I
subunit,O,I
gene,O,O
(,O,O
CHRNA4,O,B
),O,O
is,O,O
located,O,O
in,O,O
the,O,O
candidate,O,O
region,O,O
for,O,O
three,O,O
different,O,O
phenotypes,O,O
benign,B,O
familial,I,O
neonatal,I,O
convulsions,I,O
",",O,O
autosomal,B,O
dominant,I,O
nocturnal,I,O
frontal,I,O
lobe,I,O
epilepsy,I,O
",",O,O
and,O,O
low,O,B
-,O,I
voltage,O,I
EEG,O,I
.,O,O
Recently,O,O
",",O,O
a,O,O
missense,O,O
mutation,O,O
in,O,O
transmembrane,O,O
domain,O,O
2,O,O
of,O,O
CHRNA4,O,B
was,O,O
found,O,O
to,O,O
be,O,O
associated,O,O
with,O,O
autosomal,B,O
dominant,I,O
nocturnal,I,O
frontal,I,O
lobe,I,O
epilepsy,I,O
in,O,O
one,O,O
extended,O,O
pedigree,O,O
.,O,O
We,O,O
have,O,O
determined,O,O
the,O,O
genomic,O,O
organization,O,O
of,O,O
CHRNA4,O,B
",",O,O
which,O,O
consists,O,O
of,O,O
six,O,O
exons,O,O
distributed,O,O
over,O,O
approximately,O,O
17,O,O
kb,O,O
of,O,O
genomic,O,O
DNA,O,O
.,O,O
The,O,O
nucleotide,O,O
sequence,O,O
obtained,O,O
from,O,O
the,O,O
genomic,O,O
regions,O,O
adjacent,O,O
to,O,O
the,O,O
exon,O,O
boundaries,O,O
enabled,O,O
us,O,O
to,O,O
develop,O,O
a,O,O
set,O,O
of,O,O
primer,O,O
pairs,O,O
for,O,O
PCR,O,O
amplification,O,O
of,O,O
the,O,O
complete,O,O
coding,O,O
region,O,O
.,O,O
The,O,O
sequence,O,O
analysis,O,O
provides,O,O
the,O,O
basis,O,O
for,O,O
a,O,O
comprehensive,O,O
mutation,O,O
screening,O,O
of,O,O
CHRNA4,O,B
in,O,O
the,O,O
above,O,O
-,O,O
mentioned,O,O
phenotypes,O,O
and,O,O
possibly,O,O
in,O,O
other,O,O
types,O,O
of,O,O
idiopathic,B,O
epilepsies,I,O
.,O,O
.,O,O
Ashkenazi,O,O
Jewish,O,O
population,O,O
frequencies,O,O
for,O,O
common,O,O
mutations,O,O
in,O,O
BRCA1,O,B
and,O,O
BRCA2,O,B
.,O,O
BRCA1,O,B
and,O,O
BRCA2,O,B
are,O,O
the,O,O
two,O,O
major,O,O
identified,O,O
causes,O,O
of,O,O
inherited,B,O
breast,I,B
cancer,I,I
",",O,O
with,O,O
mutations,O,O
in,O,O
either,O,O
gene,O,O
conferring,O,O
up,O,O
to,O,O
80,O,O
-,O,O
90,O,O
%,O,O
lifetime,O,O
risk,O,O
of,O,O
breast,B,B
cancer,I,I
in,O,O
carrier,O,O
females,O,O
.,O,O
Mutations,O,O
in,O,O
BRCA1,O,B
account,O,O
for,O,O
approximately,O,O
45,O,O
%,O,O
of,O,O
familial,B,O
breast,I,B
cancer,I,I
and,O,O
90,O,O
%,O,O
of,O,O
inherited,B,O
breast,I,B
/,I,I
ovarian,I,I
cancer,I,I
",",O,O
whereas,O,O
mutations,O,O
in,O,O
BRCA2,O,B
account,O,O
for,O,O
a,O,O
comparable,O,O
percentage,O,O
of,O,O
inherited,B,O
breast,I,B
cancer,I,I
cases,O,O
.,O,O
Over,O,O
85,O,O
distinct,O,O
BRCA1,O,B
mutations,O,O
and,O,O
a,O,O
growing,O,O
list,O,O
of,O,O
BRCA2,O,B
mutations,O,O
have,O,O
been,O,O
identified,O,O
",",O,O
with,O,O
the,O,O
majority,O,O
resulting,O,O
in,O,O
protein,O,O
truncation,O,O
.,O,O
A,O,O
specific,O,O
BRCA1,O,B
mutation,O,O
",",O,O
185delAG,O,O
",",O,O
has,O,O
a,O,O
reported,O,O
increased,O,O
carrier,O,O
frequency,O,O
of,O,O
approximately,O,O
0,O,O
.,O,O
9,O,O
%,O,O
in,O,O
the,O,O
Ashkenazi,O,O
Jewish,O,O
population,O,O
",",O,O
but,O,O
is,O,O
also,O,O
found,O,O
in,O,O
rare,O,O
non,O,O
-,O,O
Jewish,O,O
patients,O,O
with,O,O
a,O,O
different,O,O
haplotype,O,O
.,O,O
The,O,O
6174delT,O,O
mutation,O,O
in,O,O
BRCA2,O,B
was,O,O
recently,O,O
identified,O,O
as,O,O
a,O,O
frequent,O,O
mutation,O,O
in,O,O
8,O,O
out,O,O
of,O,O
107,O,O
Ashkenazi,O,O
Jewish,O,O
women,O,O
diagnosed,O,O
with,O,O
breast,B,B
cancer,I,I
by,O,O
age,O,O
50,O,O
(,O,O
ref,O,O
.,O,O
8,O,O
),O,O
",",O,O
as,O,O
well,O,O
as,O,O
in,O,O
three,O,O
Ashkenazi,O,O
male,B,O
breast,I,B
cancer,I,I
patients,O,O
.,O,O
We,O,O
have,O,O
conducted,O,O
a,O,O
large,O,O
-,O,O
scale,O,O
population,O,O
study,O,O
to,O,O
investigate,O,O
the,O,O
prevalence,O,O
of,O,O
specific,O,O
BRCA1,O,B
and,O,O
BRCA2,O,B
mutations,O,O
in,O,O
Ashkenazi,O,O
Jewish,O,O
individuals,O,O
who,O,O
were,O,O
unselected,O,O
for,O,O
breast,B,B
cancer,I,I
.,O,O
BRCA1,O,B
mutation,O,O
screening,O,O
on,O,O
approximately,O,O
3,O,O
",",O,O
Ashkenazi,O,O
Jewish,O,O
samples,O,O
determined,O,O
a,O,O
carrier,O,O
frequency,O,O
of,O,O
1,O,O
.,O,O
%,O,O
for,O,O
the,O,O
185delAG,O,O
mutation,O,O
and,O,O
0,O,O
.,O,O
13,O,O
%,O,O
for,O,O
the,O,O
5382insC,O,O
mutation,O,O
.,O,O
BRCA2,O,B
analysis,O,O
on,O,O
3,O,O
",",O,O
individuals,O,O
from,O,O
the,O,O
same,O,O
population,O,O
showed,O,O
a,O,O
carrier,O,O
frequency,O,O
of,O,O
1,O,O
.,O,O
52,O,O
%,O,O
for,O,O
the,O,O
6174delT,O,O
mutation,O,O
.,O,O
This,O,O
expanded,O,O
population,O,O
-,O,O
based,O,O
study,O,O
confirms,O,O
that,O,O
the,O,O
BRCA1,O,O
185delAG,O,O
mutation,O,O
and,O,O
the,O,O
BRCA2,O,O
6174delT,O,O
mutation,O,O
constitute,O,O
the,O,O
two,O,O
most,O,O
frequent,O,O
mutation,O,O
alleles,O,O
predisposing,O,O
to,O,O
hereditary,B,O
breast,I,B
cancer,I,I
among,O,O
the,O,O
Ashkenazim,O,O
",",O,O
and,O,O
suggests,O,O
a,O,O
relatively,O,O
lower,O,O
penetrance,O,O
for,O,O
the,O,O
6174delT,O,O
mutation,O,O
in,O,O
BRCA2,O,O
Dual,O,O
roles,O,O
of,O,O
ATM,O,O
in,O,O
the,O,O
cellular,O,O
response,O,O
to,O,O
radiation,O,O
and,O,O
in,O,O
cell,O,O
growth,O,O
control,O,O
.,O,O
The,O,O
gene,O,B
mutated,O,O
in,O,O
ataxia,B,B
-,I,I
telangiectasia,I,I
(,O,O
AT,B,B
),O,O
patients,O,O
",",O,O
denoted,O,O
ATM,O,O
",",O,O
encodes,O,O
a,O,O
putative,O,O
protein,O,O
or,O,O
lipid,O,O
kinase,O,O
.,O,O
To,O,O
elucidate,O,O
the,O,O
functions,O,O
of,O,O
ATM,O,O
",",O,O
we,O,O
disrupted,O,O
the,O,O
mouse,O,O
ATM,O,O
gene,O,O
through,O,O
homologous,O,O
recombination,O,O
in,O,O
mice,O,O
.,O,O
Consistent,O,O
with,O,O
cellular,O,O
defects,O,O
of,O,O
AT,B,B
patients,O,O
",",O,O
the,O,O
ATM,O,O
-,O,O
/,O,O
-,O,O
cells,O,O
are,O,O
hypersensitive,O,O
to,O,O
gamma,O,O
-,O,O
irradiation,O,O
and,O,O
defective,O,O
in,O,O
cell,O,O
-,O,O
cycle,O,O
arrest,O,O
following,O,O
radiation,O,O
",",O,O
correlating,O,O
with,O,O
a,O,O
defective,O,O
up,O,O
-,O,O
regulation,O,O
of,O,O
p53,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
ATM,O,O
-,O,O
/,O,O
-,O,O
mouse,O,O
thymocytes,O,O
are,O,O
more,O,O
resistant,O,O
to,O,O
apoptosis,O,O
induced,O,O
by,O,O
gamma,O,O
-,O,O
irradiation,O,O
than,O,O
normal,O,O
thymocytes,O,O
.,O,O
ATM,O,O
-,O,O
/,O,O
-,O,O
fibroblasts,O,O
are,O,O
inefficient,O,O
in,O,O
G1,O,O
to,O,O
S,O,O
-,O,O
phase,O,O
progression,O,O
following,O,O
serum,O,O
stimulation,O,O
and,O,O
senesce,O,O
after,O,O
only,O,O
a,O,O
few,O,O
passages,O,O
in,O,O
culture,O,O
.,O,O
They,O,O
have,O,O
an,O,O
increased,O,O
constitutive,O,O
level,O,O
of,O,O
p21CP1,O,O
/,O,O
WAF1,O,O
.,O,O
The,O,O
ATM,O,B
protein,O,O
is,O,O
therefore,O,O
critical,O,O
both,O,O
for,O,O
cellular,O,O
responses,O,O
to,O,O
ionizing,O,O
radiation,O,O
and,O,O
for,O,O
normal,O,O
cell,O,O
-,O,O
cycle,O,O
progression,O,O
.,O,O
ATM,O,B
+,O,O
/,O,O
-,O,O
fibroblasts,O,O
and,O,O
thymocytes,O,O
showed,O,O
intermediately,O,O
defective,O,O
responses,O,O
to,O,O
irradiation,O,O
but,O,O
no,O,O
growth,O,O
defect,O,O
",",O,O
suggesting,O,O
that,O,O
the,O,O
increased,O,O
cancer,B,B
risk,O,O
of,O,O
AT,B,B
heterozygotes,O,O
could,O,O
be,O,O
attributable,O,O
to,O,O
poor,O,O
checkpoint,O,O
function,O,O
.,O,O
.,O,O
Targeted,O,O
disruption,O,O
of,O,O
ATM,O,O
leads,O,O
to,O,O
growth,B,O
retardation,I,O
",",O,O
chromosomal,B,O
fragmentation,I,O
during,I,O
meiosis,I,O
",",O,O
immune,B,O
defects,I,O
",",O,O
and,O,O
thymic,B,O
lymphoma,I,O
.,O,O
ATM,O,O
",",O,O
the,O,O
gene,O,O
mutated,O,O
in,O,O
the,O,O
inherited,B,O
human,I,O
disease,I,O
ataxia,B,B
-,I,I
telangiectasia,I,I
",",O,O
is,O,O
a,O,O
member,O,O
of,O,O
a,O,O
family,O,O
of,O,O
kinases,O,O
involved,O,O
in,O,O
DNA,O,O
metabolism,O,O
and,O,O
cell,O,O
-,O,O
cycle,O,O
checkpoint,O,O
control,O,O
.,O,O
To,O,O
help,O,O
clarify,O,O
the,O,O
physiological,O,O
roles,O,O
of,O,O
the,O,O
ATM,O,O
protein,O,O
",",O,O
we,O,O
disrupted,O,O
the,O,O
ATM,O,O
gene,O,O
in,O,O
mice,O,O
through,O,O
homologous,O,O
recombination,O,O
.,O,O
Initial,O,O
evaluation,O,O
of,O,O
the,O,O
ATM,O,O
knockout,O,O
animals,O,O
indicates,O,O
that,O,O
inactivation,O,O
of,O,O
the,O,O
mouse,O,O
ATM,O,O
gene,O,O
recreates,O,O
much,O,O
of,O,O
the,O,O
phenotype,O,O
of,O,O
ataxia,B,B
-,I,I
telangiectasia,I,I
.,O,O
The,O,O
homozygous,O,O
mutant,O,O
(,O,O
ATM,O,O
-,O,O
/,O,O
-,O,O
),O,O
mice,O,O
are,O,O
viable,O,O
",",O,O
growth,O,O
-,O,O
retarded,O,O
",",O,O
and,O,O
infertile,O,O
.,O,O
The,O,O
infertility,B,O
of,O,O
ATM,O,O
-,O,O
/,O,O
-,O,O
mice,O,O
results,O,O
from,O,O
meiotic,O,O
failure,O,O
.,O,O
Meiosis,O,O
is,O,O
arrested,O,O
at,O,O
the,O,O
zygotene,O,O
/,O,O
pachytene,O,O
stage,O,O
of,O,O
prophase,O,O
I,O,O
as,O,O
a,O,O
result,O,O
of,O,O
abnormal,O,O
chromosomal,O,O
synapsis,O,O
and,O,O
subsequent,O,O
chromosome,O,O
fragmentation,O,O
.,O,O
Immune,B,O
defects,I,O
also,O,O
are,O,O
evident,O,O
in,O,O
ATM,O,O
-,O,O
/,O,O
-,O,O
mice,O,O
",",O,O
including,O,O
reduced,O,O
numbers,O,O
of,O,O
B220,O,B
+,O,I
CD43,O,B
-,O,I
pre,O,I
-,O,I
B,O,I
cells,O,I
",",O,O
thymocytes,O,O
",",O,O
and,O,O
peripheral,O,O
T,O,B
cells,O,I
",",O,O
as,O,O
well,O,O
as,O,O
functional,O,O
impairment,O,O
of,O,O
T,O,B
-,O,I
cell,O,I
-,O,I
dependent,O,I
immune,O,I
responses,O,I
.,O,O
The,O,O
cerebella,O,O
of,O,O
ATM,O,O
-,O,O
/,O,O
-,O,O
mice,O,O
appear,O,O
normal,O,O
by,O,O
histologic,O,O
examination,O,O
at,O,O
3,O,O
to,O,O
4,O,O
months,O,O
and,O,O
the,O,O
mice,O,O
have,O,O
no,O,O
gross,O,O
behavioral,B,O
abnormalities,I,O
.,O,O
The,O,O
majority,O,O
of,O,O
mutant,O,O
mice,O,O
rapidly,O,O
develop,O,O
thymic,B,O
lymphomas,I,O
and,O,O
die,O,O
before,O,O
4,O,O
months,O,O
of,O,O
age,O,O
.,O,O
These,O,O
findings,O,O
indicate,O,O
that,O,O
the,O,O
ATM,O,O
gene,O,O
product,O,O
plays,O,O
an,O,O
essential,O,O
role,O,O
in,O,O
a,O,O
diverse,O,O
group,O,O
of,O,O
cellular,O,O
processes,O,O
",",O,O
including,O,O
meiosis,O,O
",",O,O
the,O,O
normal,O,O
growth,O,O
of,O,O
somatic,O,O
tissues,O,O
",",O,O
immune,O,O
development,O,O
",",O,O
and,O,O
tumor,B,O
suppression,O,O
.,O,O
Cloning,O,O
and,O,O
characterization,O,O
of,O,O
human,O,O
very,O,O
-,O,O
long,O,O
-,O,O
chain,O,O
acyl,O,O
-,O,O
CoA,O,O
dehydrogenase,O,O
cDNA,O,O
",",O,O
chromosomal,O,O
assignment,O,O
of,O,O
the,O,O
gene,O,B
and,O,O
identification,O,O
in,O,O
four,O,O
patients,O,O
of,O,O
nine,O,O
different,O,O
mutations,O,O
within,O,O
the,O,O
VLCAD,O,B
gene,O,I
.,O,O
Very,O,O
-,O,O
long,O,O
-,O,O
chain,O,O
acyl,O,O
-,O,O
CoA,O,O
dehydrogenase,O,O
(,O,O
VLCAD,O,B
),O,O
is,O,O
one,O,O
of,O,O
four,O,O
straight,O,O
-,O,O
chain,O,O
acyl,O,O
-,O,O
CoA,O,O
dehydrogenase,O,O
(,O,O
ACD,O,O
),O,O
enzymes,O,O
",",O,O
which,O,O
are,O,O
all,O,O
nuclear,O,O
encoded,O,O
mitochondrial,O,O
flavoproteins,O,O
catalyzing,O,O
the,O,O
initial,O,O
step,O,O
in,O,O
fatty,O,O
acid,O,O
beta,O,O
-,O,O
oxidation,O,O
.,O,O
We,O,O
have,O,O
used,O,O
the,O,O
very,O,O
fast,O,O
",",O,O
Rapid,O,O
Amplification,O,O
of,O,O
cDNA,O,O
Ends,O,O
(,O,O
RACE,O,O
),O,O
based,O,O
strategy,O,O
to,O,O
obtain,O,O
the,O,O
sequence,O,O
of,O,O
cDNAs,O,O
encoding,O,O
human,O,O
VLCAD,O,B
from,O,O
placenta,O,O
and,O,O
fibroblasts,O,O
.,O,O
Alignment,O,O
of,O,O
the,O,O
predicted,O,O
amino,O,O
acid,O,O
sequence,O,O
of,O,O
human,O,O
VLCAD,O,B
with,O,O
those,O,O
of,O,O
the,O,O
other,O,O
human,O,O
ACD,O,O
enzymes,O,O
revealed,O,O
extensive,O,O
sequence,O,O
homology,O,O
.,O,O
Moreover,O,O
",",O,O
human,O,O
VLCAD,O,B
and,O,O
human,O,O
acyl,O,B
-,O,I
CoA,O,I
oxidase,O,I
showed,O,O
extensive,O,O
sequence,O,O
homology,O,O
corroborating,O,O
the,O,O
notion,O,O
that,O,O
these,O,O
genes,O,O
are,O,O
evolutionarily,O,O
related,O,O
.,O,O
Southern,O,O
blot,O,O
analysis,O,O
of,O,O
genomic,O,O
DNA,O,O
from,O,O
hybrid,O,O
cell,O,O
lines,O,O
was,O,O
used,O,O
to,O,O
localize,O,O
the,O,O
VLCAD,O,B
gene,O,I
to,O,O
human,O,O
chromosome,O,O
17p11,O,O
.,O,O
2,O,O
-,O,O
p11,O,O
.,O,O
13105,O,O
.,O,O
Using,O,O
Northern,O,O
and,O,O
Western,O,O
blot,O,O
analysis,O,O
to,O,O
investigate,O,O
the,O,O
tissue,O,O
specific,O,O
distribution,O,O
of,O,O
VLCAD,O,B
mRNA,O,I
and,O,O
protein,O,O
in,O,O
several,O,O
human,O,O
tissues,O,O
we,O,O
showed,O,O
that,O,O
VLCAD,O,B
is,O,O
most,O,O
abundant,O,O
in,O,O
heart,O,O
and,O,O
skeletal,O,O
muscle,O,O
.,O,O
This,O,O
agrees,O,O
well,O,O
with,O,O
the,O,O
fact,O,O
that,O,O
cardiac,O,O
and,O,O
muscle,O,O
symptoms,O,O
are,O,O
characteristic,O,O
for,O,O
patients,O,O
with,O,O
VLCAD,B,B
deficiency,I,I
.,O,O
Northern,O,O
blot,O,O
analysis,O,O
and,O,O
sequencing,O,O
of,O,O
cloned,O,O
PCR,O,O
amplified,O,O
VLCAD,O,B
cDNA,O,I
from,O,O
four,O,O
unrelated,O,O
patients,O,O
with,O,O
VLCAD,B,B
deficiency,I,I
showed,O,O
that,O,O
VLCAD,O,B
mRNA,O,I
was,O,O
undetectable,O,O
in,O,O
one,O,O
patient,O,O
and,O,O
that,O,O
the,O,O
other,O,O
three,O,O
have,O,O
mutations,O,O
in,O,O
both,O,O
VLCAD,O,B
alleles,O,I
.,O,O
Western,O,O
blot,O,O
analysis,O,O
of,O,O
patient,O,O
fibroblasts,O,O
showed,O,O
that,O,O
the,O,O
identified,O,O
mutations,O,O
result,O,O
in,O,O
severely,O,O
reduced,O,O
amounts,O,O
of,O,O
VLCAD,O,B
protein,O,O
.,O,O
Molecular,O,O
bases,O,O
of,O,O
combined,B,O
subtotal,I,O
deficiencies,I,O
of,I,O
C6,I,O
and,I,O
C7,I,O
:,O,O
their,O,O
effects,O,O
in,O,O
combination,O,O
with,O,O
other,O,O
C6,B,O
and,I,O
C7,I,O
deficiencies,I,O
.,O,O
Combined,B,O
subtotal,I,O
deficiency,I,O
of,I,O
C6,I,O
and,I,O
C7,I,O
",",O,O
in,O,O
which,O,O
both,O,O
proteins,O,O
are,O,O
expressed,O,O
at,O,O
very,O,O
low,O,O
levels,O,O
",",O,O
has,O,O
been,O,O
observed,O,O
in,O,O
homozygous,O,O
form,O,O
in,O,O
two,O,O
families,O,O
.,O,O
A,O,O
defect,O,O
at,O,O
the,O,O
5,O,O
splice,O,O
donor,O,O
site,O,O
of,O,O
intron,O,O
15,O,O
of,O,O
the,O,O
C6,O,B
gene,O,O
explains,O,O
the,O,O
low,O,O
molecular,O,O
weight,O,O
of,O,O
the,O,O
C6,O,B
protein,O,O
and,O,O
is,O,O
probably,O,O
responsible,O,O
for,O,O
its,O,O
low,O,O
expressed,O,O
concentration,O,O
.,O,O
The,O,O
C7,O,B
defect,O,O
is,O,O
more,O,O
enigmatic,O,O
the,O,O
protein,O,O
is,O,O
of,O,O
normal,O,O
molecular,O,O
weight,O,O
",",O,O
low,O,O
circulating,O,O
concentration,O,O
",",O,O
and,O,O
altered,O,O
isoelectric,O,O
point,O,O
.,O,O
An,O,O
Arg,O,B
>,O,I
Ser,O,I
codon,O,O
substitution,O,O
in,O,O
exon,O,O
11,O,O
is,O,O
the,O,O
only,O,O
molecular,O,O
alteration,O,O
within,O,O
the,O,O
mature,O,B
C7,O,I
protein,O,O
.,O,O
These,O,O
defects,O,O
are,O,O
associated,O,O
with,O,O
a,O,O
characteristic,O,O
set,O,O
of,O,O
polymorphic,O,O
DNA,O,O
markers,O,O
in,O,O
the,O,O
C6,O,B
/,O,I
C7,O,I
region,O,O
",",O,O
forming,O,O
a,O,O
distinct,O,O
haplotype,O,O
.,O,O
The,O,O
haplotype,O,O
has,O,O
been,O,O
found,O,O
in,O,O
combination,O,O
with,O,O
a,O,O
number,O,O
of,O,O
other,O,O
haplotypes,O,O
containing,O,O
defective,O,O
genes,O,O
that,O,O
lead,O,O
either,O,O
to,O,O
C6,B,B
or,I,O
C7,I,B
deficiency,I,O
",",O,O
but,O,O
with,O,O
different,O,O
consequences,O,O
.,O,O
Where,O,O
it,O,O
is,O,O
combined,O,O
with,O,O
a,O,O
C6,B,B
-,I,I
deficient,I,I
gene,O,O
",",O,O
the,O,O
serum,O,O
C7,O,B
levels,O,O
can,O,O
be,O,O
surprisingly,O,O
high,O,O
",",O,O
possibly,O,O
because,O,O
there,O,O
is,O,O
no,O,O
C6,O,B
generating,O,O
C56,O,O
to,O,O
consume,O,O
the,O,O
C7,O,B
.,O,O
In,O,O
contrast,O,O
",",O,O
where,O,O
the,O,O
C7,O,B
genes,O,O
are,O,O
both,O,O
defective,O,O
(,O,O
but,O,O
still,O,O
partially,O,O
functional,O,O
),O,O
",",O,O
there,O,O
may,O,O
be,O,O
a,O,O
profound,O,O
deficit,O,O
of,O,O
circulating,O,O
C7,O,B
because,O,O
there,O,O
is,O,O
ample,O,O
C6,O,B
to,O,O
produce,O,O
C56,O,O
and,O,O
consume,O,O
the,O,O
already,O,O
small,O,O
amount,O,O
of,O,O
C7,O,B
.,O,O
Each,O,O
molecular,O,O
defect,O,O
has,O,O
also,O,O
been,O,O
found,O,O
in,O,O
isolation,O,O
and,O,O
has,O,O
the,O,O
expected,O,O
effect,O,O
.,O,O
Genetic,O,O
bases,O,O
of,O,O
human,O,O
complement,B,B
C7,I,I
deficiency,I,I
.,O,O
Complement,B,B
C7,I,I
deficiency,I,I
(,O,O
C7D,B,B
),O,O
is,O,O
associated,O,O
frequently,O,O
with,O,O
recurrent,O,O
bacterial,B,O
infections,I,O
",",O,O
especially,O,O
meningitis,B,O
caused,O,O
by,O,O
Neisseria,B,B
meningitidis,I,I
.,O,O
We,O,O
report,O,O
in,O,O
this,O,O
work,O,O
the,O,O
molecular,O,O
bases,O,O
of,O,O
C7D,B,B
in,O,O
two,O,O
unrelated,O,O
Japanese,O,O
males,O,O
.,O,O
We,O,O
used,O,O
exon,O,O
-,O,O
specific,O,O
PCR,O,O
/,O,O
single,O,O
-,O,O
strand,O,O
conformation,O,O
polymorphism,O,O
analysis,O,O
as,O,O
a,O,O
screening,O,O
step,O,O
for,O,O
mutations,O,O
.,O,O
Subsequent,O,O
direct,O,O
sequencing,O,O
of,O,O
the,O,O
target,O,O
exons,O,O
identified,O,O
homozygous,O,O
mutations,O,O
in,O,O
exon,O,O
16,O,O
of,O,O
case,O,O
1,O,O
and,O,O
in,O,O
exon,O,O
15,O,O
of,O,O
case,O,O
2,O,O
.,O,O
The,O,O
mutation,O,O
of,O,O
case,O,O
1,O,O
was,O,O
a,O,O
homozygous,O,O
T,O,B
to,O,O
A,O,O
transversion,O,O
at,O,O
nucleotide,O,O
2250,O,O
",",O,O
the,O,O
third,O,O
nucleotide,O,O
of,O,O
the,O,O
codon,O,O
TGT,O,O
for,O,O
Cys728,O,O
",",O,O
leading,O,O
to,O,O
a,O,O
stop,O,O
codon,O,O
TGA,O,O
(,O,O
C728X,O,O
),O,O
.,O,O
In,O,O
case,O,O
2,O,O
",",O,O
a,O,O
homozygous,O,O
2,O,O
-,O,O
bp,O,O
deletion,O,O
(,O,O
2137delTG,O,O
/,O,O
2138delGT,O,O
/,O,O
2139delTG,O,O
),O,O
caused,O,O
a,O,O
frameshift,O,O
",",O,O
generating,O,O
a,O,O
premature,O,O
termination,O,O
codon,O,O
4,O,O
to,O,O
6,O,O
nucleotides,O,O
downstream,O,O
.,O,O
Family,O,O
study,O,O
in,O,O
case,O,O
1,O,O
confirmed,O,O
the,O,O
genetic,O,O
nature,O,O
of,O,O
the,O,O
defect,O,O
.,O,O
Moreover,O,O
",",O,O
we,O,O
detected,O,O
a,O,O
novel,O,O
polymorphism,O,O
in,O,O
intron,O,O
11,O,O
that,O,O
presumably,O,O
is,O,O
linked,O,O
to,O,O
the,O,O
mutation,O,O
responsible,O,O
for,O,O
C7D,B,O
in,O,O
case,O,O
1,O,O
.,O,O
Our,O,O
results,O,O
indicate,O,O
that,O,O
the,O,O
pathogenesis,O,O
of,O,O
C7D,B,B
is,O,O
heterogeneous,O,O
like,O,O
most,O,O
of,O,O
the,O,O
other,O,O
deficiencies,B,O
of,I,O
complement,I,O
components,I,O
.,O,O
.,O,O
HPRT,B,B
-,I,I
APRT,I,I
-,I,I
deficient,I,I
mice,O,O
are,O,O
not,O,O
a,O,O
model,O,O
for,O,O
lesch,B,O
-,I,O
nyhan,I,O
syndrome,I,O
.,O,O
Complete,B,O
hypoxanthine,I,O
-,I,O
guanine,I,O
phosphoribosyl,I,O
-,I,O
transferase,I,O
(,I,O
HPRT,I,B
),I,O
deficiency,I,O
in,O,O
humans,O,O
results,O,O
in,O,O
the,O,O
Lesch,B,O
-,I,O
Nyhan,I,O
syndrome,I,O
which,O,O
is,O,O
characterized,O,O
",",O,O
among,O,O
other,O,O
features,O,O
",",O,O
by,O,O
compulsive,O,O
self,O,O
-,O,O
injurious,O,O
behavior,O,O
.,O,O
HPRT,B,B
-,I,I
deficient,I,I
mice,O,I
generated,O,O
using,O,O
mouse,O,O
embryonic,O,O
stem,O,O
cells,O,O
exhibit,O,O
none,O,O
of,O,O
the,O,O
behavioral,O,O
symptoms,O,O
associated,O,O
with,O,O
the,O,O
Lesch,B,B
-,I,I
Nyhan,I,I
syndrome,I,I
.,O,O
Administration,O,O
of,O,O
drugs,O,O
that,O,O
inhibit,O,O
adenine,O,B
phosphoribosyltransferase,O,I
(,O,O
APRT,O,O
),O,O
in,O,O
HPRT,B,B
-,I,I
deficient,I,I
mice,O,I
has,O,O
produced,O,O
the,O,O
suggestion,O,O
that,O,O
deficiency,B,O
of,I,O
APRT,I,O
in,O,O
combination,O,O
with,O,O
HPRT,B,B
-,I,I
deficiency,I,I
in,O,O
mice,O,I
may,O,O
lead,O,O
to,O,O
self,O,O
-,O,O
mutilation,O,O
behavior,O,O
[,O,O
C,O,O
.,O,O
L,O,O
.,O,O
Wu,O,B
and,O,O
D,O,B
.,O,O
W,O,B
.,O,O
Melton,O,I
(,O,O
1993,O,O
),O,O
Nature,O,O
Genet,O,O
.,O,O
3,O,O
",",O,O
235,O,O
-,O,O
240,O,O
],O,O
.,O,O
To,O,O
test,O,O
this,O,O
proposition,O,O
",",O,O
we,O,O
bred,O,O
HPRT,B,O
-,I,O
APRT,I,O
-,I,O
deficient,I,O
mice,O,O
.,O,O
Although,O,O
the,O,O
doubly,O,O
-,O,O
deficient,O,O
mice,O,O
excrete,O,O
adenine,O,O
and,O,O
its,O,O
highly,O,O
insoluble,O,O
derivative,O,O
",",O,O
2,O,O
",",O,O
8,O,O
-,O,O
dihydroxyadenine,O,O
",",O,O
which,O,O
are,O,O
also,O,O
associated,O,O
with,O,O
human,O,O
APRT,B,O
deficiency,I,O
",",O,O
additional,O,O
abnormalities,O,O
or,O,O
any,O,O
self,O,O
-,O,O
injurious,O,O
behavior,O,O
were,O,O
not,O,O
detected,O,O
.,O,O
Thus,O,O
",",O,O
APRT,B,B
-,I,I
HPRT,I,I
-,I,I
deficient,I,O
mice,O,O
",",O,O
which,O,O
are,O,O
devoid,O,O
of,O,O
any,O,O
purine,O,O
salvage,O,O
pathways,O,O
",",O,O
show,O,O
no,O,O
novel,O,O
phenotype,O,O
and,O,O
are,O,O
not,O,O
a,O,O
model,O,O
for,O,O
the,O,O
behavioral,B,O
abnormalities,I,O
associated,O,O
with,O,O
the,O,O
Lesch,B,B
-,I,I
Nyhan,I,I
syndrome,I,I
as,O,O
previously,O,O
suggested,O,O
Somatic,O,O
alterations,O,O
of,O,O
the,O,O
DPC4,O,B
gene,O,I
in,O,O
human,O,O
colorectal,B,B
cancers,I,I
in,O,O
vivo,O,O
.,O,O
BACKGROUND,O,O
&,O,O
AIMS,O,O
The,O,O
chromosome,O,O
region,O,O
18q21,O,O
has,O,O
been,O,O
shown,O,O
to,O,O
be,O,O
frequently,O,O
deleted,O,O
in,O,O
colorectal,B,B
cancers,I,I
",",O,O
and,O,O
such,O,O
frequent,O,O
allelic,O,O
loss,O,O
is,O,O
a,O,O
hallmark,O,O
of,O,O
the,O,O
presence,O,O
of,O,O
a,O,O
tumor,O,O
-,O,O
suppressor,O,O
gene,O,O
.,O,O
The,O,O
DPC4,O,O
gene,O,O
",",O,O
which,O,O
is,O,O
located,O,O
at,O,O
18q21,O,O
",",O,O
has,O,O
been,O,O
identified,O,O
as,O,O
a,O,O
tumor,O,O
-,O,O
suppressor,O,O
gene,O,O
from,O,O
examination,O,O
of,O,O
pancreatic,B,B
cancers,I,I
.,O,O
The,O,O
aim,O,O
of,O,O
the,O,O
present,O,O
study,O,O
was,O,O
to,O,O
determine,O,O
if,O,O
it,O,O
might,O,O
also,O,O
be,O,O
altered,O,O
in,O,O
colorectal,B,B
cancers,I,I
.,O,O
METHODS,O,O
Mutation,O,O
analyses,O,O
of,O,O
the,O,O
DPC4,O,B
gene,O,I
were,O,O
performed,O,O
on,O,O
complementary,O,O
DNA,O,O
samples,O,O
from,O,O
31,O,O
primary,O,O
colorectal,B,B
cancer,I,I
specimens,O,O
using,O,O
a,O,O
combination,O,O
of,O,O
polymerase,O,O
chain,O,O
reaction,O,O
",",O,O
single,O,O
-,O,O
strand,O,O
conformation,O,O
polymorphism,O,O
",",O,O
and,O,O
DNA,O,O
sequencing,O,O
.,O,O
RESULTS,O,O
Four,O,O
missense,O,O
mutations,O,O
producing,O,O
amino,O,O
acid,O,O
substitutions,O,O
and,O,O
a,O,O
somatic,O,O
12,O,O
-,O,O
base,O,O
pair,O,O
deletion,O,O
in,O,O
the,O,O
coding,O,O
region,O,O
of,O,O
the,O,O
DPC4,O,B
gene,O,O
were,O,O
detected,O,O
in,O,O
the,O,O
31,O,O
cancers,B,O
(,O,O
16,O,O
%,O,O
;,O,O
5,O,O
of,O,O
31,O,O
),O,O
.,O,O
CONCLUSIONS,O,O
The,O,O
DPC4,O,B
gene,O,O
may,O,O
play,O,O
a,O,O
role,O,O
as,O,O
a,O,O
tumor,O,O
-,O,O
suppressor,O,O
gene,O,O
in,O,O
a,O,O
fraction,O,O
of,O,O
colorectal,B,B
cancers,I,I
;,O,O
however,O,O
",",O,O
while,O,O
allelic,O,O
loss,O,O
at,O,O
18q21,O,O
is,O,O
very,O,O
often,O,O
seen,O,O
in,O,O
colorectal,B,B
cancers,I,I
",",O,O
only,O,O
a,O,O
minority,O,O
show,O,O
DPC4,O,B
mutations,O,O
",",O,O
suggesting,O,O
that,O,O
there,O,O
might,O,O
be,O,O
another,O,O
tumor,O,O
-,O,O
suppressor,O,O
gene,O,O
in,O,O
this,O,O
chromosome,O,O
region,O,O
.,O,O
.,O,O
Pleiotropic,O,O
defects,O,O
in,O,O
ataxia,B,B
-,I,I
telangiectasia,I,I
protein,O,O
-,O,O
deficient,O,O
mice,O,O
.,O,O
We,O,O
have,O,O
generated,O,O
a,O,O
mouse,O,O
model,O,O
for,O,O
ataxia,B,B
-,I,I
telangiectasia,I,I
by,O,O
using,O,O
gene,O,O
targeting,O,O
to,O,O
generate,O,O
mice,O,O
that,O,O
do,O,O
not,O,O
express,O,O
the,O,O
Atm,O,B
protein,O,O
.,O,O
Atm,O,B
-,O,I
deficient,O,I
mice,O,O
are,O,O
retarded,O,O
in,O,O
growth,O,O
",",O,O
do,O,O
not,O,O
produce,O,O
mature,O,O
sperm,O,O
",",O,O
and,O,O
exhibit,O,O
severe,O,O
defects,O,O
in,O,O
T,O,B
cell,O,I
maturation,O,I
while,O,O
going,O,O
on,O,O
to,O,O
develop,O,O
thymomas,B,O
.,O,O
Atm,O,B
-,O,I
deficient,O,I
fibroblasts,O,O
grow,O,O
poorly,O,O
in,O,O
culture,O,O
and,O,O
display,O,O
a,O,O
high,O,O
level,O,O
of,O,O
double,O,O
-,O,O
stranded,O,O
chromosome,O,O
breaks,O,O
.,O,O
Atm,O,B
-,O,I
deficient,O,I
thymocytes,O,O
undergo,O,O
spontaneous,O,O
apoptosis,O,O
in,O,O
vitro,O,O
significantly,O,O
more,O,O
than,O,O
controls,O,O
.,O,O
Atm,O,B
-,O,I
deficient,O,I
mice,O,O
then,O,O
exhibit,O,O
many,O,O
of,O,O
the,O,O
same,O,O
symptoms,O,O
found,O,O
in,O,O
ataxia,B,B
-,I,I
telangiectasia,I,I
patients,O,O
and,O,O
in,O,O
cells,O,O
derived,O,O
from,O,O
them,O,O
.,O,O
Furthermore,O,O
",",O,O
we,O,O
demonstrate,O,O
that,O,O
the,O,O
Atm,O,O
protein,O,O
exists,O,O
as,O,O
two,O,O
discrete,O,O
molecular,O,O
species,O,O
",",O,O
and,O,O
that,O,O
loss,O,O
of,O,O
one,O,O
or,O,O
of,O,O
both,O,O
of,O,O
these,O,O
can,O,O
lead,O,O
to,O,O
the,O,O
development,O,O
of,O,O
the,O,O
disease,O,O
.,O,O
The,O,O
DCC,O,O
protein,O,O
and,O,O
prognosis,O,O
in,O,O
colorectal,B,B
cancer,I,I
.,O,O
BACKGROUND,O,O
Allelic,O,O
loss,O,O
of,O,O
chromosome,O,O
18q,O,O
predicts,O,O
a,O,O
poor,O,O
outcome,O,O
in,O,O
patients,O,O
with,O,O
stage,B,O
II,I,O
colorectal,I,B
cancer,I,I
.,O,O
Although,O,O
the,O,O
specific,O,O
gene,O,O
inactivated,O,O
by,O,O
this,O,O
allelic,O,O
loss,O,O
has,O,O
not,O,O
been,O,O
elucidated,O,O
",",O,O
the,O,O
DCC,O,B
(,O,O
deleted,O,O
in,O,O
colorectal,B,B
cancer,I,I
),O,O
gene,O,O
is,O,O
a,O,O
candidate,O,O
.,O,O
We,O,O
investigated,O,O
whether,O,O
the,O,O
expression,O,O
of,O,O
the,O,O
DCC,O,B
protein,O,O
in,O,O
tumor,B,O
cells,O,O
is,O,O
a,O,O
prognostic,O,O
marker,O,O
in,O,O
colorectal,B,B
carcinoma,I,I
.,O,O
METHODS,O,O
The,O,O
expression,O,O
of,O,O
DCC,O,B
was,O,O
evaluated,O,O
immunohistochemically,O,O
in,O,O
132,O,O
paraffin,O,O
-,O,O
embedded,O,O
samples,O,O
from,O,O
patients,O,O
with,O,O
curatively,O,O
resected,O,O
stage,B,O
II,I,O
and,I,O
III,I,O
colorectal,I,B
carcinomas,I,I
.,O,O
The,O,O
Cox,O,O
proportional,O,O
-,O,O
hazards,O,O
model,O,O
was,O,O
used,O,O
to,O,O
adjust,O,O
for,O,O
covariates,O,O
including,O,O
age,O,O
",",O,O
sex,O,O
",",O,O
tumor,B,B
site,O,I
",",O,O
degree,O,O
of,O,O
tumor,B,B
differentiation,O,I
",",O,O
and,O,O
use,O,O
of,O,O
adjuvant,O,O
therapy,O,O
.,O,O
RESULTS,O,O
The,O,O
expression,O,O
of,O,O
DCC,O,B
was,O,O
a,O,O
strong,O,O
positive,O,O
predictive,O,O
factor,O,O
for,O,O
survival,O,O
in,O,O
both,O,O
stage,B,O
II,I,O
and,I,O
stage,I,O
III,I,O
colorectal,I,B
carcinomas,I,I
.,O,O
In,O,O
patients,O,O
with,O,O
stage,O,O
II,O,O
disease,O,O
whose,O,O
tumors,B,O
expressed,O,O
DCC,O,B
",",O,O
the,O,O
five,O,O
-,O,O
year,O,O
survival,O,O
rate,O,O
was,O,O
94,O,O
.,O,O
3,O,O
percent,O,O
",",O,O
whereas,O,O
in,O,O
patients,O,O
with,O,O
DCC,B,B
-,I,I
negative,I,I
tumors,I,O
",",O,O
the,O,O
survival,O,O
rate,O,O
was,O,O
61,O,O
.,O,O
percent,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
In,O,O
patients,O,O
with,O,O
stage,B,O
III,I,O
disease,I,O
",",O,O
the,O,O
respective,O,O
survival,O,O
rates,O,O
were,O,O
59,O,O
.,O,O
percent,O,O
and,O,O
33,O,O
.,O,O
2,O,O
percent,O,O
(,O,O
P,O,O
=,O,O
0,O,O
.,O,O
),O,O
.,O,O
CONCLUSIONS,O,O
DCC,O,B
is,O,O
a,O,O
prognostic,O,O
marker,O,O
in,O,O
patients,O,O
with,O,O
stage,B,O
II,I,O
or,I,O
stage,I,O
III,I,O
colorectal,I,B
cancer,I,I
.,O,O
In,O,O
stage,B,O
II,I,O
colorectal,I,B
carcinomas,I,I
",",O,O
the,O,O
absence,O,O
of,O,O
DCC,O,B
identifies,O,O
a,O,O
subgroup,O,O
of,O,O
patients,O,O
with,O,O
lesions,O,O
that,O,O
behave,O,O
like,O,O
stage,B,O
III,I,O
cancers,I,I
.,O,O
These,O,O
findings,O,O
may,O,O
thus,O,O
have,O,O
therapeutic,O,O
implications,O,O
in,O,O
this,O,O
group,O,O
of,O,O
patients,O,O
Association,O,O
of,O,O
anxiety,B,O
-,I,O
related,I,O
traits,I,O
with,O,O
a,O,O
polymorphism,O,O
in,O,O
the,O,O
serotonin,O,B
transporter,O,I
gene,O,I
regulatory,O,I
region,O,I
.,O,O
Transporter,O,O
-,O,O
facilitated,O,O
uptake,O,O
of,O,O
serotonin,O,B
(,O,O
5,O,I
-,O,I
hydroxytryptamine,O,I
or,O,O
5,O,B
-,O,I
HT,O,I
),O,O
has,O,O
been,O,O
implicated,O,O
in,O,O
anxiety,B,O
in,O,O
humans,O,O
and,O,O
animal,O,O
models,O,O
and,O,O
is,O,O
the,O,O
site,O,O
of,O,O
action,O,O
of,O,O
widely,O,O
used,O,O
uptake,O,O
-,O,O
inhibiting,O,O
antidepressant,O,O
and,O,O
antianxiety,O,O
drugs,O,O
.,O,O
Human,O,O
5,O,B
-,O,I
HT,O,I
transporter,O,I
(,O,O
5,O,B
-,O,I
HTT,O,I
),O,O
gene,O,O
transcription,O,O
is,O,O
modulated,O,O
by,O,O
a,O,O
common,O,O
polymorphism,O,O
in,O,O
its,O,O
upstream,O,O
regulatory,O,O
region,O,O
.,O,O
The,O,O
short,O,O
variant,O,O
of,O,O
the,O,O
polymorphism,O,O
reduces,O,O
the,O,O
transcriptional,O,O
efficiency,O,O
of,O,O
the,O,O
5,O,B
-,O,I
HTT,O,I
gene,O,I
promoter,O,O
",",O,O
resulting,O,O
in,O,O
decreased,O,O
5,O,B
-,O,I
HTT,O,I
expression,O,O
and,O,O
5,O,B
-,O,I
HT,O,I
uptake,O,O
in,O,O
lymphoblasts,O,O
.,O,O
Association,O,O
studies,O,O
in,O,O
two,O,O
independent,O,O
samples,O,O
totaling,O,O
505,O,O
individuals,O,O
revealed,O,O
that,O,O
the,O,O
5,O,B
-,O,I
HTT,O,I
polymorphism,O,I
accounts,O,O
for,O,O
3,O,O
to,O,O
4,O,O
percent,O,O
of,O,O
total,O,O
variation,O,O
and,O,O
7,O,O
to,O,O
9,O,O
percent,O,O
of,O,O
inherited,O,O
variance,O,O
in,O,O
anxiety,B,O
-,I,O
related,I,O
personality,I,O
traits,I,O
in,O,O
individuals,O,O
as,O,O
well,O,O
as,O,O
sibships,O,O
.,O,O
.,O,O
Phenotypic,O,O
and,O,O
genotypic,O,O
overlap,O,O
between,O,O
atelosteogenesis,B,B
type,I,I
2,I,I
and,O,O
diastrophic,B,B
dysplasia,I,I
.,O,O
Mutations,O,O
in,O,O
the,O,O
diastrophic,B,B
dysplasia,I,I
sulfate,O,O
transporter,O,O
gene,O,O
DTDST,O,O
have,O,O
been,O,O
associated,O,O
with,O,O
a,O,O
family,O,O
of,O,O
chondrodysplasias,B,O
that,O,O
comprises,O,O
",",O,O
in,O,O
order,O,O
of,O,O
increasing,O,O
severity,O,O
",",O,O
diastrophic,B,B
dysplasia,I,I
(,O,O
DTD,B,O
),O,O
",",O,O
atelosteogenesis,B,B
type,I,I
2,I,I
(,O,O
AO2,B,O
),O,O
",",O,O
and,O,O
achondrogenesis,B,B
type,I,I
1B,I,I
(,O,O
ACG1B,B,O
),O,O
.,O,O
To,O,O
learn,O,O
more,O,O
about,O,O
the,O,O
molecular,O,O
basis,O,O
of,O,O
DTDST,B,B
chondrodysplasias,I,I
and,O,O
about,O,O
genotype,O,O
-,O,O
phenotype,O,O
correlations,O,O
",",O,O
we,O,O
studied,O,O
fibroblast,O,O
cultures,O,O
of,O,O
three,O,O
new,O,O
patients,O,O
one,O,O
with,O,O
AO,B,B
-,I,I
2,I,I
",",O,O
one,O,O
with,O,O
DTD,B,B
",",O,O
and,O,O
one,O,O
with,O,O
an,O,O
intermediate,O,O
phenotype,O,O
(,O,O
AO2,B,B
/,O,I
DTD,B,I
),O,O
.,O,O
Reduced,O,O
incorporation,O,O
of,O,O
inorganic,O,O
sulfate,O,O
into,O,O
macromolecules,O,O
was,O,O
found,O,O
in,O,O
all,O,O
three,O,O
.,O,O
Each,O,O
of,O,O
the,O,O
three,O,O
patients,O,O
was,O,O
found,O,O
to,O,O
be,O,O
heterozygous,O,O
for,O,O
a,O,O
c862t,O,O
transition,O,O
predicting,O,O
a,O,O
R279W,O,O
substitution,O,O
in,O,O
the,O,O
third,O,O
extracellular,O,O
loop,O,O
of,O,O
DTDST,O,B
.,O,O
In,O,O
two,O,O
patients,O,O
(,O,O
DTD,B,B
and,O,O
AO2,B,B
/,O,I
DTD,B,I
),O,O
",",O,O
no,O,O
other,O,O
structural,O,O
mutation,O,O
was,O,O
found,O,O
",",O,O
but,O,O
polymerase,O,O
chain,O,O
reaction,O,O
amplification,O,O
and,O,O
single,O,O
-,O,O
strand,O,O
conformation,O,O
polymorphism,O,O
analysis,O,O
of,O,O
fibroblast,O,O
cDNA,O,O
showed,O,O
reduced,O,O
mRNA,O,O
levels,O,O
of,O,O
the,O,O
wild,O,O
-,O,O
type,O,O
DTDST,O,B
allele,O,O
these,O,O
two,O,O
patients,O,O
may,O,O
be,O,O
compound,O,O
heterozygotes,O,O
for,O,O
the,O,O
mutation,O,O
(,O,O
as,O,O
yet,O,O
uncharacterized,O,O
at,O,O
the,O,O
DNA,O,O
level,O,O
),O,O
",",O,O
which,O,O
causes,O,O
reduced,O,O
expression,O,O
of,O,O
DTDST,O,B
.,O,O
The,O,O
third,O,O
patient,O,O
(,O,O
with,O,O
AO2,B,O
),O,O
had,O,O
the,O,O
R279W,O,B
mutation,O,O
compounded,O,O
with,O,O
a,O,O
novel,O,O
mutation,O,O
",",O,O
the,O,O
deletion,O,O
of,O,O
cytosine,O,O
418,O,O
(,O,O
delta,O,O
c418,O,O
),O,O
",",O,O
predicting,O,O
a,O,O
frameshift,O,O
with,O,O
premature,O,O
termination,O,O
.,O,O
Also,O,O
the,O,O
delta,O,O
c418,O,O
allele,O,O
was,O,O
underrepresented,O,O
in,O,O
the,O,O
cDNA,O,O
",",O,O
in,O,O
accordance,O,O
with,O,O
previous,O,O
observations,O,O
that,O,O
premature,O,O
stop,O,O
codons,O,O
reduce,O,O
mRNA,O,O
levels,O,O
.,O,O
The,O,O
presence,O,O
of,O,O
the,O,O
DTDST,O,B
R279W,O,I
mutation,O,O
in,O,O
a,O,O
total,O,O
of,O,O
11,O,O
patients,O,O
with,O,O
AO2,B,O
or,O,O
DTD,B,B
emphasizes,O,O
the,O,O
overlap,O,O
between,O,O
these,O,O
conditions,O,O
.,O,O
This,O,O
mutation,O,O
has,O,O
not,O,O
been,O,O
found,O,O
so,O,O
far,O,O
in,O,O
8,O,O
analyzed,O,O
ACG1B,B,O
patients,O,O
",",O,O
suggesting,O,O
that,O,O
it,O,O
allows,O,O
some,O,O
residual,O,O
activity,O,O
of,O,O
the,O,O
sulfate,O,O
transporter,O,O
.,O,O
Identification,O,O
of,O,O
WASP,O,B
mutations,O,O
",",O,O
mutation,O,O
hotspots,O,O
and,O,O
genotype,O,O
-,O,O
phenotype,O,O
disparities,O,O
in,O,O
24,O,O
patients,O,O
with,O,O
the,O,O
Wiskott,B,B
-,I,I
Aldrich,I,I
syndrome,I,I
.,O,O
The,O,O
Wiskott,B,B
-,I,I
Aldrich,I,I
syndrome,I,I
(,O,O
WAS,B,B
),O,O
",",O,O
an,O,O
X,B,O
-,I,O
linked,I,O
immunodeficiency,I,O
disease,I,O
caused,O,O
by,O,O
mutation,O,O
in,O,O
the,O,O
recently,O,O
isolated,O,O
gene,O,O
encoding,O,O
WAS,B,B
protein,O,I
(,O,O
WASP,O,B
),O,O
",",O,O
is,O,O
known,O,O
to,O,O
be,O,O
associated,O,O
with,O,O
extensive,O,O
clinical,O,O
heterogeneity,O,O
.,O,O
Cumulative,O,O
mutation,O,O
data,O,O
have,O,O
revealed,O,O
that,O,O
WASP,O,B
genotypes,O,I
are,O,O
also,O,O
highly,O,O
variable,O,O
among,O,O
WAS,B,B
patients,O,O
",",O,O
but,O,O
the,O,O
relationship,O,O
of,O,O
phenotype,O,O
with,O,O
genotype,O,O
in,O,O
this,O,O
disease,O,O
remains,O,O
unclear,O,O
.,O,O
To,O,O
address,O,O
this,O,O
issue,O,O
we,O,O
characterized,O,O
WASP,O,B
mutations,O,O
in,O,O
24,O,O
unrelated,O,O
WAS,B,O
patients,O,O
",",O,O
including,O,O
18,O,O
boys,O,O
with,O,O
severe,O,O
classical,O,O
WAS,B,O
and,O,O
6,O,O
boys,O,O
expressing,O,O
mild,O,O
forms,O,O
of,O,O
the,O,O
disease,O,O
",",O,O
and,O,O
then,O,O
examined,O,O
the,O,O
degree,O,O
of,O,O
correlation,O,O
of,O,O
these,O,O
as,O,O
well,O,O
as,O,O
all,O,O
previously,O,O
published,O,O
WASP,O,B
mutations,O,O
with,O,O
disease,O,O
severity,O,O
.,O,O
By,O,O
analysis,O,O
of,O,O
these,O,O
compiled,O,O
mutation,O,O
data,O,O
",",O,O
we,O,O
demonstrated,O,O
clustering,O,O
of,O,O
WASP,O,B
mutations,O,O
within,O,O
the,O,O
four,O,O
most,O,O
N,O,O
-,O,O
terminal,O,O
exons,O,O
of,O,O
the,O,O
gene,O,O
and,O,O
also,O,O
identified,O,O
several,O,O
sites,O,O
within,O,O
this,O,O
region,O,O
as,O,O
hotspots,O,O
for,O,O
WASP,O,B
mutation,O,O
.,O,O
These,O,O
characteristics,O,O
were,O,O
observed,O,O
",",O,O
however,O,O
",",O,O
in,O,O
both,O,O
severe,O,O
and,O,O
mild,O,O
cases,O,O
of,O,O
the,O,O
disease,O,O
.,O,O
Similarly,O,O
",",O,O
while,O,O
the,O,O
cumulative,O,O
data,O,O
revealed,O,O
a,O,O
predominance,O,O
of,O,O
missense,O,O
mutations,O,O
among,O,O
the,O,O
WASP,O,B
gene,O,I
lesions,O,I
observed,O,O
in,O,O
boys,O,O
with,O,O
isolated,B,O
thrombocytopenia,I,O
",",O,O
missense,O,O
mutations,O,O
were,O,O
not,O,O
exclusively,O,O
associated,O,O
with,O,O
milder,O,O
WAS,B,B
phenotypes,O,I
",",O,O
but,O,O
also,O,O
comprised,O,O
a,O,O
substantial,O,O
portion,O,O
(,O,O
38,O,O
%,O,O
),O,O
of,O,O
the,O,O
WASP,O,B
gene,O,I
defects,O,I
found,O,O
in,O,O
patients,O,O
with,O,O
severe,O,O
disease,O,O
.,O,O
These,O,O
findings,O,O
",",O,O
as,O,O
well,O,O
as,O,O
the,O,O
detection,O,O
of,O,O
identical,O,O
WASP,O,B
mutations,O,O
in,O,O
patients,O,O
with,O,O
disparate,O,O
phenotypes,O,O
",",O,O
reveal,O,O
a,O,O
lack,O,O
of,O,O
phenotype,O,O
concordance,O,O
with,O,O
genotype,O,O
in,O,O
WAS,B,B
and,O,O
thus,O,O
imply,O,O
that,O,O
phenotypic,O,O
outcome,O,O
in,O,O
this,O,O
disease,O,O
cannot,O,O
be,O,O
reliably,O,O
predicted,O,O
solely,O,O
on,O,O
the,O,O
basis,O,O
of,O,O
WASP,O,B
genotypes,O,O
.,O,O
Germline,O,O
mutations,O,O
in,O,O
the,O,O
3,O,O
',O,O
part,O,O
of,O,O
APC,B,B
exon,O,I
15,O,I
do,O,O
not,O,O
result,O,O
in,O,O
truncated,O,O
proteins,O,O
and,O,O
are,O,O
associated,O,O
with,O,O
attenuated,O,O
adenomatous,B,B
polyposis,I,I
coli,I,I
.,O,O
Familial,B,O
adenomatous,I,B
polyposis,I,I
(,O,O
FAP,B,O
),O,O
is,O,O
an,O,O
inherited,O,O
predisposition,O,O
to,O,O
colorectal,B,O
cancer,I,B
characterized,O,O
by,O,O
the,O,O
development,O,O
of,O,O
numerous,O,O
adenomatous,B,B
polyps,I,I
predominantly,O,O
in,O,O
the,O,O
colorectal,O,O
region,O,O
.,O,O
Germline,O,O
mutations,O,O
in,O,O
the,O,O
adenomatous,B,B
polyposis,I,I
coli,I,I
(,O,O
APC,B,O
),O,O
gene,O,O
are,O,O
responsible,O,O
for,O,O
most,O,O
cases,O,O
of,O,O
FAP,B,O
.,O,O
Mutations,O,O
at,O,O
the,O,O
5,O,O
end,O,O
of,O,O
APC,B,B
are,O,O
known,O,O
to,O,O
be,O,O
associated,O,O
with,O,O
a,O,O
relatively,O,O
mild,O,O
form,O,O
of,O,O
the,O,O
disease,O,O
",",O,O
called,O,O
attenuated,B,O
adenomatous,I,O
polyposis,I,O
coli,I,O
(,O,O
AAPC,B,B
),O,O
.,O,O
We,O,O
identified,O,O
a,O,O
frameshift,O,O
mutation,O,O
in,O,O
the,O,O
3,O,O
part,O,O
of,O,O
exon,O,O
15,O,O
",",O,O
resulting,O,O
in,O,O
a,O,O
stop,O,O
codon,O,O
at,O,O
1862,O,O
",",O,O
in,O,O
a,O,O
large,O,O
Dutch,O,O
kindred,O,O
with,O,O
AAPC,B,B
.,O,O
Western,O,O
blot,O,O
analysis,O,O
of,O,O
lymphoblastoid,O,O
cell,O,O
lines,O,O
derived,O,O
from,O,O
affected,O,O
family,O,O
members,O,O
from,O,O
this,O,O
kindred,O,O
",",O,O
as,O,O
well,O,O
as,O,O
from,O,O
a,O,O
previously,O,O
reported,O,O
Swiss,O,O
family,O,O
carrying,O,O
a,O,O
frameshift,O,O
mutation,O,O
at,O,O
codon,O,O
1987,O,O
and,O,O
displaying,O,O
a,O,O
similar,O,O
attenuated,O,O
phenotype,O,O
",",O,O
showed,O,O
only,O,O
the,O,O
wild,O,O
-,O,O
type,O,O
APC,B,B
protein,O,O
.,O,O
Our,O,O
study,O,O
indicates,O,O
that,O,O
chain,O,O
-,O,O
terminating,O,O
mutations,O,O
located,O,O
in,O,O
the,O,O
3,O,O
part,O,O
of,O,O
APC,B,B
do,O,O
not,O,O
result,O,O
in,O,O
detectable,O,O
truncated,O,O
polypeptides,O,O
and,O,O
we,O,O
hypothesize,O,O
that,O,O
this,O,O
is,O,O
likely,O,O
to,O,O
be,O,O
the,O,O
basis,O,O
for,O,O
the,O,O
observed,O,O
AAPC,B,O
phenotype,O,O
.,O,O
Complete,O,O
genomic,O,O
sequence,O,O
and,O,O
analysis,O,O
of,O,O
117,O,O
kb,O,O
of,O,O
human,O,O
DNA,O,O
containing,O,O
the,O,O
gene,O,O
BRCA1,O,B
.,O,O
Over,O,O
100,O,O
distinct,O,O
disease,O,O
-,O,O
associated,O,O
mutations,O,O
have,O,O
been,O,O
identified,O,O
in,O,O
the,O,O
breast,B,B
-,I,I
ovarian,I,I
cancer,I,I
susceptibility,O,I
gene,O,I
BRCA1,O,O
.,O,O
Loss,O,O
of,O,O
the,O,O
wild,O,O
-,O,O
type,O,O
allele,O,O
in,O,O
>,O,O
90,O,O
%,O,O
of,O,O
tumors,B,O
from,O,O
patients,O,O
with,O,O
inherited,O,O
BRCA1,O,O
mutations,O,O
indicates,O,O
tumor,B,O
suppressive,O,O
function,O,O
.,O,O
The,O,O
low,O,O
incidence,O,O
of,O,O
somatic,O,O
mutations,O,O
suggests,O,O
that,O,O
BRCA1,O,O
inactivation,O,O
in,O,O
sporadic,O,O
tumors,B,O
occurs,O,O
by,O,O
alternative,O,O
mechanisms,O,O
",",O,O
such,O,O
as,O,O
interstitial,O,O
chromosomal,O,O
deletion,O,O
or,O,O
reduced,O,O
transcription,O,O
.,O,O
To,O,O
identify,O,O
possible,O,O
features,O,O
of,O,O
the,O,O
BRCA1,O,O
genomic,O,O
region,O,O
that,O,O
may,O,O
contribute,O,O
to,O,O
chromosomal,O,O
instability,O,O
as,O,O
well,O,O
as,O,O
potential,O,O
transcriptional,O,O
regulatory,O,O
elements,O,O
",",O,O
a,O,O
117,O,O
",",O,O
143,O,O
-,O,O
bp,O,O
DNA,O,O
sequence,O,O
encompassing,O,O
BRCA1,O,O
was,O,O
obtained,O,O
by,O,O
random,O,O
sequencing,O,O
of,O,O
four,O,O
cosmids,O,O
identified,O,O
from,O,O
a,O,O
human,O,O
chromosome,O,O
17,O,O
specific,O,O
library,O,O
.,O,O
The,O,O
24,O,O
exons,O,O
of,O,O
BRCA1,O,B
span,O,O
an,O,O
81,O,O
-,O,O
kb,O,O
region,O,O
that,O,O
has,O,O
an,O,O
unusually,O,O
high,O,O
density,O,O
of,O,O
Alu,O,O
repetitive,O,O
DNA,O,O
(,O,O
41,O,O
.,O,O
5,O,O
%,O,O
),O,O
",",O,O
but,O,O
relatively,O,O
low,O,O
density,O,O
(,O,O
4,O,O
.,O,O
8,O,O
%,O,O
),O,O
of,O,O
other,O,O
repetitive,O,O
sequences,O,O
.,O,O
BRCA1,O,B
intron,O,O
lengths,O,O
range,O,O
in,O,O
size,O,O
from,O,O
403,O,O
bp,O,O
to,O,O
9,O,O
.,O,O
2,O,O
kb,O,O
and,O,O
contain,O,O
the,O,O
intragenic,O,O
microsatellite,O,O
markers,O,O
D17S1323,O,O
",",O,O
D17S1322,O,O
",",O,O
and,O,O
D17S855,O,O
",",O,O
which,O,O
localize,O,O
to,O,O
introns,O,O
12,O,O
",",O,O
19,O,O
",",O,O
and,O,O
20,O,O
",",O,O
respectively,O,O
.,O,O
In,O,O
addition,O,O
to,O,O
BRCA1,O,B
",",O,O
the,O,O
contig,O,O
contains,O,O
two,O,O
complete,O,O
genes,O,O
Rho7,O,B
",",O,O
a,O,O
member,O,O
of,O,O
the,O,O
rho,O,B
family,O,I
of,O,I
GTP,O,I
binding,O,I
proteins,O,I
",",O,O
and,O,O
VAT1,O,B
",",O,O
an,O,O
abundant,O,O
membrane,O,O
protein,O,O
of,O,O
cholinergic,O,O
synaptic,O,O
vesicles,O,O
.,O,O
Partial,O,O
sequences,O,O
of,O,O
the,O,O
1A1,O,B
-,O,I
3B,O,I
B,O,I
-,O,I
box,O,I
protein,O,I
pseudogene,O,I
and,O,O
IFP,O,B
35,O,I
",",O,O
an,O,O
interferon,O,B
induced,O,I
leucine,O,I
zipper,O,I
protein,O,I
",",O,O
reside,O,O
within,O,O
the,O,O
contig,O,O
.,O,O
An,O,O
L21,O,B
ribosomal,O,I
protein,O,I
pseudogene,O,I
is,O,O
embedded,O,O
in,O,O
BRCA1,O,O
intron,O,O
13,O,O
.,O,O
The,O,O
order,O,O
of,O,O
genes,O,O
on,O,O
the,O,O
chromosome,O,O
is,O,O
centromere,O,O
-,O,O
1FP,O,O
35,O,O
-,O,O
VAT1,O,O
-,O,O
Rho7,O,O
-,O,O
BRCA1,O,O
-,O,O
1A1,O,O
-,O,O
3B,O,O
-,O,O
telomere,O,O
Identification,O,O
of,O,O
a,O,O
RING,O,O
protein,O,O
that,O,O
can,O,O
interact,O,O
in,O,O
vivo,O,O
with,O,O
the,O,O
BRCA1,O,O
gene,O,O
product,O,O
.,O,O
The,O,O
hereditary,B,O
breast,I,B
and,I,O
ovarian,I,B
cancer,I,I
gene,O,O
",",O,O
BRCA1,O,O
",",O,O
encodes,O,O
a,O,O
large,O,O
polypeptide,O,O
that,O,O
contains,O,O
the,O,O
cysteine,O,O
-,O,O
rich,O,O
RING,O,O
motif,O,O
",",O,O
a,O,O
zinc,O,O
-,O,O
binding,O,O
domain,O,O
found,O,O
in,O,O
a,O,O
variety,O,O
of,O,O
regulatory,O,O
proteins,O,O
.,O,O
Here,O,O
we,O,O
describe,O,O
a,O,O
novel,O,O
protein,O,O
that,O,O
interacts,O,O
in,O,O
vivo,O,O
with,O,O
the,O,O
N,O,O
-,O,O
terminal,O,O
region,O,O
of,O,O
BRCA1,O,O
.,O,O
This,O,O
BRCA1,O,O
-,O,O
associated,O,O
RING,O,O
domain,O,O
(,O,O
BARD1,O,B
),O,O
protein,O,O
contains,O,O
an,O,O
N,O,O
-,O,O
terminal,O,O
RING,O,O
motif,O,O
",",O,O
three,O,O
tandem,O,O
ankyrin,O,O
repeats,O,O
",",O,O
and,O,O
a,O,O
C,O,O
-,O,O
terminal,O,O
sequence,O,O
with,O,O
significant,O,O
homology,O,O
to,O,O
the,O,O
phylogenetically,O,O
conserved,O,O
BRCT,O,O
domains,O,O
that,O,O
lie,O,O
near,O,O
the,O,O
C,O,O
terminus,O,O
of,O,O
BRCA1,O,O
.,O,O
The,O,O
BARD1,O,B
/,O,I
BRCA1,O,I
interaction,O,O
is,O,O
disrupted,O,O
by,O,O
BRCA1,O,B
missense,O,O
mutations,O,O
that,O,O
segregate,O,O
with,O,O
breast,B,B
cancer,I,I
susceptibility,O,I
",",O,O
indicating,O,O
that,O,O
BARD1,O,B
may,O,O
be,O,O
involved,O,O
in,O,O
mediating,O,O
tumour,B,B
suppression,O,I
by,O,O
BRCA1,O,B
.,O,O
Detection,O,O
of,O,O
heterozygous,O,O
mutations,O,O
in,O,O
BRCA1,O,B
using,O,O
high,O,O
density,O,O
oligonucleotide,O,O
arrays,O,O
and,O,O
two,O,O
-,O,O
colour,O,O
fluorescence,O,O
analysis,O,O
.,O,O
The,O,O
ability,O,O
to,O,O
scan,O,O
a,O,O
large,O,O
gene,O,B
rapidly,O,O
and,O,O
accurately,O,O
for,O,O
all,O,O
possible,O,O
heterozygous,O,O
mutations,O,O
in,O,O
large,O,O
numbers,O,O
of,O,O
patient,O,O
samples,O,O
will,O,O
be,O,O
critical,O,O
for,O,O
the,O,O
future,O,O
of,O,O
medicine,O,O
.,O,O
We,O,O
have,O,O
designed,O,O
high,O,O
-,O,O
density,O,O
arrays,O,O
consisting,O,O
of,O,O
over,O,O
96,O,O
",",O,O
600,O,O
oligonucleotides,O,O
20,O,O
-,O,O
nucleotides,O,O
(,O,O
nt,O,O
),O,O
in,O,O
length,O,O
to,O,O
screen,O,O
for,O,O
a,O,O
wide,O,O
range,O,O
of,O,O
heterozygous,O,O
mutations,O,O
in,O,O
the,O,O
3,O,O
.,O,O
45,O,O
-,O,O
kilobases,O,O
(,O,O
kb,O,O
),O,O
exon,O,O
11,O,O
of,O,O
the,O,O
hereditary,B,B
breast,I,I
and,I,I
ovarian,I,I
cancer,I,I
gene,O,I
BRCA1,O,O
.,O,O
Reference,O,O
and,O,O
test,O,O
samples,O,O
were,O,O
co,O,O
-,O,O
hybridized,O,O
to,O,O
these,O,O
arrays,O,O
and,O,O
differences,O,O
in,O,O
hybridization,O,O
patterns,O,O
quantitated,O,O
by,O,O
two,O,O
-,O,O
colour,O,O
analysis,O,O
.,O,O
Fourteen,O,O
of,O,O
fifteen,O,O
patient,O,O
samples,O,O
with,O,O
known,O,O
mutations,O,O
were,O,O
accurately,O,O
diagnosed,O,O
",",O,O
and,O,O
no,O,O
FALSE,O,O
positive,O,O
mutations,O,O
were,O,O
identified,O,O
in,O,O
20,O,O
control,O,O
samples,O,O
.,O,O
Eight,O,O
single,O,O
nucleotide,O,O
polymorphisms,O,O
were,O,O
also,O,O
readily,O,O
detected,O,O
.,O,O
DNA,O,O
chip,O,O
-,O,O
based,O,O
assays,O,O
may,O,O
provide,O,O
a,O,O
valuable,O,O
new,O,O
technology,O,O
for,O,O
high,O,O
-,O,O
throughput,O,O
cost,O,O
-,O,O
efficient,O,O
detection,O,O
of,O,O
genetic,O,O
alterations,O,O
.,O,O
Autosomal,O,O
dominant,O,O
primary,O,O
hyperparathyroidism,B,O
and,I,O
jaw,I,O
tumor,I,O
syndrome,I,O
associated,O,O
with,O,O
renal,B,O
hamartomas,I,O
and,O,O
cystic,B,O
kidney,I,O
disease,I,O
:,O,O
linkage,O,O
to,O,O
1q21,O,O
-,O,O
q32,O,O
and,O,O
loss,O,O
of,O,O
the,O,O
wild,O,O
type,O,O
allele,O,O
in,O,O
renal,B,O
hamartomas,I,O
.,O,O
Hereditary,B,O
hyperparathyroidism,I,B
-,I,I
jaw,I,I
tumor,I,I
syndrome,I,I
(,O,O
HPT,B,B
-,I,I
JT,I,I
),O,O
is,O,O
an,O,O
autosomal,B,O
dominant,I,O
disease,I,O
(,O,O
OMIM,O,O
145001,O,O
),O,O
that,O,O
has,O,O
recently,O,O
been,O,O
mapped,O,O
to,O,O
chromosomal,O,O
region,O,O
1q21,O,O
-,O,O
q32,O,O
(,O,O
HRPT2,O,O
),O,O
.,O,O
Here,O,O
we,O,O
report,O,O
two,O,O
families,O,O
with,O,O
HPT,B,B
-,I,I
JT,I,I
syndrome,I,I
in,O,O
which,O,O
adult,B,O
renal,I,O
hamartomas,I,O
or,O,O
cystic,B,O
kidney,I,O
disease,I,O
were,O,O
prominent,O,O
associated,O,O
features,O,O
",",O,O
possibly,O,O
representing,O,O
a,O,O
new,O,O
phenotypic,O,O
variant,O,O
of,O,O
the,O,O
HPT,B,B
-,I,I
JT,I,I
syndrome,I,I
.,O,O
In,O,O
the,O,O
first,O,O
family,O,O
",",O,O
renal,B,B
lesions,I,I
were,O,O
present,O,O
in,O,O
five,O,O
out,O,O
of,O,O
six,O,O
affected,O,O
individuals,O,O
",",O,O
whereas,O,O
HPT,B,B
and,O,O
JT,B,B
were,O,O
seen,O,O
in,O,O
four,O,O
and,O,O
two,O,O
cases,O,O
",",O,O
respectively,O,O
.,O,O
In,O,O
the,O,O
second,O,O
family,O,O
",",O,O
JT,B,B
was,O,O
found,O,O
in,O,O
three,O,O
of,O,O
the,O,O
five,O,O
affected,O,O
individuals,O,O
and,O,O
two,O,O
affected,O,O
members,O,O
also,O,O
exhibited,O,O
polycystic,B,B
kidney,I,I
disease,I,I
.,O,O
The,O,O
possibility,O,O
of,O,O
the,O,O
latter,O,O
cosegregating,O,O
as,O,O
a,O,O
separate,O,O
autosomal,O,O
dominant,O,O
gene,O,B
can,O,O
not,O,O
be,O,O
ruled,O,O
out,O,O
.,O,O
A,O,O
sex,O,O
-,O,O
dependent,O,O
penetrance,O,O
of,O,O
primary,B,O
HPT,I,O
",",O,O
resulting,O,O
in,O,O
predominantly,O,O
male,O,O
-,O,O
affected,O,O
cases,O,O
was,O,O
evident,O,O
in,O,O
the,O,O
two,O,O
families,O,O
.,O,O
Twenty,O,O
microsatellite,O,O
markers,O,O
in,O,O
the,O,O
HRPT2,O,O
region,O,O
were,O,O
typed,O,O
",",O,O
in,O,O
addition,O,O
to,O,O
markers,O,O
in,O,O
the,O,O
multiple,B,O
endocrine,I,O
neoplasia,I,O
(,I,O
MEN,I,O
),I,O
types,I,O
1,I,O
and,I,O
2,I,O
regions,O,O
at,O,O
11q13,O,O
and,O,O
10q11,O,O
.,O,O
The,O,O
disease,O,O
in,O,O
these,O,O
two,O,O
kindreds,O,O
was,O,O
linked,O,O
to,O,O
five,O,O
markers,O,O
in,O,O
the,O,O
1q21,O,O
-,O,O
q32,O,O
region,O,O
(,O,O
logarithm,O,O
-,O,O
of,O,O
-,O,O
odds,O,O
scores,O,O
3,O,O
.,O,O
2,O,O
-,O,O
4,O,O
2,O,O
-,O,O
4,O,O
.,O,O
2,O,O
),O,O
",",O,O
whereas,O,O
linkage,O,O
to,O,O
the,O,O
MEN1,B,O
and,O,O
MEN2,B,O
regions,O,O
was,O,O
excluded,O,O
.,O,O
Meiotic,O,O
recombinations,O,O
detected,O,O
in,O,O
affected,O,O
individuals,O,O
placed,O,O
the,O,O
locus,O,O
telomeric,O,O
of,O,O
D1S215,O,O
",",O,O
thus,O,O
narrowing,O,O
the,O,O
HRPT2,O,O
region,O,O
from,O,O
>,O,O
60,O,O
to,O,O
approximately,O,O
34,O,O
centimorgans,O,O
.,O,O
Loss,O,O
of,O,O
heterozygosity,O,O
was,O,O
studied,O,O
in,O,O
seven,O,O
renal,B,B
hamartomas,I,I
from,O,O
two,O,O
affected,O,O
individuals,O,O
in,O,O
the,O,O
first,O,O
family,O,O
",",O,O
as,O,O
well,O,O
as,O,O
in,O,O
a,O,O
jaw,B,O
tumor,I,O
and,O,O
a,O,O
parathyroid,B,B
tumor,I,I
from,O,O
the,O,O
second,O,O
family,O,O
.,O,O
All,O,O
renal,B,B
hamartomas,I,I
showed,O,O
loss,O,O
of,O,O
heterozygosity,O,O
at,O,O
the,O,O
1q21,O,O
-,O,O
q32,O,O
region,O,O
.,O,O
The,O,O
losses,O,O
invariably,O,O
involved,O,O
the,O,O
wild,O,O
type,O,O
allele,O,O
derived,O,O
from,O,O
the,O,O
unaffected,O,O
parent,O,O
",",O,O
suggesting,O,O
the,O,O
inactivation,O,O
of,O,O
a,O,O
tumor,B,O
suppressor,O,O
gene,O,O
in,O,O
this,O,O
region,O,O
Independent,O,O
origin,O,O
of,O,O
single,O,O
and,O,O
double,O,O
mutations,O,O
in,O,O
the,O,O
human,O,O
glucose,O,O
6,O,O
-,O,O
phosphate,O,O
dehydrogenase,O,O
gene,O,O
.,O,O
The,O,O
vast,O,O
majority,O,O
of,O,O
both,O,O
polymorphic,O,O
and,O,O
sporadic,O,O
G6PD,O,B
variants,O,O
are,O,O
due,O,O
to,O,O
single,O,O
missense,O,O
mutations,O,O
.,O,O
In,O,O
the,O,O
four,O,O
polymorphic,O,O
variants,O,O
that,O,O
have,O,O
two,O,O
point,O,O
mutations,O,O
",",O,O
one,O,O
of,O,O
the,O,O
mutations,O,O
is,O,O
always,O,O
376,O,O
A,O,O
-,O,O
-,O,O
>,O,O
G,O,O
(,O,O
126,O,O
Asn,O,O
-,O,O
-,O,O
>,O,O
Asp,O,O
),O,O
",",O,O
which,O,O
on,O,O
its,O,O
own,O,O
gives,O,O
rise,O,O
to,O,O
the,O,O
nondeficient,O,O
polymorphic,O,O
variant,O,O
",",O,O
G6PD,O,B
A,O,I
.,O,O
In,O,O
a,O,O
study,O,O
of,O,O
G6PD,B,B
deficient,I,I
patients,O,O
who,O,O
presented,O,O
with,O,O
clinical,O,O
favism,B,O
in,O,O
Spain,O,O
",",O,O
we,O,O
have,O,O
found,O,O
a,O,O
new,O,O
polymorphic,O,O
variant,O,O
that,O,O
we,O,O
have,O,O
called,O,O
G6PD,O,B
Malaga,O,I
",",O,O
whose,O,O
only,O,O
abnormality,O,O
is,O,O
a,O,O
542,O,O
A,O,O
-,O,O
-,O,O
>,O,O
T,O,O
(,O,O
181,O,O
Asp,O,O
-,O,O
-,O,O
>,O,O
Val,O,O
),O,O
mutation,O,O
.,O,O
This,O,O
is,O,O
the,O,O
same,O,O
mutation,O,O
as,O,O
previously,O,O
found,O,O
in,O,O
association,O,O
with,O,O
the,O,O
mutation,O,O
of,O,O
G6PD,O,B
A,O,I
in,O,O
the,O,O
double,O,O
mutant,O,O
",",O,O
G6PD,O,B
Santamaria,O,I
.,O,O
G6PD,O,B
Malaga,O,I
is,O,O
associated,O,O
with,O,O
enzyme,B,O
deficiency,I,O
(,O,O
class,O,O
III,O,O
),O,O
",",O,O
and,O,O
the,O,O
enzymic,O,O
properties,O,O
of,O,O
G6PD,O,B
Malaga,O,I
and,O,O
G6PD,O,B
Santamaria,O,I
are,O,O
quite,O,O
similar,O,O
",",O,O
indicating,O,O
that,O,O
in,O,O
this,O,O
case,O,O
the,O,O
effects,O,O
of,O,O
the,O,O
two,O,O
mutations,O,O
are,O,O
additive,O,O
rather,O,O
than,O,O
synergistic,O,O
.,O,O
G6PD,O,B
Santamaria,O,I
might,O,O
have,O,O
been,O,O
produced,O,O
by,O,O
recombination,O,O
between,O,O
G6PD,O,B
A,O,I
and,O,O
G6PD,O,B
Malaga,O,I
;,O,O
however,O,O
haplotype,O,O
analysis,O,O
",",O,O
including,O,O
the,O,O
use,O,O
of,O,O
a,O,O
new,O,O
silent,O,O
polymorphism,O,O
",",O,O
suggests,O,O
that,O,O
the,O,O
same,O,O
542,O,O
A,O,O
-,O,O
-,O,O
T,O,O
mutation,O,O
has,O,O
taken,O,O
place,O,O
independently,O,O
in,O,O
a,O,O
G6PD,O,B
B,O,I
gene,O,O
to,O,O
give,O,O
G6PD,O,B
Malaga,O,I
and,O,O
in,O,O
a,O,O
G6PD,O,B
A,O,I
gene,O,O
to,O,O
give,O,O
G6PD,O,B
Santamaria,O,I
.,O,O
These,O,O
findings,O,O
help,O,O
to,O,O
outline,O,O
the,O,O
relationship,O,O
and,O,O
evolution,O,O
of,O,O
mutations,O,O
in,O,O
the,O,O
human,O,O
G6PD,O,B
locus,O,O
.,O,O
.,O,O
BRCA1,O,O
R841W,O,O
:,O,O
a,O,O
strong,O,O
candidate,O,O
for,O,O
a,O,O
common,O,O
mutation,O,O
with,O,O
moderate,O,O
phenotype,O,O
.,O,O
BRCA1,O,O
mutations,O,O
cause,O,O
increased,O,O
risk,O,O
for,O,O
breast,B,B
and,I,O
ovarian,I,B
cancer,I,I
",",O,O
frequently,O,O
of,O,O
early,O,O
onset,O,O
.,O,O
Many,O,O
different,O,O
mutations,O,O
occur,O,O
in,O,O
BRCA1,O,O
",",O,O
including,O,O
several,O,O
examples,O,O
of,O,O
recurrent,O,O
mutations,O,O
",",O,O
each,O,O
of,O,O
which,O,O
accounts,O,O
for,O,O
a,O,O
significant,O,O
number,O,O
of,O,O
families,O,O
with,O,O
heritable,O,O
cancer,B,B
predisposition,O,I
.,O,O
These,O,O
common,O,O
mutations,O,O
have,O,O
an,O,O
etiological,O,O
role,O,O
in,O,O
many,O,O
breast,B,B
and,I,O
ovarian,I,B
cancer,I,I
cases,O,O
and,O,O
provide,O,O
the,O,O
opportunity,O,O
to,O,O
examine,O,O
genotype,O,O
-,O,O
phenotype,O,O
correlations,O,O
and,O,O
genotype,O,O
-,O,O
environment,O,O
interactions,O,O
in,O,O
individuals,O,O
with,O,O
the,O,O
identical,O,O
BRCA1,O,O
lesion,O,O
.,O,O
We,O,O
report,O,O
a,O,O
novel,O,O
missense,O,O
change,O,O
in,O,O
BRCA1,O,O
",",O,O
2640,O,O
C,O,O
-,O,O
-,O,O
>,O,O
T,O,O
(,O,O
R841W,O,O
),O,O
",",O,O
found,O,O
in,O,O
3,O,O
cases,O,O
from,O,O
a,O,O
subject,O,O
group,O,O
of,O,O
305,O,O
breast,B,B
and,I,O
79,I,O
ovarian,I,B
cancer,I,I
cases,O,O
from,O,O
Orange,O,O
County,O,O
",",O,O
CA,O,O
.,O,O
These,O,O
are,O,O
consecutive,O,O
",",O,O
population,O,O
-,O,O
based,O,O
cases,O,O
not,O,O
selected,O,O
for,O,O
age,O,O
or,O,O
family,O,O
history,O,O
.,O,O
In,O,O
all,O,O
three,O,O
cases,O,O
",",O,O
there,O,O
is,O,O
a,O,O
strong,O,O
family,O,O
history,O,O
of,O,O
breast,B,B
",",I,O
ovarian,I,B
",",I,O
or,I,O
other,I,O
cancers,I,B
possibly,O,O
related,O,O
to,O,O
a,O,O
BRCA1,O,O
defect,O,O
and,O,O
family,O,O
members,O,O
showed,O,O
a,O,O
high,O,O
concordance,O,O
of,O,O
cancer,B,B
incidence,O,O
with,O,O
the,O,O
presence,O,O
of,O,O
R841W,O,O
.,O,O
The,O,O
age,O,O
of,O,O
cancer,B,O
onset,O,O
was,O,O
not,O,O
always,O,O
distinct,O,O
from,O,O
typical,O,O
sporadic,O,O
cases,O,O
.,O,O
Testing,O,O
of,O,O
a,O,O
sample,O,O
of,O,O
413,O,O
unrelated,O,O
individuals,O,O
to,O,O
examine,O,O
the,O,O
hypothesis,O,O
that,O,O
R841W,O,O
might,O,O
be,O,O
a,O,O
rare,O,O
polymorphism,O,O
detected,O,O
one,O,O
additional,O,O
instance,O,O
in,O,O
a,O,O
woman,O,O
with,O,O
breast,B,B
cancer,I,I
diagnosed,O,O
at,O,O
age,O,O
77,O,O
years,O,O
",",O,O
and,O,O
cancer,B,O
in,O,O
one,O,O
parent,O,O
.,O,O
R841W,O,B
is,O,O
likely,O,O
to,O,O
be,O,O
an,O,O
etiologically,O,O
significant,O,O
lesion,O,O
with,O,O
involvement,O,O
in,O,O
close,O,O
to,O,O
1,O,O
%,O,O
(,O,O
95,O,O
%,O,O
confidence,O,O
interval,O,O
of,O,O
0,O,O
-,O,O
1,O,O
.,O,O
7,O,O
%,O,O
),O,O
of,O,O
all,O,O
breast,B,B
and,I,O
ovarian,I,B
cancers,I,I
in,O,O
this,O,O
population,O,O
.,O,O
Ataxia,B,B
-,I,I
telangiectasia,I,I
:,O,O
founder,O,O
effect,O,O
among,O,O
north,O,O
African,O,O
Jews,O,O
.,O,O
The,O,O
ATM,O,O
gene,O,O
is,O,O
responsible,O,O
for,O,O
the,O,O
autosomal,B,B
recessive,I,I
disorder,I,I
ataxia,B,I
-,I,I
telangiectasia,I,I
(,O,O
A,B,B
-,I,I
T,I,I
),O,O
",",O,O
characterized,O,O
by,O,O
cerebellar,B,O
degeneration,I,O
",",O,O
immunodeficiency,B,O
and,O,O
cancer,B,B
predisposition,I,I
.,O,O
A,B,B
-,I,I
T,I,I
carriers,O,O
were,O,O
reported,O,O
to,O,O
be,O,O
moderately,O,O
cancer,B,B
-,I,I
prone,I,I
.,O,O
A,O,B
wide,O,O
variety,O,O
of,O,O
A,B,B
-,I,I
T,I,I
mutations,O,O
",",O,O
most,O,O
of,O,O
which,O,O
are,O,O
unique,O,O
to,O,O
single,O,O
families,O,O
",",O,O
were,O,O
identified,O,O
in,O,O
various,O,O
ethnic,O,O
groups,O,O
",",O,O
precluding,O,O
carrier,O,O
screening,O,O
with,O,O
mutation,O,O
-,O,O
specific,O,O
assays,O,O
.,O,O
However,O,O
",",O,O
a,O,O
single,O,O
mutation,O,O
was,O,O
observed,O,O
in,O,O
32,O,O
/,O,O
33,O,O
defective,O,O
ATM,O,O
alleles,O,O
in,O,O
Jewish,O,O
A,B,B
-,I,I
T,I,I
families,O,O
of,O,O
North,O,O
African,O,O
origin,O,O
",",O,O
coming,O,O
from,O,O
various,O,O
regions,O,O
of,O,O
Morocco,O,O
and,O,O
Tunisia,O,O
.,O,O
This,O,O
mutation,O,O
",",O,O
103C,O,O
-,O,O
-,O,O
>,O,O
T,O,O
",",O,O
results,O,O
in,O,O
a,O,O
stop,O,O
codon,O,O
at,O,O
position,O,O
35,O,O
of,O,O
the,O,O
ATM,O,B
protein,O,I
.,O,O
In,O,O
keeping,O,O
with,O,O
the,O,O
nature,O,O
of,O,O
this,O,O
mutation,O,O
",",O,O
various,O,O
antibodies,O,O
directed,O,O
against,O,O
the,O,O
ATM,O,B
protein,O,I
failed,O,O
to,O,O
defect,O,O
this,O,O
protein,O,O
in,O,O
patient,O,O
cells,O,O
.,O,O
A,O,O
rapid,O,O
carrier,O,O
detection,O,O
assay,O,O
detected,O,O
this,O,O
mutation,O,O
in,O,O
three,O,O
out,O,O
of,O,O
488,O,O
ATM,O,B
alleles,O,O
of,O,O
Jewish,O,O
Moroccan,O,O
or,O,O
Tunisian,O,O
origin,O,O
.,O,O
This,O,O
founder,O,O
effect,O,O
provides,O,O
a,O,O
unique,O,O
opportunity,O,O
for,O,O
population,O,O
-,O,O
based,O,O
screening,O,O
for,O,O
A,B,B
-,I,I
T,I,I
carriers,O,O
in,O,O
a,O,O
large,O,O
Jewish,O,O
community,O,O
.,O,O
Mutation,O,O
analysis,O,O
of,O,O
BRCA1,O,O
and,O,O
BRCA2,O,O
in,O,O
a,O,O
male,B,O
breast,I,B
cancer,I,I
population,O,O
.,O,O
A,O,O
population,O,O
-,O,O
based,O,O
series,O,O
of,O,O
54,O,O
male,B,O
breast,I,B
cancer,I,I
cases,O,O
from,O,O
Southern,O,O
California,O,O
were,O,O
analyzed,O,O
for,O,O
germ,O,O
-,O,O
line,O,O
mutations,O,O
in,O,O
the,O,O
inherited,B,O
breast,I,B
/,I,I
ovarian,I,I
cancer,I,I
genes,O,O
",",O,O
BRCA1,O,O
and,O,O
BRCA2,O,O
.,O,O
Nine,O,O
(,O,O
17,O,O
%,O,O
),O,O
of,O,O
the,O,O
patients,O,O
had,O,O
a,O,O
family,O,O
history,O,O
of,O,O
breast,B,B
and,I,O
/,I,O
or,I,O
ovarian,I,B
cancer,I,I
in,O,O
at,O,O
least,O,O
one,O,O
first,O,O
-,O,O
degree,O,O
relative,O,O
.,O,O
A,O,O
further,O,O
seven,O,O
(,O,O
13,O,O
%,O,O
),O,O
of,O,O
the,O,O
patients,O,O
reported,O,O
breast,B,B
/,I,O
ovarian,I,B
cancer,I,I
in,O,O
at,O,O
least,O,O
one,O,O
second,O,O
-,O,O
degree,O,O
relative,O,O
and,O,O
in,O,O
no,O,O
first,O,O
-,O,O
degree,O,O
relatives,O,O
.,O,O
No,O,O
germ,O,O
-,O,O
line,O,O
BRCA1,O,O
mutations,O,O
were,O,O
found,O,O
.,O,O
Two,O,O
male,B,O
breast,I,B
cancer,I,I
patients,O,O
(,O,O
4,O,O
%,O,O
of,O,O
the,O,O
total,O,O
),O,O
were,O,O
found,O,O
to,O,O
carry,O,O
novel,O,O
truncating,O,O
mutations,O,O
in,O,O
the,O,O
BRCA2,O,O
gene,O,O
.,O,O
Only,O,O
one,O,O
of,O,O
the,O,O
two,O,O
male,B,O
breast,I,B
cancer,I,I
patients,O,O
carrying,O,O
a,O,O
BRCA2,O,O
mutation,O,O
had,O,O
a,O,O
family,O,O
history,O,O
of,O,O
cancer,B,O
",",O,O
with,O,O
one,O,O
case,O,O
of,O,O
ovarian,B,B
cancer,I,I
in,O,O
a,O,O
first,O,O
-,O,O
degree,O,O
relative,O,O
.,O,O
The,O,O
remaining,O,O
eight,O,O
cases,O,O
(,O,O
89,O,O
%,O,O
),O,O
of,O,O
male,B,O
breast,I,B
cancer,I,I
with,O,O
a,O,O
family,O,O
history,O,O
of,O,O
breast,B,B
/,I,I
ovarian,I,I
cancer,I,I
in,O,O
first,O,O
-,O,O
degree,O,O
relatives,O,O
remain,O,O
unaccounted,O,O
for,O,O
by,O,O
mutations,O,O
in,O,O
either,O,O
the,O,O
BRCA1,O,O
gene,O,O
or,O,O
the,O,O
BRCA2,O,O
gene,O,O
.,O,O
.,O,O
Molecular,O,O
basis,O,O
for,O,O
Duarte,B,B
and,I,O
Los,I,B
Angeles,I,I
variant,I,I
galactosemia,I,I
.,O,O
Human,O,O
orythrocytes,O,O
that,O,O
are,O,O
homozygous,O,O
for,O,O
the,O,O
Duarte,B,B
enzyme,I,O
variant,I,O
of,I,O
galactosemia,I,I
(,O,O
D,O,B
/,O,I
D,O,I
),O,O
have,O,O
a,O,O
characteristic,O,O
isoform,O,O
on,O,O
isoelectric,O,O
focusing,O,O
and,O,O
50,O,O
%,O,O
reduction,O,O
in,O,O
galactose,O,B
-,O,I
1,O,I
-,O,I
phosphate,O,I
uridyltransferase,O,I
(,O,O
GALT,O,O
),O,O
enzyme,O,O
activity,O,O
.,O,O
The,O,O
Duarte,O,B
biochemical,O,I
phenotype,O,I
has,O,O
a,O,O
molecular,O,O
genotype,O,O
of,O,O
N314D,O,B
/,O,I
N314D,O,I
.,O,O
The,O,O
characteristic,O,O
Duarte,O,B
isoform,O,I
is,O,O
also,O,O
associated,O,O
with,O,O
a,O,O
variant,O,O
called,O,O
the,O,O
Los,O,B
Angeles,O,I
(,O,O
LA,O,B
),O,O
phenotype,O,O
",",O,O
which,O,O
has,O,O
increased,O,O
GALT,O,B
enzyme,O,I
activity,O,I
.,O,O
We,O,O
evaluated,O,O
GALT,O,B
enzyme,O,I
activity,O,I
and,O,O
screened,O,O
the,O,O
GALT,O,B
genes,O,I
of,O,O
145,O,O
patients,O,O
with,O,O
one,O,O
or,O,O
more,O,O
N314D,O,B
-,O,I
containing,O,I
alleles,O,I
.,O,O
We,O,O
found,O,O
seven,O,O
with,O,O
the,O,O
LA,O,O
biochemical,O,O
phenotype,O,O
",",O,O
and,O,O
all,O,O
had,O,O
a,O,O
1721C,O,O
-,O,O
-,O,O
>,O,O
T,O,O
transition,O,O
in,O,O
exon,O,O
7,O,O
in,O,O
cis,O,O
with,O,O
the,O,O
N314D,O,O
missense,O,O
mutation,O,O
.,O,O
The,O,O
1721C,O,O
-,O,O
-,O,O
>,O,O
T,O,O
transition,O,O
is,O,O
a,O,O
neutral,O,O
polymorphism,O,O
for,O,O
leucine,O,O
at,O,O
amino,O,O
acid,O,O
218,O,O
(,O,O
L218L,O,O
),O,O
.,O,O
In,O,O
pedigree,O,O
analyses,O,O
",",O,O
this,O,O
1721C,O,O
-,O,O
-,O,O
>,O,O
T,O,O
transition,O,O
segregated,O,O
with,O,O
the,O,O
LA,O,O
phenotype,O,O
of,O,O
increased,O,O
GALT,O,O
activity,O,O
in,O,O
three,O,O
different,O,O
biochemical,O,O
phenotypes,O,O
(,O,O
LA,O,O
/,O,O
N,O,O
",",O,O
LA,O,O
/,O,O
G,O,O
",",O,O
and,O,O
LA,O,O
/,O,O
D,O,O
),O,O
.,O,O
To,O,O
determine,O,O
the,O,O
mechanism,O,O
for,O,O
increased,O,O
activity,O,O
of,O,O
the,O,O
LA,O,B
variant,O,O
",",O,O
we,O,O
compared,O,O
GALT,O,B
mRNA,O,O
",",O,O
protein,O,O
abundance,O,O
",",O,O
and,O,O
enzyme,O,O
thermal,O,O
stability,O,O
in,O,O
lymphoblast,O,O
cell,O,O
lines,O,O
of,O,O
D,O,O
and,O,O
LA,O,B
phenotypes,O,O
with,O,O
comparable,O,O
genotypes,O,O
.,O,O
GALT,O,B
protein,O,O
abundance,O,O
was,O,O
increased,O,O
in,O,O
LA,O,B
compared,O,O
to,O,O
D,O,O
alleles,O,O
",",O,O
but,O,O
mRNA,O,O
was,O,O
similar,O,O
among,O,O
all,O,O
genotypes,O,O
.,O,O
When,O,O
LA,O,O
/,O,O
D,O,B
and,O,O
D,O,B
/,O,O
D,O,B
GALT,O,O
biochemical,O,O
phenotypes,O,O
were,O,O
compared,O,O
to,O,O
N,O,B
/,O,O
N,O,B
GALT,O,O
phenotypes,O,O
",",O,O
both,O,O
had,O,O
50,O,O
%,O,O
",",O,O
as,O,O
compared,O,O
to,O,O
21,O,O
%,O,O
",",O,O
reduction,O,O
in,O,O
GALT,O,O
activity,O,O
in,O,O
the,O,O
wild,O,O
type,O,O
(,O,O
N,O,B
/,O,O
N,O,B
),O,O
after,O,O
exposure,O,O
at,O,O
identical,O,O
initial,O,O
enzyme,O,O
activity,O,O
to,O,O
50,O,O
degrees,O,O
C,O,O
for,O,O
15,O,O
min,O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
the,O,O
codon,O,O
change,O,O
N314D,O,B
in,O,O
cis,O,O
with,O,O
the,O,O
base,O,O
-,O,O
pair,O,O
transition,O,O
1721C,O,O
-,O,O
-,O,O
>,O,O
T,O,O
produces,O,O
the,O,O
LA,B,O
variant,I,O
of,I,O
galactosemia,I,O
and,O,O
that,O,O
this,O,O
nucleotide,O,O
change,O,O
increases,O,O
GALT,O,O
activity,O,O
by,O,O
increasing,O,O
GALT,O,O
protein,O,O
abundance,O,O
without,O,O
increasing,O,O
transcription,O,O
or,O,O
decreasing,O,O
thermal,O,O
lability,O,O
.,O,O
A,O,O
favorable,O,O
codon,O,O
bias,O,O
for,O,O
the,O,O
mutated,O,O
codon,O,O
with,O,O
consequently,O,O
increased,O,O
translation,O,O
rates,O,O
is,O,O
postulated,O,O
as,O,O
the,O,O
mechanism,O,O
.,O,O
The,O,O
TSG101,O,B
tumor,B,I
susceptibility,O,I
gene,O,I
is,O,O
located,O,O
in,O,O
chromosome,O,O
11,O,O
band,O,O
p15,O,O
and,O,O
is,O,O
mutated,O,O
in,O,O
human,O,O
breast,B,B
cancer,I,I
.,O,O
Recent,O,O
work,O,O
has,O,O
identified,O,O
a,O,O
mouse,O,O
gene,O,O
(,O,O
tsg101,O,B
),O,O
whose,O,O
inactivation,O,O
in,O,O
fibroblasts,O,O
results,O,O
in,O,O
cellular,O,O
transformation,O,O
and,O,O
the,O,O
ability,O,O
to,O,O
produce,O,O
metastatic,B,O
tumors,I,O
in,O,O
nude,O,O
mice,O,O
.,O,O
Here,O,O
",",O,O
we,O,O
report,O,O
that,O,O
the,O,O
human,O,O
homolog,O,O
",",O,O
TSG101,O,B
",",O,O
which,O,O
we,O,O
isolated,O,O
and,O,O
mapped,O,O
to,O,O
chromosome,O,O
11,O,O
",",O,O
bands,O,O
15,O,O
.,O,O
1,O,O
-,O,O
15,O,O
1,O,O
-,O,O
15,O,O
.,O,O
2,O,O
",",O,O
a,O,O
region,O,O
proposed,O,O
to,O,O
contain,O,O
tumor,B,O
suppressor,O,O
gene,O,O
(,O,O
s,O,O
),O,O
",",O,O
is,O,O
mutated,O,O
at,O,O
high,O,O
frequency,O,O
in,O,O
human,O,O
breast,B,B
cancer,I,I
.,O,O
In,O,O
7,O,O
of,O,O
15,O,O
uncultured,O,O
primary,O,O
human,O,O
breast,B,B
carcinomas,I,I
",",O,O
intragenic,O,O
deletions,O,O
were,O,O
shown,O,O
in,O,O
TSG101,O,B
genomic,O,I
DNA,O,I
and,O,O
transcripts,O,O
by,O,O
gel,O,O
and,O,O
sequence,O,O
analysis,O,O
",",O,O
and,O,O
mutations,O,O
affecting,O,O
two,O,O
TSG101,O,B
alleles,O,I
were,O,O
identified,O,O
in,O,O
four,O,O
of,O,O
these,O,O
cancers,B,O
.,O,O
No,O,O
TSG101,O,B
defects,O,O
were,O,O
found,O,O
in,O,O
matched,O,O
normal,O,O
breast,O,B
tissue,O,I
from,O,O
the,O,O
breast,B,B
cancer,I,I
patients,O,O
.,O,O
These,O,O
findings,O,O
strongly,O,O
implicate,O,O
TSG101,O,B
mutations,O,O
in,O,O
human,O,O
breast,B,B
cancer,I,I
Moderate,O,O
intergenerational,O,O
and,O,O
somatic,O,O
instability,O,O
of,O,O
a,O,O
55,O,O
-,O,O
CTG,O,O
repeat,O,O
in,O,O
transgenic,O,O
mice,O,O
.,O,O
Myotonic,B,O
dystrophy,I,O
(,O,O
DM,B,B
),O,O
is,O,O
associated,O,O
with,O,O
the,O,O
expansion,O,O
of,O,O
a,O,O
(,O,O
CTG,O,O
),O,O
n,O,O
trinucleotide,O,O
repeat,O,O
in,O,O
the,O,O
3,O,O
untranslated,O,O
region,O,O
(,O,O
UTR,O,O
),O,O
of,O,O
the,O,O
DM,B,B
protein,O,I
kinase,O,I
gene,O,I
(,O,O
DMPK,O,O
),O,O
.,O,O
The,O,O
(,O,O
CTG,O,B
),O,O
n,O,O
repeat,O,O
is,O,O
polymorphic,O,O
and,O,O
varies,O,O
in,O,O
size,O,O
between,O,O
5,O,O
and,O,O
37,O,O
repeats,O,O
in,O,O
unaffected,O,O
individuals,O,O
whereas,O,O
in,O,O
affected,O,O
patients,O,O
there,O,O
are,O,O
between,O,O
50,O,O
and,O,O
4,O,O
",",O,O
CTGs,O,O
.,O,O
The,O,O
size,O,O
of,O,O
the,O,O
(,O,O
CTG,O,B
),O,O
n,O,O
repeat,O,O
",",O,O
which,O,O
increases,O,O
through,O,O
generations,O,O
",",O,O
generally,O,O
correlates,O,O
with,O,O
clinical,O,O
severity,O,O
and,O,O
age,O,O
of,O,O
onset,O,O
.,O,O
The,O,O
instability,O,O
of,O,O
the,O,O
CTG,O,B
repeat,O,I
appears,O,O
to,O,O
depend,O,O
on,O,O
its,O,O
size,O,O
as,O,O
well,O,O
as,O,O
on,O,O
the,O,O
sex,O,O
of,O,O
the,O,O
transmitting,O,O
parent,O,O
.,O,O
Moreover,O,O
",",O,O
mitotic,O,O
instability,O,O
analysis,O,O
of,O,O
different,O,O
human,O,O
DM,B,B
tissues,O,I
shows,O,O
length,O,O
mosaicism,O,O
between,O,O
different,O,O
cell,O,O
lineages,O,O
.,O,O
The,O,O
molecular,O,O
mechanisms,O,O
of,O,O
triplet,O,O
instability,O,O
remain,O,O
elusive,O,O
.,O,O
To,O,O
investigate,O,O
the,O,O
role,O,O
of,O,O
genomic,O,O
sequences,O,O
in,O,O
instability,O,O
",",O,O
we,O,O
produced,O,O
transgenic,O,O
mice,O,O
containing,O,O
a,O,O
45,O,O
-,O,O
kb,O,O
genomic,O,O
segment,O,O
with,O,O
a,O,O
55,O,O
-,O,O
CTG,O,B
repeat,O,I
cloned,O,O
from,O,O
a,O,O
mildly,O,O
affected,O,O
patient,O,O
.,O,O
In,O,O
contrast,O,O
to,O,O
other,O,O
mouse,O,O
models,O,O
containing,O,O
CAG,O,B
repeats,O,I
within,O,O
cDNAs,O,O
",",O,O
these,O,O
mice,O,O
showed,O,O
both,O,O
intergenerational,O,O
and,O,O
somatic,O,O
repeat,O,O
instability,O,O
.,O,O
.,O,O
Missense,O,O
mutations,O,O
in,O,O
the,O,O
Fas,O,B
gene,O,I
resulting,O,O
in,O,O
autoimmune,B,B
lymphoproliferative,I,I
syndrome,I,I
:,O,O
a,O,O
molecular,O,O
and,O,O
immunological,O,O
analysis,O,O
.,O,O
Programmed,O,O
cell,O,O
death,O,O
(,O,O
or,O,O
apoptosis,O,O
),O,O
is,O,O
a,O,O
physiological,O,O
process,O,O
essential,O,O
to,O,O
the,O,O
normal,O,O
development,O,O
and,O,O
homeostatic,O,O
maintenance,O,O
of,O,O
the,O,O
immune,O,O
system,O,O
.,O,O
The,O,O
Fas,O,B
/,O,I
Apo,O,I
-,O,I
1,O,I
receptor,O,O
plays,O,O
a,O,O
crucial,O,O
role,O,O
in,O,O
the,O,O
regulation,O,O
of,O,O
apoptosis,O,O
",",O,O
as,O,O
demonstrated,O,O
by,O,O
lymphoproliferation,O,O
in,O,O
MRL,O,O
-,O,O
lpr,O,O
/,O,O
lpr,O,O
mice,O,O
and,O,O
by,O,O
the,O,O
recently,O,O
described,O,O
autoimmune,B,B
lymphoproliferative,I,I
syndrome,I,I
(,O,O
ALPS,B,O
),O,O
in,O,O
humans,O,O
",",O,O
both,O,O
of,O,O
which,O,O
are,O,O
due,O,O
to,O,O
mutations,O,O
in,O,O
the,O,O
Fas,O,B
gene,O,I
.,O,O
We,O,O
describe,O,O
a,O,O
novel,O,O
family,O,O
with,O,O
ALPS,B,B
in,O,O
which,O,O
three,O,O
affected,O,O
siblings,O,O
carry,O,O
two,O,O
distinct,O,O
missense,O,O
mutations,O,O
on,O,O
both,O,O
the,O,O
Fas,O,B
gene,O,I
alleles,O,I
and,O,O
show,O,O
lack,O,O
of,O,O
Fas,O,B
-,O,I
induced,O,I
apoptosis,O,I
.,O,O
The,O,O
children,O,O
share,O,O
common,O,O
clinical,O,O
features,O,O
including,O,O
splenomegaly,B,O
and,O,O
lymphadenopathy,B,O
",",O,O
but,O,O
only,O,O
one,O,O
developed,O,O
severe,O,O
autoimmune,B,O
manifestations,I,O
.,O,O
In,O,O
all,O,O
three,O,O
siblings,O,O
",",O,O
we,O,O
demonstrated,O,O
the,O,O
presence,O,O
of,O,O
anergic,O,O
CD3,O,B
+,O,I
CD4,O,B
-,O,I
CD8,O,B
-,O,I
(,O,O
double,O,O
negative,O,O
",",O,O
[,O,O
DN,O,O
],O,O
),O,O
T,O,B
cells,O,I
;,O,O
moreover,O,O
",",O,O
a,O,O
chronic,O,O
lymphocyte,O,B
activation,O,I
was,O,O
found,O,O
",",O,O
as,O,O
demonstrated,O,O
by,O,O
the,O,O
presence,O,O
of,O,O
high,O,O
levels,O,O
of,O,O
HLA,O,B
-,O,I
DR,O,I
expression,O,I
on,O,O
peripheral,O,O
CD3,O,B
+,O,I
cells,O,I
and,O,O
by,O,O
the,O,O
presence,O,O
of,O,O
high,O,O
levels,O,O
of,O,O
serum,O,O
activation,O,O
markers,O,O
such,O,O
as,O,O
soluble,O,O
interleukin,O,O
-,O,O
2,O,O
receptor,O,O
(,O,O
slL,O,O
-,O,O
2R,O,O
),O,O
and,O,O
soluble,O,O
CD30,O,O
(,O,O
sCD30,O,O
),O,O
.,O,O
The,O,O
ataxia,B,B
-,I,I
telangiectasia,I,I
gene,O,I
product,O,O
",",O,O
a,O,O
constitutively,O,O
expressed,O,O
nuclear,O,O
protein,O,O
that,O,O
is,O,O
not,O,O
up,O,O
-,O,O
regulated,O,O
following,O,O
genome,O,O
damage,O,O
.,O,O
The,O,O
product,O,O
of,O,O
the,O,O
ataxia,B,B
-,I,I
telangiectasia,I,I
gene,O,I
(,O,O
ATM,O,B
),O,O
was,O,O
identified,O,O
by,O,O
using,O,O
an,O,O
antiserum,O,O
developed,O,O
to,O,O
a,O,O
peptide,O,O
corresponding,O,O
to,O,O
the,O,O
deduced,O,O
amino,O,O
acid,O,O
sequence,O,O
.,O,O
The,O,O
ATM,O,B
protein,O,O
is,O,O
a,O,O
single,O,O
",",O,O
high,O,O
-,O,O
molecular,O,O
weight,O,O
protein,O,O
predominantly,O,O
confined,O,O
to,O,O
the,O,O
nucleus,O,O
of,O,O
human,O,O
fibroblasts,O,O
",",O,O
but,O,O
is,O,O
present,O,O
in,O,O
both,O,O
nuclear,O,O
and,O,O
microsomal,O,O
fractions,O,O
from,O,O
human,O,O
lymphoblast,O,O
cells,O,O
and,O,O
peripheral,O,O
blood,O,O
lymphocytes,O,O
.,O,O
ATM,O,B
protein,O,O
levels,O,O
and,O,O
localization,O,O
remain,O,O
constant,O,O
throughout,O,O
all,O,O
stages,O,O
of,O,O
the,O,O
cell,O,O
cycle,O,O
.,O,O
Truncated,O,O
ATM,O,B
protein,O,I
was,O,O
not,O,O
detected,O,O
in,O,O
lymphoblasts,O,O
from,O,O
ataxia,B,B
-,I,I
telangiectasia,I,I
patients,O,O
homozygous,O,O
for,O,O
mutations,O,O
leading,O,O
to,O,O
premature,O,O
protein,O,O
termination,O,O
.,O,O
Exposure,O,O
of,O,O
normal,O,O
human,O,O
cells,O,O
to,O,O
gamma,O,O
-,O,O
irradiation,O,O
and,O,O
the,O,O
radiomimetic,O,O
drug,O,O
neocarzinostatin,O,O
had,O,O
no,O,O
effect,O,O
on,O,O
ATM,O,B
protein,O,I
levels,O,I
",",O,O
in,O,O
contrast,O,O
to,O,O
a,O,O
noted,O,O
rise,O,O
in,O,O
p53,O,B
levels,O,I
over,O,O
the,O,O
same,O,O
time,O,O
interval,O,O
.,O,O
These,O,O
findings,O,O
are,O,O
consistent,O,O
with,O,O
a,O,O
role,O,O
for,O,O
the,O,O
ATM,O,O
protein,O,O
in,O,O
ensuring,O,O
the,O,O
fidelity,O,O
of,O,O
DNA,O,O
repair,O,O
and,O,O
cell,O,O
cycle,O,O
regulation,O,O
following,O,O
genome,O,O
damage,O,O
.,O,O
Type,O,O
III,O,O
collagen,O,B
is,O,O
crucial,O,O
for,O,O
collagen,O,O
I,O,O
fibrillogenesis,O,O
and,O,O
for,O,O
normal,O,O
cardiovascular,O,O
development,O,O
.,O,O
Type,O,O
III,O,O
collagen,O,B
is,O,O
a,O,O
fibrillar,O,O
forming,O,O
collagen,O,O
comprising,O,O
three,O,O
alpha1,O,O
(,O,O
III,O,O
),O,O
chains,O,O
and,O,O
is,O,O
expressed,O,O
in,O,O
early,O,O
embryos,O,O
and,O,O
throughout,O,O
embryogenesis,O,O
.,O,O
In,O,O
the,O,O
adult,O,O
",",O,O
type,O,O
III,O,B
collagen,O,I
is,O,O
a,O,O
major,O,O
component,O,O
of,O,O
the,O,O
extracellular,O,O
matrix,O,O
in,O,O
a,O,O
variety,O,O
of,O,O
internal,O,O
organs,O,O
and,O,O
skin,O,O
.,O,O
Mutations,O,O
in,O,O
the,O,O
COL3A1,O,B
gene,O,I
have,O,O
been,O,O
implicated,O,O
as,O,O
a,O,O
cause,O,O
of,O,O
type,B,O
IV,I,O
Ehlers,I,B
-,I,I
Danlos,I,I
syndrome,I,I
",",O,O
a,O,O
disease,O,O
leading,O,O
to,O,O
aortic,B,B
rupture,I,I
in,O,O
early,O,O
adult,O,O
life,O,O
.,O,O
To,O,O
directly,O,O
study,O,O
the,O,O
role,O,O
of,O,O
Col3a1,O,B
in,O,O
development,O,O
and,O,O
disease,O,O
",",O,O
we,O,O
have,O,O
inactivated,O,O
the,O,O
Col3a1,O,B
gene,O,I
in,O,O
embryonic,O,O
stem,O,O
cells,O,O
by,O,O
homologous,O,O
recombination,O,O
.,O,O
The,O,O
mutated,O,O
allele,O,O
was,O,O
transmitted,O,O
through,O,O
the,O,O
mouse,O,O
germ,O,O
line,O,O
and,O,O
homozygous,O,O
mutant,O,O
animals,O,O
were,O,O
derived,O,O
from,O,O
heterozygous,O,O
intercrosses,O,O
.,O,O
About,O,O
10,O,O
%,O,O
of,O,O
the,O,O
homozygous,O,O
mutant,O,O
animals,O,O
survived,O,O
to,O,O
adulthood,O,O
but,O,O
have,O,O
a,O,O
much,O,O
shorter,O,O
life,O,O
span,O,O
compared,O,O
with,O,O
wild,O,O
-,O,O
type,O,O
mice,O,O
.,O,O
The,O,O
major,O,O
cause,O,O
of,O,O
death,O,O
of,O,O
mutant,O,O
mice,O,O
was,O,O
rupture,O,O
of,O,O
the,O,O
major,O,O
blood,O,O
vessels,O,O
",",O,O
similar,O,O
to,O,O
patients,O,O
with,O,O
type,B,O
IV,I,O
Ehlers,I,B
-,I,I
Danlos,I,I
syndrome,I,I
.,O,O
Ultrastructural,O,O
analysis,O,O
of,O,O
tissues,O,O
from,O,O
mutant,O,O
mice,O,O
revealed,O,O
that,O,O
type,O,O
III,O,O
collagen,O,B
is,O,O
essential,O,O
for,O,O
normal,O,O
collagen,O,B
I,O,I
fibrillogenesis,O,O
in,O,O
the,O,O
cardiovascular,O,O
system,O,O
and,O,O
other,O,O
organs,O,O
.,O,O
Nonsense,O,O
mutation,O,O
in,O,O
exon,O,O
3,O,O
of,O,O
the,O,O
proteolipid,O,O
protein,O,O
gene,O,O
(,O,O
PLP,O,B
),O,O
in,O,O
a,O,O
family,O,O
with,O,O
an,O,O
unusual,O,O
form,O,O
of,O,O
Pelizaeus,B,O
-,I,O
Merzbacher,I,O
disease,I,O
.,O,O
We,O,O
report,O,O
a,O,O
G,O,B
-,O,I
-,O,I
>,O,I
A,O,I
transition,O,O
at,O,O
nucleotide,O,O
431,O,O
of,O,O
the,O,O
proteolipid,O,B
protein,O,I
gene,O,I
(,O,O
PLP,O,B
),O,O
results,O,O
in,O,O
a,O,O
nonsense,O,O
codon,O,O
in,O,O
a,O,O
family,O,O
with,O,O
an,O,O
unusual,O,O
form,O,O
of,O,O
Pelizaeus,B,B
-,I,I
Merzbacher,I,I
disease,I,I
(,O,O
PMD,B,B
),O,O
.,O,O
The,O,O
mutation,O,O
",",O,O
which,O,O
creates,O,O
a,O,O
second,O,O
AluI,O,O
restriction,O,O
site,O,O
",",O,O
results,O,O
in,O,O
a,O,O
nonsense,O,O
mutation,O,O
in,O,O
PLP,O,B
.,O,O
The,O,O
clinical,O,O
picture,O,O
resembles,O,O
somewhat,O,O
that,O,O
of,O,O
X,B,O
-,I,O
linked,I,O
spastic,I,O
paraplegia,I,O
(,O,O
SPG,B,B
),O,O
.,O,O
It,O,O
differs,O,O
from,O,O
this,O,O
and,O,O
both,O,O
the,O,O
classical,O,O
and,O,O
connatal,O,O
forms,O,O
of,O,O
PMD,B,B
in,O,O
that,O,O
it,O,O
is,O,O
relatively,O,O
mild,O,O
in,O,O
form,O,O
",",O,O
onset,O,O
is,O,O
delayed,O,O
beyond,O,O
age,O,O
2,O,O
years,O,O
",",O,O
nystagmus,B,O
is,O,O
absent,O,O
",",O,O
tremors,B,O
are,O,O
prominent,O,O
",",O,O
mental,B,O
retardation,I,O
is,O,O
not,O,O
severe,O,O
",",O,O
some,O,O
patients,O,O
show,O,O
dementia,B,O
or,O,O
personality,B,O
disorders,I,O
",",O,O
the,O,O
disease,O,O
is,O,O
progressive,O,O
rather,O,O
than,O,O
static,O,O
in,O,O
some,O,O
",",O,O
and,O,O
several,O,O
females,O,O
show,O,O
signs,O,O
of,O,O
disease,O,O
.,O,O
The,O,O
nonsense,O,O
mutation,O,O
",",O,O
which,O,O
is,O,O
in,O,O
exon,O,O
3B,O,O
",",O,O
should,O,O
block,O,O
the,O,O
synthesis,O,O
of,O,O
normal,O,O
PLP,O,B
but,O,O
spare,O,O
DM20,O,O
",",O,O
the,O,O
isoform,O,O
whose,O,O
persistence,O,O
has,O,O
been,O,O
associated,O,O
with,O,O
mild,O,O
forms,O,O
of,O,O
PLP,B,B
-,I,I
associated,I,I
disease,I,I
in,O,O
both,O,O
humans,O,O
and,O,O
mice,O,O
.,O,O
Common,O,O
BRCA1,O,O
variants,O,O
and,O,O
susceptibility,O,O
to,O,O
breast,B,B
and,I,O
ovarian,I,B
cancer,I,I
in,O,O
the,O,O
general,O,O
population,O,O
.,O,O
Most,O,O
multiple,O,O
case,O,O
families,O,O
of,O,O
young,O,O
onset,O,O
breast,B,B
cancer,I,I
and,O,O
ovarian,B,B
cancer,I,I
are,O,O
thought,O,O
to,O,O
be,O,O
due,O,O
to,O,O
highly,O,O
penetrant,O,O
mutations,O,O
in,O,O
the,O,O
predisposing,O,O
genes,O,O
BRCA1,O,B
and,O,O
BRCA2,O,B
.,O,O
However,O,O
",",O,O
these,O,O
mutations,O,O
are,O,O
uncommon,O,O
in,O,O
the,O,O
population,O,O
and,O,O
they,O,O
probably,O,O
account,O,O
for,O,O
only,O,O
a,O,O
few,O,O
percent,O,O
of,O,O
all,O,O
breast,B,B
cancer,I,I
incidence,O,O
.,O,O
A,O,O
much,O,O
larger,O,O
fraction,O,O
of,O,O
breast,B,B
cancer,I,I
might,O,O
",",O,O
in,O,O
principle,O,O
",",O,O
be,O,O
due,O,O
to,O,O
common,O,O
variants,O,O
which,O,O
confer,O,O
more,O,O
modest,O,O
individual,O,O
risks,O,O
.,O,O
There,O,O
are,O,O
several,O,O
common,O,O
polymorphisms,O,O
in,O,O
the,O,O
BRCA1,O,B
gene,O,I
which,O,O
generate,O,O
amino,O,O
acid,O,O
substitutions,O,O
.,O,O
We,O,O
have,O,O
examined,O,O
the,O,O
frequency,O,O
of,O,O
four,O,O
of,O,O
these,O,O
polymorphisms,O,O
Gln356Arg,O,O
",",O,O
Pro871Leu,O,O
",",O,O
Glu1038Gly,O,O
and,O,O
Ser1613Gly,O,O
in,O,O
large,O,O
series,O,O
of,O,O
breast,B,B
and,I,O
ovarian,I,B
cancer,I,I
cases,O,O
and,O,O
matched,O,O
controls,O,O
.,O,O
Due,O,O
to,O,O
strong,O,O
linkage,O,O
disequilibrium,O,O
",",O,O
these,O,O
four,O,O
sites,O,O
generate,O,O
only,O,O
three,O,O
haplotypes,O,O
with,O,O
a,O,O
frequency,O,O
>,O,O
1,O,O
.,O,O
3,O,O
%,O,O
.,O,O
The,O,O
most,O,O
common,O,O
haplotypes,O,O
",",O,O
defined,O,O
by,O,O
the,O,O
alleles,O,O
Gln356Pro871Glu1038Ser1613,O,O
and,O,O
Gln356Leu871Gly1038Gly1613,O,O
",",O,O
have,O,O
frequencies,O,O
of,O,O
0,O,O
.,O,O
57,O,O
and,O,O
0,O,O
.,O,O
32,O,O
respectively,O,O
",",O,O
and,O,O
these,O,O
frequencies,O,O
do,O,O
not,O,O
differ,O,O
significantly,O,O
between,O,O
patient,O,O
and,O,O
control,O,O
groups,O,O
.,O,O
Thus,O,O
the,O,O
most,O,O
common,O,O
polymorphisms,O,O
of,O,O
the,O,O
BRCA1,O,B
gene,O,I
do,O,O
not,O,O
make,O,O
a,O,O
significant,O,O
contribution,O,O
to,O,O
breast,B,B
or,I,O
ovarian,I,B
cancer,I,I
risk,O,O
.,O,O
However,O,O
",",O,O
our,O,O
data,O,O
suggest,O,O
that,O,O
the,O,O
Arg356,O,O
allele,O,O
may,O,O
have,O,O
a,O,O
different,O,O
genotype,O,O
distribution,O,O
in,O,O
breast,B,B
cancer,I,I
patients,O,O
from,O,O
that,O,O
in,O,O
controls,O,O
(,O,O
Arg356,O,O
homozygotes,O,O
are,O,O
more,O,O
frequent,O,O
in,O,O
the,O,O
control,O,O
groups,O,O
",",O,O
P,O,O
=,O,O
0,O,O
.,O,O
),O,O
",",O,O
indicating,O,O
that,O,O
it,O,O
may,O,O
be,O,O
protective,O,O
against,O,O
breast,B,B
cancer,I,I
.,O,O
If,O,O
this,O,O
finding,O,O
can,O,O
be,O,O
confirmed,O,O
",",O,O
it,O,O
may,O,O
provide,O,O
an,O,O
insight,O,O
into,O,O
the,O,O
structural,O,O
features,O,O
of,O,O
the,O,O
BRCA1,O,O
protein,O,O
that,O,O
are,O,O
important,O,O
for,O,O
its,O,O
function,O,O
.,O,O
Kniest,B,O
dysplasia,I,O
:,O,O
Dr,O,O
.,O,O
W,O,O
.,O,O
Kniest,O,O
",",O,O
his,O,O
patient,O,O
",",O,O
the,O,O
molecular,O,O
defect,O,O
.,O,O
Kniest,B,O
dysplasia,I,O
is,O,O
a,O,O
severe,O,O
chondrodysplasia,B,O
caused,O,O
by,O,O
the,O,O
defective,B,O
formation,I,O
of,I,O
type,I,O
II,I,O
collagen,I,O
.,O,O
We,O,O
report,O,O
about,O,O
Dr,O,O
.,O,O
Kniest,O,B
",",O,O
who,O,O
first,O,O
described,O,O
the,O,O
condition,O,O
in,O,O
1952,O,O
",",O,O
and,O,O
his,O,O
patient,O,O
",",O,O
who,O,O
",",O,O
at,O,O
the,O,O
age,O,O
of,O,O
50,O,O
years,O,O
is,O,O
severely,B,O
handicapped,I,O
with,O,O
short,B,O
stature,I,O
",",O,O
restricted,B,O
joint,I,O
mobility,I,O
",",O,O
and,O,O
blindness,B,O
but,O,O
is,O,O
mentally,O,O
alert,O,O
and,O,O
leads,O,O
an,O,O
active,O,O
life,O,O
.,O,O
Molecular,O,O
analysis,O,O
of,O,O
the,O,O
patients,O,O
DNA,O,O
showed,O,O
a,O,O
single,O,O
base,O,O
(,O,O
G,O,O
),O,O
deletion,O,O
involving,O,O
the,O,O
GT,O,O
dinucleotide,O,O
at,O,O
the,O,O
start,O,O
of,O,O
intron,O,O
18,O,O
destroying,O,O
a,O,O
splice,O,O
site,O,O
of,O,O
the,O,O
COL2A1,O,B
gene,O,O
.,O,O
This,O,O
is,O,O
in,O,O
accordance,O,O
with,O,O
molecular,O,O
findings,O,O
in,O,O
other,O,O
patients,O,O
with,O,O
Kniest,B,B
dysplasia,I,I
and,O,O
confirms,O,O
",",O,O
in,O,O
the,O,O
original,O,O
patient,O,O
",",O,O
that,O,O
the,O,O
disorder,O,O
is,O,O
caused,O,O
by,O,O
small,O,O
inframe,O,O
deletions,O,O
often,O,O
due,O,O
to,O,O
exon,O,O
skipping,O,O
as,O,O
a,O,O
result,O,O
of,O,O
COL2A1,O,B
splice,O,I
site,O,I
mutations,O,I
.,O,O
Cloning,O,O
of,O,O
the,O,O
homogentisate,O,O
1,O,O
",",O,O
2,O,O
-,O,O
dioxygenase,O,O
gene,O,O
",",O,O
the,O,O
key,O,O
enzyme,O,O
of,O,O
alkaptonuria,B,B
in,O,O
mouse,O,O
.,O,O
We,O,O
determined,O,O
48,O,O
amino,O,O
acid,O,O
residues,O,O
from,O,O
five,O,O
peptides,O,O
from,O,O
the,O,O
homogeneous,O,O
monomer,O,O
of,O,O
homogentisate,O,O
1,O,O
",",O,O
2,O,O
-,O,O
dioxygenase,O,O
(,O,O
HGO,O,B
;,O,O
E,O,O
.,O,O
C,O,O
.,O,O
1,O,O
.,O,O
13,O,O
.,O,O
11,O,O
.,O,O
15,O,O
),O,O
of,O,O
mouse,O,O
liver,O,O
.,O,O
After,O,O
digestion,O,O
with,O,O
trypsin,O,O
",",O,O
peptides,O,O
were,O,O
separated,O,O
by,O,O
reversed,O,O
phase,O,O
chromatography,O,O
and,O,O
amino,O,O
acid,O,O
sequenced,O,O
.,O,O
The,O,O
deduced,O,O
codon,O,O
sequence,O,O
of,O,O
three,O,O
peptides,O,O
was,O,O
used,O,O
to,O,O
derive,O,O
degenerated,O,O
oligomeres,O,O
.,O,O
By,O,O
combining,O,O
these,O,O
oligos,O,O
",",O,O
we,O,O
were,O,O
able,O,O
to,O,O
amplify,O,O
fragments,O,O
from,O,O
100,O,O
to,O,O
300,O,O
bases,O,O
(,O,O
b,O,O
),O,O
from,O,O
mouse,O,B
liver,O,I
cDNA,O,I
by,O,O
polymerase,O,O
chain,O,O
reaction,O,O
after,O,O
reverse,O,O
transcription,O,O
(,O,O
RT,O,O
-,O,O
PCR,O,O
),O,O
.,O,O
A,O,O
fragment,O,O
of,O,O
200,O,O
b,O,O
was,O,O
cloned,O,O
and,O,O
used,O,O
as,O,O
a,O,O
probe,O,O
to,O,O
screen,O,O
a,O,O
mouse,O,B
liver,O,I
cDNA,O,I
library,O,O
.,O,O
One,O,O
clone,O,O
from,O,O
this,O,O
library,O,O
contained,O,O
the,O,O
complete,O,O
cDNA,O,O
-,O,O
insert,O,O
for,O,O
HGO,O,B
as,O,O
determined,O,O
by,O,O
sequencing,O,O
.,O,O
The,O,O
cDNA,O,O
encodes,O,O
for,O,O
a,O,O
protein,O,O
of,O,O
50,O,B
kDa,O,I
",",O,O
as,O,O
predicted,O,O
.,O,O
The,O,O
cDNA,O,O
of,O,O
mouse,O,O
HGO,O,B
has,O,O
an,O,O
overall,O,O
identity,O,O
of,O,O
41,O,O
%,O,O
to,O,O
the,O,O
corresponding,O,O
gene,O,O
hmgA,O,B
from,O,O
Aspergillus,O,O
.,O,O
Sequence,O,O
similarities,O,O
to,O,O
human,O,O
expressed,O,O
sequence,O,O
tags,O,O
(,O,O
EST,O,O
),O,O
clones,O,O
ranged,O,O
from,O,O
70,O,O
%,O,O
to,O,O
20,O,O
%,O,O
.,O,O
The,O,O
positions,O,O
of,O,O
122,O,O
conserved,O,O
amino,O,O
acids,O,O
could,O,O
be,O,O
determined,O,O
by,O,O
multiple,O,O
sequence,O,O
alignment,O,O
.,O,O
We,O,O
identified,O,O
one,O,O
first,O,O
intron,O,O
of,O,O
928,O,O
b,O,O
in,O,O
the,O,O
mouse,O,B
gene,O,I
.,O,O
The,O,O
gene,O,O
for,O,O
HGO,O,B
seems,O,O
to,O,O
be,O,O
expressed,O,O
in,O,O
various,O,O
tissues,O,O
",",O,O
as,O,O
shown,O,O
by,O,O
RT,O,O
-,O,O
PCR,O,O
on,O,O
different,O,O
cDNAs,O,O
.,O,O
FISH,O,O
experiments,O,O
with,O,O
the,O,O
whole,O,O
murine,O,B
cDNA,O,I
as,O,O
probe,O,O
clearly,O,O
revealed,O,O
signals,O,O
at,O,O
the,O,O
human,O,O
chromosomal,O,O
band,O,O
3q13,O,O
.,O,O
3,O,O
-,O,O
q21,O,O
.,O,O
This,O,O
corresponds,O,O
well,O,O
to,O,O
the,O,O
previous,O,O
assignment,O,O
of,O,O
the,O,O
locus,O,O
for,O,O
the,O,O
human,O,O
alkaptonuria,B,B
gene,O,I
(,O,O
AKU,O,I
),O,O
to,O,O
the,O,O
same,O,O
chromosomal,O,O
region,O,O
by,O,O
multipoint,O,O
linkage,O,O
analysis,O,O
.,O,O
We,O,O
therefore,O,O
conclude,O,O
that,O,O
the,O,O
HGO,O,B
cDNA,O,I
encodes,O,O
the,O,O
gene,O,O
responsible,O,O
for,O,O
alkaptonuria,B,O
.,O,O
PTEN,O,B
",",O,O
a,O,O
putative,O,O
protein,O,O
tyrosine,O,O
phosphatase,O,O
gene,O,O
mutated,O,O
in,O,O
human,O,O
brain,B,B
",",I,O
breast,I,B
",",I,O
and,I,O
prostate,I,B
cancer,I,I
.,O,O
Mapping,O,O
of,O,O
homozygous,O,O
deletions,O,O
on,O,O
human,O,O
chromosome,O,O
10q23,O,O
has,O,O
led,O,O
to,O,O
the,O,O
isolation,O,O
of,O,O
a,O,O
candidate,O,O
tumor,B,O
suppressor,O,O
gene,O,O
",",O,O
PTEN,O,B
",",O,O
that,O,O
appears,O,O
to,O,O
be,O,O
mutated,O,O
at,O,O
considerable,O,O
frequency,O,O
in,O,O
human,O,O
cancers,B,B
.,O,O
In,O,O
preliminary,O,O
screens,O,O
",",O,O
mutations,O,O
of,O,O
PTEN,O,B
were,O,O
detected,O,O
in,O,O
31,O,O
%,O,O
(,O,O
13,O,O
/,O,O
42,O,O
),O,O
of,O,O
glioblastoma,B,O
cell,O,O
lines,O,O
and,O,O
xenografts,O,O
",",O,O
100,O,O
%,O,O
(,O,O
4,O,O
/,O,O
4,O,O
),O,O
of,O,O
prostate,B,O
cancer,I,O
cell,O,O
lines,O,O
",",O,O
6,O,O
%,O,O
(,O,O
4,O,O
/,O,O
65,O,O
),O,O
of,O,O
breast,B,O
cancer,I,O
cell,O,O
lines,O,O
and,O,O
xenografts,O,O
",",O,O
and,O,O
17,O,O
%,O,O
(,O,O
3,O,O
/,O,O
18,O,O
),O,O
of,O,O
primary,B,O
glioblastomas,I,O
.,O,O
The,O,O
predicted,O,O
PTEN,O,B
product,O,O
has,O,O
a,O,O
protein,O,O
tyrosine,O,O
phosphatase,O,O
domain,O,O
and,O,O
extensive,O,O
homology,O,O
to,O,O
tensin,O,O
",",O,O
a,O,O
protein,O,O
that,O,O
interacts,O,O
with,O,O
actin,O,O
filaments,O,O
at,O,O
focal,O,O
adhesions,O,O
.,O,O
These,O,O
homologies,O,O
suggest,O,O
that,O,O
PTEN,O,B
may,O,O
suppress,O,O
tumor,B,B
cell,O,I
growth,O,O
by,O,O
antagonizing,O,O
protein,O,O
tyrosine,O,O
kinases,O,O
and,O,O
may,O,O
regulate,O,O
tumor,B,B
cell,O,I
invasion,O,O
and,O,O
metastasis,B,O
through,O,O
interactions,O,O
at,O,O
focal,O,O
adhesions,O,O
.,O,O
Heterogeneity,O,O
in,O,O
Schwartz,B,B
-,I,I
Jampel,I,I
chondrodystrophic,I,I
myotonia,I,I
.,O,O
The,O,O
Schwartz,B,B
-,I,I
Jampel,I,I
syndrome,I,I
(,O,O
SJS,B,B
;,O,O
chondrodystrophic,B,I
myotonia,I,I
;,O,O
McK,O,O
255,O,O
",",O,O
800,O,O
),O,O
is,O,O
a,O,O
recessively,B,B
inherited,I,I
condition,I,I
defined,O,O
by,O,O
myotonia,B,O
",",O,O
short,B,O
stature,I,O
",",O,O
and,O,O
bone,B,O
dysplasia,I,O
.,O,O
Genetic,O,O
linkage,O,O
between,O,O
SJS,B,B
and,O,O
chromosomal,O,O
region,O,O
1q36,O,O
-,O,O
34,O,O
has,O,O
been,O,O
observed,O,O
in,O,O
several,O,O
families,O,O
",",O,O
but,O,O
the,O,O
gene,O,O
has,O,O
not,O,O
yet,O,O
been,O,O
identified,O,O
.,O,O
We,O,O
studied,O,O
the,O,O
clinical,O,O
and,O,O
radiological,O,O
features,O,O
in,O,O
81,O,O
patients,O,O
from,O,O
the,O,O
literature,O,O
and,O,O
5,O,O
own,O,O
patients,O,O
trying,O,O
to,O,O
identify,O,O
distinct,O,O
subgroups,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
we,O,O
tested,O,O
genetic,O,O
linkage,O,O
to,O,O
the,O,O
SJS,B,B
locus,O,O
on,O,O
chromosome,O,O
1,O,O
in,O,O
one,O,O
family,O,O
with,O,O
two,O,O
affected,O,O
sibs,O,O
.,O,O
We,O,O
found,O,O
that,O,O
a,O,O
group,O,O
of,O,O
patients,O,O
have,O,O
mild,O,O
skeletal,O,O
changes,O,O
which,O,O
may,O,O
be,O,O
secondary,O,O
consequences,O,O
of,O,O
myotonia,B,O
",",O,O
while,O,O
another,O,O
group,O,O
of,O,O
patients,O,O
appear,O,O
to,O,O
have,O,O
primary,O,O
bone,B,B
dysplasia,I,I
with,O,O
myotonia,B,O
.,O,O
Within,O,O
this,O,O
latter,O,O
group,O,O
",",O,O
there,O,O
are,O,O
differences,O,O
in,O,O
age,O,O
of,O,O
manifestation,O,O
",",O,O
clinical,O,O
course,O,O
and,O,O
pattern,O,O
of,O,O
bone,O,B
changes,O,I
.,O,O
We,O,O
tentatively,O,O
isolate,O,O
three,O,O
different,O,O
types,O,O
of,O,O
SJS,B,B
type,I,I
1A,I,I
",",O,O
usually,O,O
recognized,O,O
in,O,O
childhood,O,O
",",O,O
with,O,O
moderate,O,O
bone,B,O
dysplasia,I,O
",",O,O
corresponding,O,O
to,O,O
the,O,O
original,O,O
descriptions,O,O
of,O,O
Schwartz,O,B
",",O,O
Jampel,O,B
and,O,O
Aberfeld,O,B
;,O,O
type,O,O
1B,O,O
",",O,O
similar,O,O
to,O,O
type,O,O
1A,O,O
but,O,O
recognizable,O,O
at,O,O
birth,O,O
",",O,O
with,O,O
more,O,O
pronounced,O,O
bone,B,O
dysplasia,I,O
resembling,O,O
Kniest,B,B
dysplasia,I,I
;,O,O
and,O,O
type,O,O
2,O,O
",",O,O
manifest,O,O
at,O,O
birth,O,O
",",O,O
with,O,O
increased,O,O
mortality,O,O
and,O,O
bone,B,O
dysplasia,I,O
resembling,O,O
Pyle,B,B
disease,I,I
.,O,O
Genetic,O,O
analysis,O,O
of,O,O
the,O,O
family,O,O
with,O,O
two,O,O
sibs,O,O
affected,O,O
by,O,O
SJS,B,B
type,I,I
2,I,I
showed,O,O
evidence,O,O
against,O,O
linkage,O,O
to,O,O
chromosome,O,O
1p36,O,O
-,O,O
34,O,O
.,O,O
CONCLUSIONS,O,O
SJS,B,B
is,O,O
clinically,O,O
and,O,O
radiologically,O,O
heterogeneous,O,O
.,O,O
The,O,O
causes,O,O
of,O,O
heterogeneity,O,O
are,O,O
not,O,O
known,O,O
yet,O,O
but,O,O
are,O,O
likely,O,O
to,O,O
include,O,O
both,O,O
different,O,O
mutations,O,O
at,O,O
the,O,O
SJS,B,B
locus,O,I
on,O,O
chromosome,O,O
1,O,B
and,O,O
the,O,O
presence,O,O
of,O,O
a,O,O
second,O,O
SJS,B,B
locus,O,I
.,O,O
A,O,O
tentative,O,O
clinico,O,O
-,O,O
radiological,O,O
classification,O,O
can,O,O
be,O,O
useful,O,O
for,O,O
the,O,O
characterization,O,O
of,O,O
patients,O,O
and,O,O
the,O,O
development,O,O
of,O,O
genotype,O,O
-,O,O
phenotype,O,O
correlations,O,O
.,O,O
A,O,O
clinical,O,O
overview,O,O
of,O,O
WT1,O,B
gene,O,I
mutations,O,I
.,O,O
Mutations,O,O
in,O,O
the,O,O
WT1,O,B
gene,O,I
were,O,O
anticipated,O,O
to,O,O
explain,O,O
the,O,O
genetic,O,O
basis,O,O
of,O,O
the,O,O
childhood,O,O
kidney,B,O
cancer,I,B
",",O,O
Wilms,B,B
tumour,I,I
(,O,O
WT,B,B
),O,O
.,O,O
Six,O,O
years,O,O
on,O,O
",",O,O
we,O,O
review,O,O
100,O,O
reports,O,O
of,O,O
intragenic,O,O
WT1,O,B
mutations,O,O
and,O,O
examine,O,O
the,O,O
accompanying,O,O
clinical,O,O
phenotypes,O,O
.,O,O
While,O,O
only,O,O
5,O,O
%,O,O
of,O,O
sporadic,B,O
Wilms,I,B
tumours,I,O
have,O,O
intragenic,O,O
WT1,O,B
mutations,O,O
",",O,O
>,O,O
90,O,O
%,O,O
of,O,O
patients,O,O
with,O,O
the,O,O
Denys,B,B
-,I,I
Drash,I,I
syndrome,I,I
(,O,O
renal,B,B
nephropathy,I,I
",",O,O
gonadal,B,B
anomaly,I,I
",",O,O
predisposition,B,O
to,I,O
WT,I,B
),O,O
carry,O,O
constitutional,O,O
intragenic,O,O
WT1,O,B
mutations,O,O
.,O,O
WT1,O,B
mutations,O,O
have,O,O
also,O,O
been,O,O
reported,O,O
in,O,O
juvenile,B,O
granulosa,I,B
cell,I,I
tumour,I,I
",",O,O
non,B,O
-,I,O
asbestos,I,O
related,I,O
mesothelioma,I,B
",",O,O
desmoplastic,B,B
small,I,I
round,I,I
cell,I,I
tumour,I,I
and,O,O
",",O,O
most,O,O
recently,O,O
",",O,O
acute,B,B
myeloid,I,I
leukemia,I,I
.,O,O
A,O,O
mutation,O,O
in,O,O
autosomal,B,O
dominant,I,O
myotonia,I,O
congenita,I,O
affects,O,O
pore,O,O
properties,O,O
of,O,O
the,O,O
muscle,O,O
chloride,O,O
channel,O,O
.,O,O
Autosomal,B,O
dominant,I,O
myotonia,I,O
congenita,I,O
is,O,O
an,O,O
inherited,B,O
disorder,I,O
of,I,O
skeletal,I,O
muscle,I,O
caused,O,O
by,O,O
mutations,O,O
in,O,O
a,O,O
voltage,O,O
-,O,O
gated,O,O
Cl,O,B
-,O,I
channel,O,I
gene,O,I
(,O,O
CLCN1,O,O
",",O,O
7q35,O,O
),O,O
.,O,O
Here,O,O
",",O,O
we,O,O
report,O,O
that,O,O
a,O,O
mutation,O,O
predicting,O,O
the,O,O
substitution,O,O
of,O,O
Gly,O,O
230,O,O
by,O,O
glutamic,O,O
acid,O,O
(,O,O
G230E,O,O
),O,O
between,O,O
segments,O,O
D3,O,O
and,O,O
D4,O,O
dramatically,O,O
alters,O,O
the,O,O
pore,O,O
properties,O,O
of,O,O
a,O,O
recombinant,O,O
human,O,O
muscle,O,O
Cl,O,B
-,O,I
channel,O,I
(,O,O
hCIC,O,O
-,O,O
1,O,O
),O,O
expressed,O,O
in,O,O
a,O,O
mammalian,O,O
cell,O,O
line,O,O
(,O,O
tsA201,O,O
),O,O
.,O,O
The,O,O
G230E,O,B
mutation,O,O
causes,O,O
substantial,O,O
changes,O,O
in,O,O
anion,O,O
and,O,O
cation,O,O
selectivity,O,O
as,O,O
well,O,O
as,O,O
a,O,O
fundamental,O,O
change,O,O
in,O,O
rectification,O,O
of,O,O
the,O,O
current,O,O
-,O,O
voltage,O,O
relationship,O,O
.,O,O
Whereas,O,O
wild,O,O
-,O,O
type,O,O
channels,O,O
are,O,O
characterized,O,O
by,O,O
pronounced,O,O
inward,O,O
rectification,O,O
and,O,O
a,O,O
Cl,O,O
>,O,O
thiocyanate,O,O
>,O,O
Br,O,O
>,O,O
NO,O,O
(,O,O
3,O,O
),O,O
>,O,O
I,O,O
>,O,O
CH,O,O
(,O,O
3,O,O
),O,O
SO,O,O
(,O,O
3,O,O
),O,O
selectivity,O,O
",",O,O
G230E,O,B
exhibits,O,O
outward,O,O
rectification,O,O
at,O,O
positive,O,O
potentials,O,O
and,O,O
a,O,O
thiocyanate,O,O
>,O,O
NO,O,O
(,O,O
3,O,O
),O,O
>,O,O
I,O,O
>,O,O
Br,O,O
>,O,O
Cl,O,O
>,O,O
CH,O,O
(,O,O
3,O,O
),O,O
SO,O,O
(,O,O
3,O,O
),O,O
selectivity,O,O
.,O,O
Furthermore,O,O
",",O,O
the,O,O
cation,O,O
-,O,O
to,O,O
-,O,O
anion,O,O
permeability,O,O
ratio,O,O
of,O,O
the,O,O
mutant,O,O
is,O,O
much,O,O
greater,O,O
than,O,O
that,O,O
of,O,O
the,O,O
wild,O,O
-,O,O
type,O,O
channel,O,O
.,O,O
Voltage,O,O
-,O,O
dependent,O,O
blocks,O,O
by,O,O
intracellular,O,O
and,O,O
extracellular,O,O
iodide,O,O
help,O,O
to,O,O
distinguish,O,O
two,O,O
distinct,O,O
ion,O,O
binding,O,O
sites,O,O
within,O,O
the,O,O
hClC,O,O
-,O,O
1,O,O
conduction,O,O
pathway,O,O
.,O,O
Both,O,O
binding,O,O
sites,O,O
are,O,O
preserved,O,O
in,O,O
the,O,O
mutant,O,O
but,O,O
have,O,O
decreased,O,O
affinities,O,O
for,O,O
iodide,O,O
.,O,O
These,O,O
findings,O,O
suggest,O,O
that,O,O
Gly,O,B
230,O,I
is,O,O
critical,O,O
for,O,O
normal,O,O
ion,O,O
conductance,O,O
in,O,O
hClC,O,B
-,O,I
1,O,I
and,O,O
that,O,O
this,O,O
residue,O,O
resides,O,O
within,O,O
the,O,O
channel,O,O
pore,O,O
.,O,O
The,O,O
incidence,O,O
of,O,O
PAX6,O,B
mutation,O,O
in,O,O
patients,O,O
with,O,O
simple,O,O
aniridia,B,O
:,O,O
an,O,O
evaluation,O,O
of,O,O
mutation,O,O
detection,O,O
in,O,O
12,O,O
cases,O,O
.,O,O
Twelve,O,O
aniridia,B,O
patients,O,O
",",O,O
five,O,O
with,O,O
a,O,O
family,O,O
history,O,O
and,O,O
seven,O,O
presumed,O,O
to,O,O
be,O,O
sporadic,O,B
",",O,O
were,O,O
exhaustively,O,O
screened,O,O
in,O,O
order,O,O
to,O,O
test,O,O
what,O,O
proportion,O,O
of,O,O
people,O,O
with,O,O
aniridia,B,O
",",O,O
uncomplicated,O,O
by,O,O
associated,O,O
anomalies,O,O
",",O,O
carry,O,O
mutations,O,O
in,O,O
the,O,O
human,O,O
PAX6,O,B
gene,O,O
.,O,O
Mutations,O,O
were,O,O
detected,O,O
in,O,O
90,O,O
%,O,O
of,O,O
the,O,O
cases,O,O
.,O,O
Three,O,O
mutation,O,O
detection,O,O
techniques,O,O
were,O,O
used,O,O
to,O,O
determine,O,O
if,O,O
one,O,O
method,O,O
was,O,O
superior,O,O
for,O,O
this,O,O
gene,O,B
.,O,O
The,O,O
protein,O,O
truncation,O,O
test,O,O
(,O,O
PTT,O,O
),O,O
was,O,O
used,O,O
on,O,O
RT,O,O
-,O,O
PCR,O,O
products,O,O
",",O,O
SSCP,O,O
on,O,O
genomic,O,O
PCR,O,O
amplifications,O,O
",",O,O
and,O,O
chemical,O,O
cleavage,O,O
of,O,O
mismatch,O,O
on,O,O
both,O,O
RT,O,O
-,O,O
PCR,O,O
and,O,O
genomic,O,O
amplifications,O,O
.,O,O
For,O,O
RT,O,B
-,O,I
PCR,O,I
products,O,O
",",O,O
only,O,O
the,O,O
translated,O,O
portion,O,O
of,O,O
the,O,O
gene,O,O
was,O,O
screened,O,O
.,O,O
On,O,O
genomic,O,O
products,O,O
exons,O,O
1,O,O
to,O,O
13,O,O
(,O,O
including,O,O
740,O,O
bp,O,O
of,O,O
the,O,O
3,O,O
untranslated,O,O
sequence,O,O
and,O,O
all,O,O
intron,O,O
/,O,O
exon,O,O
boundaries,O,O
),O,O
were,O,O
screened,O,O
",",O,O
as,O,O
was,O,O
a,O,O
neuroretina,O,O
specific,O,O
enhancer,O,O
in,O,O
intron,O,O
4,O,O
.,O,O
Ten,O,O
of,O,O
the,O,O
possible,O,O
12,O,O
mutations,O,O
in,O,O
the,O,O
five,O,O
familial,O,O
cases,O,O
and,O,O
five,O,O
of,O,O
the,O,O
sporadic,O,O
patients,O,O
were,O,O
found,O,O
",",O,O
all,O,O
of,O,O
which,O,O
conformed,O,O
to,O,O
a,O,O
functional,O,O
outcome,O,O
of,O,O
haploinsufficiency,O,O
.,O,O
Five,O,O
were,O,O
splice,O,O
site,O,O
mutations,O,O
(,O,O
one,O,O
in,O,O
the,O,O
donor,O,O
site,O,O
of,O,O
intron,O,O
4,O,O
",",O,O
two,O,O
in,O,O
the,O,O
donor,O,O
site,O,O
of,O,O
intron,O,O
6,O,O
",",O,O
one,O,O
in,O,O
each,O,O
of,O,O
the,O,O
acceptor,O,O
sites,O,O
of,O,O
introns,O,O
8,O,O
and,O,O
9,O,O
),O,O
and,O,O
five,O,O
were,O,O
nonsense,O,O
mutations,O,O
in,O,O
exons,O,O
8,O,O
",",O,O
9,O,O
",",O,O
10,O,O
",",O,O
11,O,O
",",O,O
and,O,O
12,O,O
.,O,O
SSCP,O,O
analysis,O,O
of,O,O
individually,O,O
amplified,O,O
exons,O,O
",",O,O
with,O,O
which,O,O
nine,O,O
of,O,O
the,O,O
10,O,O
mutations,O,O
were,O,O
seen,O,O
",",O,O
was,O,O
the,O,O
most,O,O
useful,O,O
detection,O,O
method,O,O
for,O,O
PAX6,O,O
.,O,O
.,O,O
Insulin,O,B
gene,O,I
region,O,I
contributes,O,O
to,O,O
genetic,O,O
susceptibility,O,O
to,O,O
",",O,O
but,O,O
may,O,O
not,O,O
to,O,O
low,O,O
incidence,O,O
of,O,O
",",O,O
insulin,B,B
-,I,I
dependent,I,I
diabetes,I,I
mellitus,I,I
in,O,O
Japanese,O,O
.,O,O
In,O,O
the,O,O
Caucasian,O,O
population,O,O
",",O,O
it,O,O
has,O,O
been,O,O
demonstrated,O,O
that,O,O
the,O,O
insulin,O,B
gene,O,I
(,O,O
INS,O,B
),O,O
region,O,O
contains,O,O
the,O,O
insulin,B,B
-,I,I
dependent,I,I
diabetes,I,I
mellitus,I,I
locus,O,O
(,O,O
IDDM2,O,O
),O,O
.,O,O
In,O,O
the,O,O
Japanese,O,O
population,O,O
",",O,O
however,O,O
",",O,O
there,O,O
has,O,O
been,O,O
no,O,O
report,O,O
demonstrating,O,O
the,O,O
contribution,O,O
of,O,O
IDDM2,O,B
to,O,O
the,O,O
pathogenesis,O,O
of,O,O
IDDM,B,B
.,O,O
We,O,O
conducted,O,O
an,O,O
association,O,O
study,O,O
of,O,O
IDDM,B,B
in,O,O
a,O,O
large,O,O
number,O,O
of,O,O
Japanese,O,O
subjects,O,O
with,O,O
multiple,O,O
polymorphisms,O,O
in,O,O
INS,O,B
region,O,O
.,O,O
We,O,O
found,O,O
a,O,O
significant,O,O
association,O,O
of,O,O
the,O,O
INS,O,B
region,O,O
with,O,O
IDDM,B,B
.,O,O
Alleles,O,O
positively,O,O
associated,O,O
with,O,O
IDDM,B,O
in,O,O
INS,O,B
region,O,I
were,O,O
the,O,O
same,O,O
as,O,O
those,O,O
positively,O,O
-,O,O
associated,O,O
with,O,O
IDDM,B,O
in,O,O
Caucasian,O,O
population,O,O
",",O,O
although,O,O
positively,O,O
-,O,O
associated,O,O
alleles,O,O
are,O,O
very,O,O
common,O,O
(,O,O
allele,O,O
frequencies,O,O
>,O,O
0,O,O
.,O,O
9,O,O
),O,O
in,O,O
the,O,O
Japanese,O,O
general,O,O
population,O,O
.,O,O
These,O,O
data,O,O
suggest,O,O
that,O,O
IDDM2,O,B
is,O,O
involved,O,O
in,O,O
the,O,O
genetic,O,O
susceptibility,O,O
to,O,O
IDDM,B,O
in,O,O
Japanese,O,O
.,O,O
The,O,O
high,O,O
frequencies,O,O
of,O,O
disease,O,O
-,O,O
associated,O,O
alleles,O,O
in,O,O
the,O,O
general,O,O
population,O,O
suggest,O,O
that,O,O
IDDM2,O,B
locus,O,O
is,O,O
not,O,O
responsible,O,O
for,O,O
the,O,O
low,O,O
incidence,O,O
of,O,O
IDDM,B,B
in,O,O
Japanese,O,O
.,O,O
The,O,O
human,O,O
complement,O,O
C9,O,B
gene,O,O
:,O,O
identification,O,O
of,O,O
two,O,O
mutations,O,O
causing,O,O
deficiency,O,O
and,O,O
revision,O,O
of,O,O
the,O,O
gene,O,O
structure,O,O
.,O,O
The,O,O
ninth,O,O
component,O,O
of,O,O
human,O,O
complement,O,O
(,O,O
C9,O,B
),O,O
is,O,O
the,O,O
last,O,O
of,O,O
the,O,O
terminal,O,O
complement,O,O
components,O,O
creating,O,O
the,O,O
membrane,O,O
attack,O,O
complex,O,O
.,O,O
C9,O,B
is,O,O
a,O,O
single,O,O
-,O,O
chain,O,O
serum,O,O
protein,O,O
that,O,O
is,O,O
encoded,O,O
by,O,O
a,O,O
gene,O,O
located,O,O
on,O,O
chromosome,O,O
5p,O,O
.,O,O
Deficiency,B,O
of,I,O
terminal,I,O
complement,I,O
components,I,O
is,O,O
generally,O,O
associated,O,O
with,O,O
recurrent,O,O
neisseria,B,O
infections,I,O
.,O,O
We,O,O
studied,O,O
a,O,O
previously,O,O
described,O,O
Swiss,O,O
family,O,O
with,O,O
inherited,B,O
C9,I,B
deficiency,I,O
.,O,O
To,O,O
identify,O,O
the,O,O
genetic,O,O
basis,O,O
of,O,O
C9,B,B
deficiency,I,O
",",O,O
we,O,O
developed,O,O
an,O,O
approach,O,O
using,O,O
exon,O,O
-,O,O
specific,O,O
PCR,O,O
and,O,O
direct,O,O
DNA,O,O
sequencing,O,O
.,O,O
As,O,O
a,O,O
cause,O,O
of,O,O
C9,B,B
deficiency,I,I
",",O,O
we,O,O
found,O,O
two,O,O
different,O,O
point,O,O
mutations,O,O
",",O,O
both,O,O
generating,O,O
TGA,O,O
stop,O,O
codons,O,O
in,O,O
the,O,O
coding,O,O
sequence,O,O
.,O,O
One,O,O
mutation,O,O
",",O,O
a,O,O
C,O,B
to,O,I
A,O,I
exchange,O,I
",",O,O
was,O,O
detected,O,O
in,O,O
exon,O,O
2,O,O
at,O,O
cDNA,O,O
position,O,O
166,O,O
",",O,O
the,O,O
other,O,O
",",O,O
a,O,O
C,O,B
to,O,I
T,O,I
exchange,O,I
",",O,O
was,O,O
located,O,O
in,O,O
exon,O,O
4,O,O
(,O,O
cDNA,O,O
position,O,O
464,O,O
),O,O
.,O,O
In,O,O
family,O,O
studies,O,O
of,O,O
three,O,O
first,O,O
-,O,O
degree,O,O
relatives,O,O
with,O,O
heterozygous,O,O
C9,B,B
deficiency,I,I
",",O,O
we,O,O
demonstrated,O,O
that,O,O
the,O,O
two,O,O
mutations,O,O
are,O,O
segregating,O,O
independently,O,O
.,O,O
Therefore,O,O
",",O,O
these,O,O
mutations,O,O
are,O,O
sufficient,O,O
to,O,O
explain,O,O
the,O,O
complete,O,O
deficiency,O,O
of,O,O
both,O,O
the,O,O
probands,O,O
studied,O,O
.,O,O
DNA,O,B
sequencing,O,I
of,O,O
the,O,O
exon,O,O
-,O,O
intron,O,O
junctions,O,O
revealed,O,O
a,O,O
number,O,O
of,O,O
revisions,O,O
regarding,O,O
the,O,O
boundaries,O,O
between,O,O
exons,O,O
4,O,O
",",O,O
5,O,O
",",O,O
and,O,O
6,O,O
as,O,O
well,O,O
as,O,O
between,O,O
exons,O,O
10,O,O
and,O,O
11,O,O
.,O,O
No,O,O
additional,O,O
introns,O,O
were,O,O
detected,O,O
in,O,O
exons,O,O
6,O,O
and,O,O
10,O,O
.,O,O
Furthermore,O,O
",",O,O
DNA,O,O
marker,O,O
studies,O,O
were,O,O
conducted,O,O
using,O,O
known,O,O
polymorphisms,O,O
of,O,O
the,O,O
C6,O,B
",",O,O
C7,O,B
",",O,O
and,O,O
C9,O,B
genes,O,O
",",O,O
confirming,O,O
the,O,O
linkage,O,O
of,O,O
the,O,O
observed,O,O
C9,O,B
mutations,O,O
with,O,O
defined,O,O
haplotypes,O,O
.,O,O
.,O,O
BRCA1,O,O
mutations,O,O
in,O,O
women,O,O
attending,O,O
clinics,O,O
that,O,O
evaluate,O,O
the,O,O
risk,O,O
of,O,O
breast,B,B
cancer,I,I
.,O,O
BACKGROUND,O,O
To,O,O
define,O,O
the,O,O
incidence,O,O
of,O,O
BRCA1,O,O
mutations,O,O
among,O,O
patients,O,O
seen,O,O
in,O,O
clinics,O,O
that,O,O
evaluate,O,O
the,O,O
risk,O,O
of,O,O
breast,B,B
cancer,I,I
",",O,O
we,O,O
analyzed,O,O
DNA,O,O
samples,O,O
from,O,O
women,O,O
seen,O,O
in,O,O
this,O,O
setting,O,O
and,O,O
constructed,O,O
probability,O,O
tables,O,O
to,O,O
provide,O,O
estimates,O,O
of,O,O
the,O,O
likelihood,O,O
of,O,O
finding,O,O
a,O,O
BRCA1,O,O
mutation,O,O
in,O,O
individual,O,O
families,O,O
.,O,O
METHODS,O,O
Clinical,O,O
information,O,O
",",O,O
family,O,O
histories,O,O
",",O,O
and,O,O
blood,O,O
for,O,O
DNA,O,O
analysis,O,O
were,O,O
obtained,O,O
from,O,O
263,O,O
women,O,O
with,O,O
breast,B,B
cancer,I,I
.,O,O
Conformation,O,O
-,O,O
sensitive,O,O
gel,O,O
electrophoresis,O,O
and,O,O
DNA,O,O
sequencing,O,O
were,O,O
used,O,O
to,O,O
identify,O,O
BRCA1,O,O
mutations,O,O
.,O,O
RESULTS,O,O
BRCA1,O,O
mutations,O,O
were,O,O
identified,O,O
in,O,O
16,O,O
percent,O,O
of,O,O
women,O,O
with,O,O
a,O,O
family,O,O
history,O,O
of,O,O
breast,B,B
cancer,I,I
.,O,O
Only,O,O
7,O,O
percent,O,O
of,O,O
women,O,O
from,O,O
families,O,O
with,O,O
a,O,O
history,O,O
of,O,O
breast,B,B
cancer,I,I
but,O,O
not,O,O
ovarian,B,O
cancer,I,O
had,O,O
BRCA1,O,O
mutations,O,O
.,O,O
The,O,O
rates,O,O
were,O,O
higher,O,O
among,O,O
women,O,O
from,O,O
families,O,O
with,O,O
a,O,O
history,O,O
of,O,O
both,O,O
breast,B,B
and,I,O
ovarian,I,O
cancer,I,O
.,O,O
Among,O,O
family,O,O
members,O,O
",",O,O
an,O,O
average,O,O
age,O,O
of,O,O
less,O,O
than,O,O
55,O,O
years,O,O
at,O,O
the,O,O
diagnosis,O,O
of,O,O
breast,B,B
cancer,I,I
",",O,O
the,O,O
presence,O,O
of,O,O
ovarian,B,O
cancer,I,O
",",O,O
the,O,O
presence,O,O
of,O,O
breast,B,B
and,I,O
ovarian,I,O
cancer,I,O
in,O,O
the,O,O
same,O,O
woman,O,O
",",O,O
and,O,O
Ashkenazi,O,O
Jewish,O,O
ancestry,O,O
were,O,O
all,O,O
associated,O,O
with,O,O
an,O,O
increased,O,O
risk,O,O
of,O,O
detecting,O,O
a,O,O
BRCA1,O,O
mutation,O,O
.,O,O
No,O,O
association,O,O
was,O,O
found,O,O
between,O,O
the,O,O
presence,O,O
of,O,O
bilateral,O,O
breast,B,B
cancer,I,I
or,O,O
the,O,O
number,O,O
of,O,O
breast,B,B
cancers,I,I
in,O,O
a,O,O
family,O,O
and,O,O
the,O,O
detection,O,O
of,O,O
a,O,O
BRCA1,O,O
mutation,O,O
",",O,O
or,O,O
between,O,O
the,O,O
position,O,O
of,O,O
the,O,O
mutation,O,O
in,O,O
the,O,O
BRCA1,O,O
gene,O,O
and,O,O
the,O,O
presence,O,O
of,O,O
ovarian,B,B
cancer,I,I
in,O,O
a,O,O
family,O,O
.,O,O
CONCLUSIONS,O,O
Among,O,O
women,O,O
with,O,O
breast,B,B
cancer,I,I
and,O,O
a,O,O
family,O,O
history,O,O
of,O,O
the,O,O
disease,O,O
",",O,O
the,O,O
percentage,O,O
with,O,O
BRCA1,O,O
coding,O,O
-,O,O
region,O,O
mutations,O,O
is,O,O
less,O,O
than,O,O
the,O,O
45,O,O
percent,O,O
predicted,O,O
by,O,O
genetic,O,O
-,O,O
linkage,O,O
analysis,O,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
even,O,O
in,O,O
a,O,O
referral,O,O
clinic,O,O
specializing,O,O
in,O,O
screening,O,O
women,O,O
from,O,O
high,O,O
-,O,O
risk,O,O
families,O,O
",",O,O
the,O,O
majority,O,O
of,O,O
tests,O,O
for,O,O
BRCA1,O,O
mutations,O,O
will,O,O
be,O,O
negative,O,O
and,O,O
therefore,O,O
uninformative,O,O
.,O,O
Mutations,O,O
in,O,O
the,O,O
arginine,O,B
-,O,I
rich,O,I
protein,O,I
gene,O,I
(,O,O
ARP,O,O
),O,O
in,O,O
pancreatic,B,O
cancer,I,O
.,O,O
The,O,O
ARP,O,O
gene,O,O
encodes,O,O
a,O,O
highly,O,O
conserved,O,O
arginine,O,B
-,O,I
rich,O,I
protein,O,I
from,O,O
chromosomal,O,O
band,O,O
3p21,O,O
.,O,O
1,O,O
1,O,O
.,O,O
At,O,O
the,O,O
cytogenetic,O,O
level,O,O
this,O,O
region,O,O
is,O,O
frequently,O,O
deleted,O,O
in,O,O
a,O,O
variety,O,O
of,O,O
different,O,O
solid,B,O
tumors,I,O
",",O,O
although,O,O
not,O,O
in,O,O
pancreatic,B,O
cancer,I,O
.,O,O
We,O,O
have,O,O
reported,O,O
the,O,O
presence,O,O
of,O,O
a,O,O
specific,O,O
mutation,O,O
(,O,O
ATG50,O,B
-,O,I
-,O,I
>,O,I
AGG,O,I
),O,O
or,O,O
deletion,O,O
of,O,O
codon,O,O
50,O,O
of,O,O
the,O,O
ARP,O,B
gene,O,O
in,O,O
different,O,O
tumor,B,O
types,I,O
(,O,O
Shridhar,O,O
et,O,O
al,O,O
.,O,O
",",O,O
1996,O,O
",",O,O
1996a,O,O
),O,O
.,O,O
In,O,O
the,O,O
present,O,O
study,O,O
",",O,O
we,O,O
have,O,O
observed,O,O
mutations,O,O
involving,O,O
codon,O,O
50,O,O
in,O,O
11,O,O
of,O,O
37,O,O
pancreatic,B,B
tumors,I,I
.,O,O
The,O,O
frequency,O,O
of,O,O
codon,O,O
50,O,O
mutation,O,O
is,O,O
roughly,O,O
the,O,O
same,O,O
in,O,O
pancreatic,B,B
tumors,I,I
as,O,O
in,O,O
the,O,O
other,O,O
types,O,O
of,O,O
tumors,B,O
previously,O,O
examined,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
we,O,O
have,O,O
detected,O,O
mutations,O,O
at,O,O
codon,O,O
51,O,O
in,O,O
multiple,O,O
PCR,O,O
subclones,O,O
in,O,O
two,O,O
other,O,O
pancreatic,B,B
tumors,I,I
.,O,O
Mutations,O,O
in,O,O
the,O,O
ARP,O,B
gene,O,I
are,O,O
thus,O,O
commonly,O,O
observed,O,O
in,O,O
pancreatic,B,B
cancer,I,I
",",O,O
as,O,O
well,O,O
as,O,O
many,O,O
other,O,O
cancers,B,O
.,O,O
Difficulties,O,O
in,O,O
the,O,O
ascertainment,O,O
of,O,O
C9,B,B
deficiency,I,I
:,O,O
lessons,O,O
to,O,O
be,O,O
drawn,O,O
from,O,O
a,O,O
compound,O,O
heterozygote,O,O
C9,B,B
-,I,I
deficient,I,I
subject,O,I
.,O,O
A,O,O
group,O,O
of,O,O
patients,O,O
with,O,O
long,O,O
-,O,O
surviving,O,O
mismatched,O,O
kidney,O,O
allografts,O,O
were,O,O
investigated,O,O
for,O,O
complement,O,O
function,O,O
using,O,O
haemolytic,O,O
assays,O,O
in,O,O
agarose,O,O
gels,O,O
.,O,O
One,O,O
patient,O,O
was,O,O
found,O,O
to,O,O
have,O,O
no,O,O
alternative,O,O
pathway,O,O
activity,O,O
but,O,O
a,O,O
low,O,O
normal,O,O
classical,O,O
pathway,O,O
.,O,O
Surprisingly,O,O
",",O,O
investigation,O,O
revealed,O,O
that,O,O
the,O,O
patients,O,O
complement,O,O
was,O,O
normal,O,O
for,O,O
all,O,O
components,O,O
except,O,O
C9,O,B
",",O,O
which,O,O
was,O,O
functionally,O,O
absent,O,O
.,O,O
The,O,O
patient,O,O
was,O,O
shown,O,O
to,O,O
be,O,O
heterozygous,O,O
for,O,O
DNA,O,O
markers,O,O
in,O,O
the,O,O
C6,O,B
",",O,O
C7,O,B
and,O,O
C9,O,B
region,O,O
of,O,O
chromosome,O,O
5,O,O
and,O,O
therefore,O,O
appears,O,O
to,O,O
be,O,O
a,O,O
compound,O,O
heterozygote,O,O
for,O,O
two,O,O
uncharacterized,O,O
C9,B,B
deficiency,I,I
genes,O,I
.,O,O
Serological,O,O
analysis,O,O
by,O,O
ELISA,O,O
revealed,O,O
that,O,O
he,O,O
has,O,O
trace,O,O
concentrations,O,O
of,O,O
a,O,O
non,O,O
-,O,O
functional,O,O
C9,O,B
molecule,O,O
.,O,O
Western,O,O
blot,O,O
analysis,O,O
was,O,O
not,O,O
sufficiently,O,O
sensitive,O,O
to,O,O
permit,O,O
detection,O,O
of,O,O
this,O,O
molecule,O,O
.,O,O
We,O,O
hypothesize,O,O
that,O,O
the,O,O
patient,O,O
is,O,O
heterozygous,O,O
for,O,O
a,O,O
complete,B,O
deficiency,I,O
of,I,O
C9,I,B
and,O,O
for,O,O
a,O,O
gene,O,O
directing,O,O
hyposynthesis,O,O
of,O,O
a,O,O
defective,O,O
C9,O,B
.,O,O
We,O,O
also,O,O
suggest,O,O
that,O,O
C9,B,B
deficiency,I,I
may,O,O
be,O,O
more,O,O
common,O,O
among,O,O
Caucasians,O,B
than,O,O
has,O,O
been,O,O
reported,O,O
.,O,O
Screening,O,O
for,O,O
ESR,O,B
mutations,O,O
in,O,O
breast,B,B
and,I,O
ovarian,I,B
cancer,I,I
patients,O,O
.,O,O
In,O,O
the,O,O
present,O,O
study,O,O
",",O,O
leukocyte,O,O
DNA,O,O
from,O,O
143,O,O
patients,O,O
with,O,O
familial,O,O
clustering,O,O
of,O,O
breast,B,B
and,I,O
/,I,O
or,I,O
ovarian,I,B
cancer,I,I
and,O,O
tumour,B,O
DNA,O,O
from,O,O
96,O,O
breast,B,B
carcinomas,I,I
were,O,O
screened,O,O
for,O,O
base,O,O
mutations,O,O
in,O,O
the,O,O
estrogen,O,B
receptor,O,I
gene,O,I
(,O,O
ESR,O,B
),O,O
.,O,O
Three,O,O
patients,O,O
with,O,O
a,O,O
family,O,O
history,O,O
of,O,O
cancer,B,B
were,O,O
carrying,O,O
a,O,O
Gly160Cys,O,O
germline,O,O
substitution,O,O
.,O,O
This,O,O
alteration,O,O
was,O,O
also,O,O
detected,O,O
in,O,O
eight,O,O
(,O,O
four,O,O
females,O,O
and,O,O
four,O,O
males,O,O
),O,O
of,O,O
729,O,O
controls,O,O
(,O,O
366,O,O
female,O,O
",",O,O
363,O,O
males,O,O
),O,O
",",O,O
indicating,O,O
that,O,O
the,O,O
substitution,O,O
probably,O,O
represents,O,O
a,O,O
polymorphism,O,O
.,O,O
However,O,O
",",O,O
in,O,O
the,O,O
229,O,O
female,O,O
controls,O,O
in,O,O
whom,O,O
family,O,O
history,O,O
of,O,O
cancer,B,B
was,O,O
known,O,O
",",O,O
one,O,O
of,O,O
two,O,O
who,O,O
had,O,O
a,O,O
sister,O,O
with,O,O
breast,B,B
cancer,I,I
was,O,O
carrying,O,O
the,O,O
variant,O,O
allele,O,O
.,O,O
Hence,O,O
",",O,O
a,O,O
possible,O,O
clinical,O,O
significance,O,O
of,O,O
the,O,O
glycine,O,B
into,O,O
cysteine,O,B
cannot,O,O
be,O,O
completely,O,O
ruled,O,O
out,O,O
and,O,O
should,O,O
be,O,O
further,O,O
investigated,O,O
.,O,O
Somatic,O,O
mutations,O,O
were,O,O
not,O,O
detected,O,O
in,O,O
any,O,O
of,O,O
the,O,O
tumours,B,O
studied,O,O
",",O,O
and,O,O
the,O,O
present,O,O
data,O,O
do,O,O
not,O,O
provide,O,O
support,O,O
for,O,O
somatic,O,O
ESR,O,O
base,O,O
mutations,O,O
as,O,O
an,O,O
important,O,O
mechanism,O,O
for,O,O
hormonal,O,O
therapy,O,O
resistance,O,O
in,O,O
estrogen,B,B
receptor,I,I
-,I,I
positive,I,I
breast,I,I
carcinomas,I,I
.,O,O
Molecular,O,O
bases,O,O
of,O,O
C7,B,B
deficiency,I,I
:,O,O
three,O,O
different,O,O
defects,O,O
.,O,O
The,O,O
molecular,O,O
basis,O,O
of,O,O
C7,B,B
deficiency,I,I
has,O,O
been,O,O
investigated,O,O
in,O,O
two,O,O
Irish,O,O
families,O,O
and,O,O
a,O,O
number,O,O
of,O,O
Israeli,O,O
families,O,O
of,O,O
Moroccan,O,O
Sephardic,O,O
Jewish,O,O
origin,O,O
.,O,O
Exon,O,O
PCR,O,O
and,O,O
sequencing,O,O
revealed,O,O
a,O,O
heterozygous,O,O
point,O,O
mutation,O,O
at,O,O
the,O,O
3,O,O
splice,O,O
acceptor,O,O
site,O,O
of,O,O
intron,O,O
1,O,O
in,O,O
one,O,O
Irish,O,O
family,O,O
.,O,O
In,O,O
the,O,O
other,O,O
Irish,O,O
family,O,O
",",O,O
exons,O,O
7,O,O
and,O,O
8,O,O
failed,O,O
to,O,O
amplify,O,O
and,O,O
they,O,O
were,O,O
shown,O,O
to,O,O
be,O,O
deleted,O,O
.,O,O
Marker,O,O
haplotype,O,O
studies,O,O
of,O,O
the,O,O
C6,O,O
and,O,O
C7,O,O
gene,O,O
region,O,O
and,O,O
Southern,O,O
blots,O,O
show,O,O
that,O,O
the,O,O
Irish,O,O
family,O,O
with,O,O
the,O,O
splice,O,O
defect,O,O
also,O,O
segregate,O,O
for,O,O
the,O,O
deletion,O,O
",",O,O
which,O,O
is,O,O
not,O,O
easily,O,O
detected,O,O
in,O,O
heterozygotes,O,O
.,O,O
The,O,O
Israeli,O,O
C7,B,O
-,I,O
deficient,I,O
cases,O,O
all,O,O
share,O,O
a,O,O
C7,O,O
haplotype,O,O
and,O,O
are,O,O
homozygous,O,O
for,O,O
a,O,O
mis,O,O
-,O,O
sense,O,O
mutation,O,O
in,O,O
exon,O,O
9,O,O
.,O,O
However,O,O
",",O,O
one,O,O
individual,O,O
is,O,O
heterozygous,O,O
for,O,O
markers,O,O
at,O,O
adjacent,O,O
C6,O,B
loci,O,I
",",O,O
showing,O,O
that,O,O
there,O,O
has,O,O
been,O,O
an,O,O
intergenic,O,O
recombination,O,O
and,O,O
suggesting,O,O
that,O,O
the,O,O
deficiency,O,O
mutation,O,O
is,O,O
of,O,O
appreciable,O,O
antiquity,O,O
.,O,O
Molecular,O,O
heterogeneity,O,O
of,O,O
classical,B,O
and,I,O
Duarte,I,B
galactosemia,I,I
:,O,O
mutation,O,O
analysis,O,O
by,O,O
denaturing,O,O
gradient,O,O
gel,O,O
electrophoresis,O,O
.,O,O
Classical,B,O
galactosemia,I,O
is,O,O
caused,O,O
by,O,O
one,O,O
common,O,O
missense,O,O
mutation,O,O
(,O,O
Q188R,O,O
),O,O
and,O,O
by,O,O
several,O,O
rare,O,O
mutations,O,O
in,O,O
the,O,O
galactose,O,B
-,O,I
1,O,I
-,O,I
phosphate,O,I
uridyltransferase,O,I
(,O,O
GALT,O,O
),O,O
gene,O,O
.,O,O
The,O,O
most,O,O
common,O,O
variant,O,O
of,O,O
GALT,O,O
",",O,O
the,O,O
Duarte,O,B
variant,O,O
",",O,O
occurs,O,O
as,O,O
two,O,O
types,O,O
",",O,O
Duarte,O,B
-,O,I
1,O,I
(,O,O
D,O,B
-,O,I
1,O,I
),O,O
and,O,O
Duarte,O,B
-,O,I
2,O,I
(,O,O
D,O,B
-,O,I
2,O,I
),O,O
",",O,O
both,O,O
of,O,O
which,O,O
carry,O,O
the,O,O
sequence,O,O
change,O,O
N314D,O,O
.,O,O
D,O,O
-,O,O
1,O,O
increases,O,O
",",O,O
whereas,O,O
D,O,O
-,O,O
2,O,O
decreases,O,O
GALT,O,B
activity,O,O
.,O,O
To,O,O
study,O,O
the,O,O
molecular,O,O
genetics,O,O
of,O,O
classical,B,O
and,I,O
Duarte,I,O
galactosemia,I,O
",",O,O
we,O,O
analyzed,O,O
the,O,O
GALT,O,B
mutations,O,O
in,O,O
30,O,O
families,O,O
with,O,O
classical,B,O
galactosemia,I,O
",",O,O
in,O,O
10,O,O
families,O,O
with,O,O
the,O,O
D,O,O
-,O,O
2,O,O
variant,O,O
and,O,O
in,O,O
3,O,O
individuals,O,O
carrying,O,O
the,O,O
D,O,O
-,O,O
1,O,O
allele,O,O
by,O,O
denaturing,O,O
gradient,O,O
gel,O,O
electrophoresis,O,O
(,O,O
DGGE,O,O
),O,O
.,O,O
DGGE,O,O
detected,O,O
59,O,O
of,O,O
the,O,O
60,O,O
classical,O,O
galactosemia,B,B
alleles,O,O
.,O,O
Q188R,O,O
accounted,O,O
for,O,O
60,O,O
%,O,O
",",O,O
K285N,O,O
accounted,O,O
for,O,O
28,O,O
%,O,O
of,O,O
these,O,O
alleles,O,O
.,O,O
Eight,O,O
novel,O,O
candidate,O,O
galactosemia,B,B
mutations,O,O
were,O,O
found,O,O
.,O,O
On,O,O
all,O,O
D,O,O
-,O,O
2,O,O
alleles,O,O
N314D,O,O
occurred,O,O
in,O,O
cis,O,O
with,O,O
two,O,O
intronic,O,O
sequence,O,O
changes,O,O
",",O,O
on,O,O
the,O,O
D,O,O
-,O,O
1,O,O
alleles,O,O
in,O,O
cis,O,O
with,O,O
a,O,O
neutral,O,O
mutation,O,O
in,O,O
exon,O,O
7,O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
the,O,O
mutations,O,O
causing,O,O
galactosemia,B,B
are,O,O
highly,O,O
heterogeneous,O,O
and,O,O
that,O,O
K285N,O,O
is,O,O
a,O,O
second,O,O
common,O,O
galactosemia,B,B
mutation,O,O
in,O,O
our,O,O
population,O,O
.,O,O
Isolation,O,O
of,O,O
full,O,O
-,O,O
length,O,O
ATM,O,O
cDNA,O,O
and,O,O
correction,O,O
of,O,O
the,O,O
ataxia,B,B
-,I,I
telangiectasia,I,I
cellular,O,I
phenotype,O,I
.,O,O
A,O,B
gene,O,O
mutated,O,O
in,O,O
the,O,O
human,O,O
genetic,B,O
disorder,I,O
ataxia,B,B
-,I,I
telangiectasia,I,I
(,O,O
A,B,B
-,I,I
T,I,I
),O,O
",",O,O
ATM,O,O
",",O,O
was,O,O
recently,O,O
identified,O,O
by,O,O
positional,O,O
cloning,O,O
.,O,O
ATM,O,B
is,O,O
a,O,O
member,O,O
of,O,O
the,O,O
phosphatidylinositol,O,O
-,O,O
3,O,O
-,O,O
kinase,O,O
superfamily,O,O
",",O,O
some,O,O
of,O,O
which,O,O
are,O,O
protein,O,O
kinases,O,O
and,O,O
appear,O,O
to,O,O
have,O,O
important,O,O
roles,O,O
in,O,O
cell,O,O
cycle,O,O
control,O,O
and,O,O
radiation,O,O
signal,O,O
transduction,O,O
.,O,O
We,O,O
describe,O,O
herein,O,O
",",O,O
to,O,O
our,O,O
knowledge,O,O
",",O,O
for,O,O
the,O,O
first,O,O
time,O,O
",",O,O
the,O,O
cloning,O,O
of,O,O
a,O,O
full,O,O
-,O,O
length,O,O
cDNA,O,O
for,O,O
ATM,O,B
and,O,O
correction,O,O
of,O,O
multiple,O,O
aspects,O,O
of,O,O
the,O,O
radio,O,O
-,O,O
sensitive,O,O
phenotype,O,O
of,O,O
A,B,B
-,I,I
T,I,I
cells,O,O
by,O,O
transfection,O,O
with,O,O
this,O,O
cDNA,O,O
.,O,O
Overexpression,O,O
of,O,O
ATM,O,B
cDNA,O,O
in,O,O
A,B,B
-,I,I
T,I,I
cells,O,O
enhanced,O,O
the,O,O
survival,O,O
of,O,O
these,O,O
cells,O,O
in,O,O
response,O,O
to,O,O
radiation,O,O
exposure,O,O
",",O,O
decreased,O,O
radiation,O,O
-,O,O
induced,O,O
chromosome,O,O
aberrations,O,O
",",O,O
reduced,O,O
radio,O,O
-,O,O
resistant,O,O
DNA,O,O
synthesis,O,O
",",O,O
and,O,O
partially,O,O
corrected,O,O
defective,O,O
cell,O,O
cycle,O,O
checkpoints,O,O
and,O,O
induction,O,O
of,O,O
stress,O,O
-,O,O
activated,O,O
protein,O,O
kinase,O,O
.,O,O
This,O,O
correction,O,O
of,O,O
the,O,O
defects,O,O
in,O,O
A,B,B
-,I,I
T,I,I
cells,O,O
provides,O,O
further,O,O
evidence,O,O
of,O,O
the,O,O
multiplicity,O,O
of,O,O
effector,O,O
functions,O,O
of,O,O
the,O,O
ATM,O,O
protein,O,O
and,O,O
suggests,O,O
possible,O,O
approaches,O,O
to,O,O
gene,O,O
therapy,O,O
.,O,O
.,O,O
Fusion,O,O
genes,O,O
resulting,O,O
from,O,O
alternative,O,O
chromosomal,O,O
translocations,O,O
are,O,O
overexpressed,O,O
by,O,O
gene,O,O
-,O,O
specific,O,O
mechanisms,O,O
in,O,O
alveolar,B,B
rhabdomyosarcoma,I,I
.,O,O
Chromosomal,O,O
translocations,O,O
identified,O,O
in,O,O
hematopoietic,B,O
and,I,O
solid,I,O
tumors,I,O
result,O,O
in,O,O
deregulated,O,O
expression,O,O
of,O,O
protooncogenes,O,B
or,O,O
creation,O,O
of,O,O
chimeric,O,O
proteins,O,O
with,O,O
tumorigenic,O,O
potential,O,O
.,O,O
In,O,O
the,O,O
pediatric,O,O
solid,B,O
tumor,I,O
alveolar,B,O
rhabdomyosarcoma,I,O
",",O,O
a,O,O
consistent,O,O
t,O,O
(,O,O
2,O,O
;,O,O
13,O,O
),O,O
(,O,O
q35,O,O
;,O,O
q14,O,O
),O,O
or,O,O
variant,O,O
t,O,O
(,O,O
1,O,O
;,O,O
13,O,O
),O,O
(,O,O
p36,O,O
;,O,O
q14,O,O
),O,O
translocation,O,O
generates,O,O
PAX3,O,B
-,O,I
FKHR,O,I
or,O,O
PAX7,O,B
-,O,I
FKHR,O,I
fusion,O,O
proteins,O,O
",",O,O
respectively,O,O
.,O,O
In,O,O
this,O,O
report,O,O
",",O,O
we,O,O
demonstrate,O,O
that,O,O
in,O,O
addition,O,O
to,O,O
functional,O,O
alterations,O,O
these,O,O
translocations,O,O
are,O,O
associated,O,O
with,O,O
fusion,O,O
product,O,O
overexpression,O,O
.,O,O
Furthermore,O,O
",",O,O
PAX3,O,B
-,O,I
FKHR,O,I
and,O,O
PAX7,O,B
-,O,I
FKHR,O,I
overexpression,O,O
occurs,O,O
by,O,O
distinct,O,O
mechanisms,O,O
.,O,O
Transcription,O,O
of,O,O
PAX3,O,B
-,O,I
FKHR,O,I
is,O,O
increased,O,O
relative,O,O
to,O,O
wild,O,O
-,O,O
type,O,O
PAX3,O,B
by,O,O
a,O,O
copy,O,O
number,O,O
-,O,O
independent,O,O
process,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
PAX7,O,B
-,O,I
FKHR,O,I
overexpression,O,O
results,O,O
from,O,O
fusion,O,O
gene,O,B
amplification,O,O
.,O,O
Thus,O,O
",",O,O
gene,O,B
-,O,I
specific,O,I
mechanisms,O,O
were,O,O
selected,O,O
to,O,O
overexpress,O,O
PAX3,O,B
-,O,I
FKHR,O,I
and,O,O
PAX7,O,B
-,O,I
FKHR,O,I
in,O,O
alveolar,B,O
rhabdomyosarcoma,I,O
",",O,O
presumably,O,O
due,O,O
to,O,O
differences,O,O
in,O,O
regulation,O,O
between,O,O
the,O,O
wild,O,O
-,O,O
type,O,O
loci,O,O
.,O,O
We,O,O
postulate,O,O
that,O,O
these,O,O
overexpression,O,O
mechanisms,O,O
ensure,O,O
a,O,O
critical,O,O
level,O,O
of,O,O
gene,O,B
product,O,O
for,O,O
the,O,O
oncogenic,O,O
effects,O,O
of,O,O
these,O,O
fusions,O,O
.,O,O
.,O,O
atm,O,B
and,O,O
p53,O,B
cooperate,O,O
in,O,O
apoptosis,O,O
and,O,O
suppression,O,O
of,O,O
tumorigenesis,O,O
",",O,O
but,O,O
not,O,O
in,O,O
resistance,O,O
to,O,O
acute,B,O
radiation,I,O
toxicity,I,O
.,O,O
Mutations,O,O
in,O,O
atm,O,B
and,O,O
p53,O,B
cause,O,O
the,O,O
human,O,O
cancer,B,B
-,I,I
associated,I,I
diseases,I,I
ataxia,B,B
-,I,I
telangiectasia,I,I
and,O,O
Li,B,B
-,I,I
Fraumeni,I,I
syndrome,I,I
",",O,O
respectively,O,O
.,O,O
The,O,O
two,O,O
genes,O,O
are,O,O
believed,O,O
to,O,O
interact,O,O
in,O,O
a,O,O
number,O,O
of,O,O
pathways,O,O
",",O,O
including,O,O
regulation,O,O
of,O,O
DNA,O,O
damage,O,O
-,O,O
induced,O,O
cell,O,O
-,O,O
cycle,O,O
checkpoints,O,O
",",O,O
apoptosis,O,O
and,O,O
radiation,O,O
sensitivity,O,O
",",O,O
and,O,O
cellular,O,O
proliferation,O,O
.,O,O
Atm,O,B
-,O,I
mice,O,I
",",O,O
as,O,O
well,O,O
as,O,O
those,O,O
for,O,O
p53,O,B
",",O,O
develop,O,O
mainly,O,O
T,B,B
-,I,I
cell,I,I
lymphomas,I,I
",",O,O
supporting,O,O
the,O,O
view,O,O
that,O,O
these,O,O
genes,O,O
have,O,O
similar,O,O
roles,O,O
in,O,O
thymocyte,O,O
development,O,O
.,O,O
To,O,O
study,O,O
the,O,O
interactions,O,O
of,O,O
these,O,O
two,O,O
genes,O,O
on,O,O
an,O,O
organismal,O,O
level,O,O
",",O,O
we,O,O
bred,O,O
mice,O,O
heterozygous,O,O
for,O,O
alleles,O,O
of,O,O
both,O,O
atm,O,B
and,O,O
p53,O,B
to,O,O
produce,O,O
all,O,O
genotypic,O,O
combinations,O,O
.,O,O
Mice,O,O
doubly,O,O
for,O,O
atm,O,B
and,O,O
p53,O,B
exhibited,O,O
a,O,O
dramatic,O,O
acceleration,O,O
of,O,O
tumour,B,O
formation,O,O
relative,O,O
to,O,O
singly,O,O
mice,O,O
",",O,O
indicating,O,O
that,O,O
both,O,O
genes,O,O
collaborate,O,O
in,O,O
a,O,O
significant,O,O
manner,O,O
to,O,O
prevent,O,O
tumorigenesis,O,O
.,O,O
With,O,O
respect,O,O
to,O,O
their,O,O
roles,O,O
in,O,O
apoptosis,O,O
",",O,O
loss,O,O
of,O,O
atm,O,B
rendered,O,O
thymocytes,O,O
only,O,O
partly,O,O
resistant,O,O
to,O,O
irradiation,O,O
-,O,O
induced,O,O
apoptosis,O,O
",",O,O
whereas,O,O
additional,O,O
loss,O,O
of,O,O
p53,O,B
engendered,O,O
complete,O,O
resistance,O,O
.,O,O
This,O,O
implies,O,O
that,O,O
the,O,O
irradiation,O,O
-,O,O
induced,O,O
atm,O,B
and,O,O
p53,O,B
apoptotic,O,O
pathways,O,O
are,O,O
not,O,O
completely,O,O
congruent,O,O
.,O,O
Finally,O,O
-,O,O
and,O,O
in,O,O
contrast,O,O
to,O,O
prior,O,O
predictions,O,O
-,O,O
atm,O,B
and,O,O
p53,O,B
do,O,O
not,O,O
appear,O,O
to,O,O
interact,O,O
in,O,O
acute,B,O
radiation,I,O
toxicity,I,O
",",O,O
suggesting,O,O
a,O,O
separate,O,O
atm,O,B
effector,O,O
pathway,O,O
for,O,O
this,O,O
DNA,O,O
damage,O,O
response,O,O
and,O,O
having,O,O
implications,O,O
for,O,O
the,O,O
prognosis,O,O
and,O,O
treatment,O,O
of,O,O
human,O,O
tumours,B,B
.,O,O
.,O,O
Trinucleotide,O,O
repeat,O,O
expansion,O,O
at,O,O
the,O,O
myotonic,B,B
dystrophy,I,I
locus,O,O
reduces,O,O
expression,O,O
of,O,O
DMAHP,O,O
.,O,O
Myotonic,B,B
dystrophy,I,I
",",O,O
or,O,O
dystrophia,B,O
myotonica,I,O
(,O,O
DM,B,B
),O,O
",",O,O
is,O,O
an,O,O
autosomal,B,O
dominant,I,O
multisystem,I,O
disorder,I,O
caused,O,O
by,O,O
the,O,O
expansion,O,O
of,O,O
a,O,O
CTG,O,O
trinucleotide,O,O
repeat,O,O
in,O,O
the,O,O
3,O,O
untranslated,O,O
region,O,O
of,O,O
the,O,O
DMPK,O,B
protein,O,I
kinase,O,I
gene,O,I
on,O,O
chromosome,O,O
19q13,O,O
.,O,O
3,O,O
(,O,O
refs,O,O
1,O,O
-,O,O
3,O,O
),O,O
.,O,O
Although,O,O
the,O,O
DM,B,O
mutation,O,O
was,O,O
identified,O,O
more,O,O
than,O,O
five,O,O
years,O,O
ago,O,O
",",O,O
the,O,O
pathogenic,O,O
mechanisms,O,O
underlying,O,O
this,O,O
most,O,O
prevalent,O,O
form,O,O
of,O,O
hereditary,O,O
adult,O,O
neuromuscular,B,O
disease,I,O
remain,O,O
elusive,O,O
.,O,O
Previous,O,O
work,O,O
from,O,O
our,O,O
laboratory,O,O
demonstrated,O,O
that,O,O
a,O,O
DNase,O,O
l,O,O
-,O,O
hypersensitive,O,O
site,O,O
located,O,O
adjacent,O,O
to,O,O
the,O,O
repeats,O,O
on,O,O
the,O,O
wild,O,O
-,O,O
type,O,O
allele,O,O
is,O,O
eliminated,O,O
by,O,O
repeat,O,O
expansion,O,O
",",O,O
indicating,O,O
that,O,O
large,O,O
CTG,O,B
-,O,I
repeat,O,I
arrays,O,I
may,O,O
be,O,O
associated,O,O
with,O,O
a,O,O
local,O,O
chromatin,O,O
environment,O,O
that,O,O
represses,O,O
gene,O,O
expression,O,O
.,O,O
Here,O,O
we,O,O
report,O,O
that,O,O
the,O,O
hypersensitive,O,O
site,O,O
contains,O,O
an,O,O
enhancer,O,O
element,O,O
that,O,O
regulates,O,O
transcription,O,O
of,O,O
the,O,O
adjacent,O,O
DMAHP,O,B
homeobox,O,I
gene,O,I
.,O,O
Analysis,O,O
of,O,O
DMAHP,O,B
expression,O,O
in,O,O
the,O,O
cells,O,O
of,O,O
DM,B,O
patients,O,O
with,O,O
loss,O,O
of,O,O
the,O,O
hypersensitive,O,O
site,O,O
revealed,O,O
a,O,O
two,O,O
-,O,O
to,O,O
fourfold,O,O
reduction,O,O
in,O,O
steady,O,O
-,O,O
state,O,O
DMAHP,O,B
transcript,O,I
levels,O,I
relative,O,O
to,O,O
wild,O,O
-,O,O
type,O,O
controls,O,O
.,O,O
Allele,O,O
-,O,O
specific,O,O
analysis,O,O
of,O,O
DMAHP,O,B
expression,O,O
showed,O,O
that,O,O
steady,O,O
-,O,O
state,O,O
transcript,O,O
levels,O,O
from,O,O
the,O,O
expanded,O,O
allele,O,O
were,O,O
greatly,O,O
reduced,O,O
in,O,O
comparison,O,O
to,O,O
those,O,O
from,O,O
the,O,O
wild,O,O
-,O,O
type,O,O
allele,O,O
.,O,O
Together,O,O
",",O,O
these,O,O
results,O,O
demonstrate,O,O
that,O,O
CTG,O,O
-,O,O
repeat,O,O
expansions,O,O
can,O,O
suppress,O,O
local,O,O
gene,O,B
expression,O,O
and,O,O
implicate,O,O
DMAHP,O,B
in,O,O
DM,B,O
pathogenesis,O,O
.,O,O
Constitutively,O,O
methylated,O,O
CpG,O,O
dinucleotides,O,O
as,O,O
mutation,O,O
hot,O,O
spots,O,O
in,O,O
the,O,O
retinoblastoma,B,B
gene,O,I
(,O,O
RB1,O,O
),O,O
.,O,O
A,O,O
wide,O,O
spectrum,O,O
of,O,O
mutations,O,O
",",O,O
ranging,O,O
from,O,O
point,O,O
mutations,O,O
to,O,O
large,O,O
deletions,O,O
",",O,O
have,O,O
been,O,O
described,O,O
in,O,O
the,O,O
retinoblastoma,B,B
gene,O,I
(,O,O
RB1,O,O
),O,O
.,O,O
Mutations,O,O
have,O,O
been,O,O
found,O,O
throughout,O,O
the,O,O
gene,O,O
;,O,O
however,O,O
",",O,O
these,O,O
genetic,O,O
alterations,O,O
do,O,O
not,O,O
appear,O,O
to,O,O
be,O,O
homogeneously,O,O
distributed,O,O
.,O,O
In,O,O
particular,O,O
",",O,O
a,O,O
significant,O,O
proportion,O,O
of,O,O
disease,O,O
-,O,O
causing,O,O
mutations,O,O
results,O,O
in,O,O
the,O,O
premature,O,O
termination,O,O
of,O,O
protein,O,O
synthesis,O,O
",",O,O
and,O,O
the,O,O
majority,O,O
of,O,O
these,O,O
mutations,O,O
occur,O,O
as,O,O
C,O,B
-,O,I
-,O,I
>,O,I
T,O,I
transitions,O,O
at,O,O
CpG,O,B
dinucleotides,O,I
(,O,O
CpGs,O,B
),O,O
.,O,O
Such,O,O
recurrent,O,O
CpG,O,B
mutations,O,O
",",O,O
including,O,O
those,O,O
found,O,O
in,O,O
RB1,O,B
",",O,O
are,O,O
likely,O,O
the,O,O
result,O,O
of,O,O
the,O,O
deamination,O,O
of,O,O
5,O,O
-,O,O
methylcytosine,O,O
within,O,O
these,O,O
CpGs,O,B
.,O,O
In,O,O
the,O,O
present,O,O
study,O,O
",",O,O
we,O,O
used,O,O
the,O,O
sodiumbisulfite,O,O
conversion,O,O
method,O,O
to,O,O
detect,O,O
cytosine,O,O
methylation,O,O
in,O,O
representative,O,O
exons,O,O
of,O,O
RB1,O,B
.,O,O
We,O,O
analyzed,O,O
DNA,O,O
from,O,O
a,O,O
variety,O,O
of,O,O
tissues,O,O
and,O,O
specifically,O,O
targeted,O,O
CGA,O,B
codons,O,O
in,O,O
RB1,O,B
",",O,O
where,O,O
recurrent,O,O
premature,O,O
termination,O,O
mutations,O,O
have,O,O
been,O,O
reported,O,O
.,O,O
We,O,O
found,O,O
that,O,O
DNA,O,O
methylation,O,O
within,O,O
RB1,O,B
exons,O,O
8,O,O
",",O,O
14,O,O
",",O,O
25,O,O
",",O,O
and,O,O
27,O,O
appeared,O,O
to,O,O
be,O,O
restricted,O,O
to,O,O
CpGs,O,O
",",O,O
including,O,O
six,O,O
CGA,O,B
codons,O,O
.,O,O
Other,O,O
codons,O,O
containing,O,O
methylated,O,O
cytosines,O,O
have,O,O
not,O,O
been,O,O
reported,O,O
to,O,O
be,O,O
mutated,O,O
.,O,O
Therefore,O,O
",",O,O
disease,O,O
-,O,O
causing,O,O
mutations,O,O
at,O,O
CpGs,O,O
in,O,O
RB1,O,O
appear,O,O
to,O,O
be,O,O
determined,O,O
by,O,O
several,O,O
factors,O,O
",",O,O
including,O,O
the,O,O
constitutive,O,O
presence,O,O
of,O,O
DNA,O,O
methylation,O,O
at,O,O
cytosines,O,O
within,O,O
CpGs,O,O
",",O,O
the,O,O
specific,O,O
codon,O,O
within,O,O
which,O,O
the,O,O
methylated,O,O
cytosine,O,O
is,O,O
located,O,O
",",O,O
and,O,O
the,O,O
particular,O,O
region,O,O
of,O,O
the,O,O
gene,O,O
within,O,O
which,O,O
that,O,O
codon,O,O
resides,O,O
.,O,O
The,O,O
von,B,B
Hippel,I,I
-,I,I
Lindau,I,I
tumor,I,I
suppressor,O,I
gene,O,I
product,O,O
interacts,O,O
with,O,O
Sp1,O,O
to,O,O
repress,O,O
vascular,O,O
endothelial,O,O
growth,O,O
factor,O,O
promoter,O,O
activity,O,O
.,O,O
The,O,O
von,B,B
Hippel,I,I
-,I,I
Lindau,I,I
tumor,I,I
suppressor,O,I
gene,O,I
(,O,O
VHL,O,B
),O,O
has,O,O
a,O,O
critical,O,O
role,O,O
in,O,O
the,O,O
pathogenesis,O,O
of,O,O
clear,B,O
-,I,O
cell,I,O
renal,I,O
cell,I,O
carcinoma,I,O
(,O,O
RCC,B,O
),O,O
",",O,O
as,O,O
VHL,O,B
mutations,O,O
have,O,O
been,O,O
found,O,O
in,O,O
both,O,O
von,B,B
Hippel,I,I
-,I,I
Lindau,I,I
disease,I,I
-,I,I
associated,I,I
and,I,O
sporadic,I,B
RCCs,I,O
.,O,O
Recent,O,O
studies,O,O
suggest,O,O
that,O,O
vascular,O,B
endothelial,O,I
growth,O,I
factor,O,I
(,O,O
VEGF,O,O
),O,O
mRNA,O,O
is,O,O
upregulated,O,O
in,O,O
RCC,B,B
-,I,I
and,I,O
von,I,O
Hippel,I,O
-,I,O
Lindau,I,O
disease,I,O
-,I,O
associated,I,O
tumors,I,O
.,O,O
We,O,O
have,O,O
therefore,O,O
assessed,O,O
the,O,O
effect,O,O
of,O,O
the,O,O
VHL,O,O
gene,O,O
product,O,O
on,O,O
VEGF,O,O
expression,O,O
.,O,O
VEGF,O,O
promoter,O,O
-,O,O
luciferase,O,O
constructs,O,O
were,O,O
transiently,O,O
cotransfected,O,O
with,O,O
a,O,O
wild,O,O
-,O,O
type,O,O
VHL,O,O
(,O,O
wt,O,O
-,O,O
VHL,O,O
),O,O
vector,O,O
in,O,O
several,O,O
cell,O,O
lines,O,O
",",O,O
including,O,O
293,O,O
embryonic,O,O
kidney,O,O
and,O,O
RCC,B,B
cell,O,I
lines,O,I
.,O,O
wt,O,O
-,O,O
VHL,O,B
protein,O,O
inhibited,O,O
VEGF,O,B
promoter,O,I
activity,O,O
in,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
manner,O,O
up,O,O
to,O,O
5,O,O
-,O,O
to,O,O
10,O,O
-,O,O
fold,O,O
.,O,O
Deletion,O,O
analysis,O,O
defined,O,O
a,O,O
144,O,O
-,O,O
bp,O,O
region,O,O
of,O,O
the,O,O
VEGF,O,B
promoter,O,I
necessary,O,O
for,O,O
VHL,O,B
repression,O,O
.,O,O
This,O,O
VHL,O,B
-,O,I
responsive,O,I
element,O,I
is,O,O
GC,O,O
rich,O,O
and,O,O
specifically,O,O
binds,O,O
the,O,O
transcription,O,O
factor,O,O
Sp1,O,B
in,O,O
crude,O,O
nuclear,O,O
extracts,O,O
.,O,O
In,O,O
Drosophila,O,O
cells,O,O
",",O,O
cotransfected,O,O
VHL,O,B
represses,O,O
Sp1,O,B
-,O,I
mediated,O,I
activation,O,I
but,O,O
not,O,O
basal,O,O
activity,O,O
of,O,O
the,O,O
VEGF,O,B
promoter,O,I
.,O,O
We,O,O
next,O,O
demonstrated,O,O
in,O,O
coimmunoprecipitates,O,O
that,O,O
VHL,O,B
and,O,O
Sp1,O,B
were,O,O
part,O,O
of,O,O
the,O,O
same,O,O
complex,O,O
and,O,O
",",O,O
by,O,O
using,O,O
a,O,O
glutathione,O,O
-,O,O
S,O,O
-,O,O
transferase,O,O
-,O,O
VHL,O,B
fusion,O,I
protein,O,I
and,O,O
purified,O,O
Sp1,O,B
",",O,O
that,O,O
VHL,O,B
and,O,O
Sp1,O,B
directly,O,O
interact,O,O
.,O,O
Furthermore,O,O
",",O,O
endogenous,O,O
VEGF,O,B
mRNA,O,I
levels,O,O
were,O,O
suppressed,O,O
in,O,O
permanent,O,O
RCC,B,B
cell,O,I
lines,O,I
expressing,O,O
wt,O,O
-,O,O
VHL,O,O
",",O,O
and,O,O
nuclear,O,O
run,O,O
-,O,O
on,O,O
studies,O,O
indicated,O,O
that,O,O
VHL,O,O
regulation,O,O
of,O,O
VEGF,O,B
occurs,O,O
at,O,O
least,O,O
partly,O,O
at,O,O
the,O,O
transcriptional,O,O
level,O,O
.,O,O
These,O,O
observations,O,O
support,O,O
a,O,O
new,O,O
mechanism,O,O
for,O,O
VHL,O,O
-,O,O
mediated,O,O
transcriptional,O,O
repression,O,O
via,O,O
a,O,O
direct,O,O
inhibitory,O,O
action,O,O
on,O,O
Sp1,O,O
and,O,O
suggest,O,O
that,O,O
loss,O,O
of,O,O
Sp1,O,O
inhibition,O,O
may,O,O
be,O,O
important,O,O
in,O,O
the,O,O
pathogenesis,O,O
of,O,O
von,B,O
Hippel,I,O
-,I,O
Lindau,I,O
disease,I,O
and,O,O
RCC,B,B
.,O,O
Adult,B,O
onset,I,O
globoid,I,B
cell,I,I
leukodystrophy,I,I
(,O,O
Krabbe,B,B
disease,I,I
),O,O
:,O,O
analysis,O,O
of,O,O
galactosylceramidase,O,B
cDNA,O,I
from,O,O
four,O,O
Japanese,O,O
patients,O,O
.,O,O
We,O,O
examined,O,O
galactosylceramidase,O,B
(,O,O
GALC,O,I
),O,O
cDNA,O,I
in,O,O
four,O,O
Japanese,O,O
patients,O,O
with,O,O
adult,B,O
onset,I,O
globoid,I,B
cell,I,I
leukodystrophy,I,I
(,O,O
Krabbe,B,B
disease,I,I
;,O,O
AO,B,O
-,I,O
GLD,I,O
),O,O
by,O,O
polymerase,O,O
chain,O,O
reaction,O,O
/,O,O
single,O,O
-,O,O
strand,O,O
conformation,O,O
polymorphism,O,O
(,O,O
PCR,O,O
-,O,O
SSCP,O,O
),O,O
analysis,O,O
",",O,O
subsequent,O,O
sequence,O,O
determination,O,O
",",O,O
and,O,O
restriction,O,O
enzyme,O,O
digestion,O,O
of,O,O
PCR,O,O
products,O,O
",",O,O
initial,O,O
symptoms,O,O
were,O,O
the,O,O
onset,O,O
of,O,O
slowly,O,O
progressive,O,O
spastic,B,O
paraplegia,I,O
from,O,O
the,O,O
middle,O,O
of,O,O
the,O,O
second,O,O
decade,O,O
",",O,O
and,O,O
all,O,O
patients,O,O
had,O,O
diminished,B,O
GALC,I,B
activity,I,O
in,O,O
their,O,O
leukocytes,O,O
.,O,O
We,O,O
identified,O,O
three,O,O
missense,O,O
mutations,O,O
(,O,O
I66M,O,B
",",O,O
G270D,O,B
",",O,O
L618S,O,B
),O,O
and,O,O
one,O,O
exon,O,O
-,O,O
6,O,O
skipping,O,O
(,O,O
535,O,O
-,O,O
573del,O,O
),O,O
.,O,O
Two,O,O
of,O,O
the,O,O
patients,O,O
had,O,O
only,O,O
the,O,O
I66M,O,B
mutant,O,I
mRNA,O,I
",",O,O
and,O,O
one,O,O
only,O,O
the,O,O
G27OD,O,B
mutant,O,I
mRNA,O,I
.,O,O
The,O,O
fourth,O,O
patient,O,O
carried,O,O
a,O,O
compound,O,O
heterozygous,O,O
mutation,O,O
of,O,O
535,O,O
-,O,O
573del,O,O
and,O,O
L618S,O,B
.,O,O
To,O,O
determine,O,O
the,O,O
enzymatic,O,O
activities,O,O
produced,O,O
by,O,O
these,O,O
mutations,O,O
",",O,O
we,O,O
constructed,O,O
mutated,O,O
GALC,O,O
cDNAs,O,O
and,O,O
expressed,O,O
them,O,O
in,O,O
COS,O,O
-,O,O
1,O,O
cells,O,O
.,O,O
Three,O,O
mutations,O,O
",",O,O
viz,O,O
.,O,O
",",O,O
G270D,O,B
",",O,O
L618S,O,B
",",O,O
and,O,O
exon,O,O
-,O,O
6,O,O
skipping,O,O
(,O,O
535,O,O
-,O,O
573del,O,O
),O,O
",",O,O
produced,O,O
diminished,B,O
GALC,I,B
activity,I,O
as,O,O
expected,O,O
.,O,O
The,O,O
I66M,O,B
mutation,O,O
in,O,O
the,O,O
wild,O,O
-,O,O
type,O,O
GALC,O,B
cDNA,O,O
(,O,O
I289,O,O
),O,O
had,O,O
normal,O,O
activity,O,O
",",O,O
but,O,O
when,O,O
this,O,O
mutation,O,O
and,O,O
the,O,O
V289,O,O
polymorphism,O,O
were,O,O
introduced,O,O
into,O,O
the,O,O
same,O,O
allele,O,O
",",O,O
it,O,O
had,O,O
decreased,O,O
activity,O,O
.,O,O
Thus,O,O
",",O,O
the,O,O
combination,O,O
of,O,O
a,O,O
unique,O,O
mutation,O,O
and,O,O
polymorphism,O,O
causes,O,O
conformational,O,O
change,O,O
in,O,O
the,O,O
GALC,O,B
enzyme,O,I
",",O,O
resulting,O,O
in,O,O
low,O,O
enzymatic,O,O
activity,O,O
.,O,O
AO,B,B
-,I,I
GLD,I,I
mutations,O,O
",",O,O
including,O,O
those,O,O
found,O,O
here,O,O
",",O,O
are,O,O
located,O,O
in,O,O
the,O,O
N,O,B
-,O,I
terminus,O,I
(,O,O
I66M,O,O
",",O,O
G270D,O,O
",",O,O
535,O,O
-,O,O
573del,O,O
),O,O
or,O,O
C,O,B
-,O,I
terminus,O,I
(,O,O
L618S,O,O
),O,O
of,O,O
the,O,O
GALC,O,B
enzyme,O,I
",",O,O
whereas,O,O
the,O,O
reported,O,O
mutations,O,O
in,O,O
the,O,O
infantile,O,O
form,O,O
(,O,O
IF,B,O
-,I,O
GLD,I,O
),O,O
are,O,O
in,O,O
the,O,O
central,O,O
domain,O,O
.,O,O
This,O,O
difference,O,O
in,O,O
mutation,O,O
sites,O,O
may,O,O
affect,O,O
the,O,O
clinical,O,O
features,O,O
of,O,O
GLD,B,B
.,O,O
